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Empty poliovirus particles, VLPs, consisting of capsid proteins VP0, VP1 and VP3, assemble 
into an icosahedral structure during normal poliovirus infection and represent a possible 
vaccine candidate. Similarly synthesis of capsid proteins in recombinant expression systems 
leads to VLP assembly and represents a potential infection free vaccine product. The poliovirus 
polyprotein P1 is cleaved by the virus encoded 3C or 3CD protease to derive the structural 
proteins. This work explored an expression cassette comprising the P1 precursor protein of 
poliovirus Mahoney (wildtype and thermostable variants), MEF-1 (wildtype) and Saukett 
(thermostable) and an adjusted 3C protease from enterovirus 71 to generate P1 cleaved polio 
proteins. Introduction of vectors containing the cassette into insect cells and yeast cells 
demonstrated successful P1 cleavage to molecules agreeing in size with polio VP0, VP3 and 
VP1. Sucrose velocity gradient analysis of recombinant poliovirus antigen from cell lysates 
indicated antigen in the fractions typical of wildtype virus particles and TEM imaging for the 
peak gradient fractions revealed empty poliovirus particles. The antigenicity of the empty 
particles was characterised to be H rather than N in most cases. Capsid stability improvements 
were studied by introducing mutations in the P1 coding region or by the addition of antiviral 
compounds. These modifications allowed continued P1 processing but the expression level 
was often modified confirming these modifications contribute to the entire capsid stability and 
consequently empty capsid yield. Novel modifications at the N-terminus of P1 led to higher 
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  Introduction 
1.1 Overview 
Polio is the medical term used to describe the consequences of poliovirus (PV) replication in 
the nervous system, which leads to paralysis. PV is a positive sense single-stranded RNA virus 
of the Picornavidae family. The majority of PV cases historically were reported among children, 
leaving them with permanent damage in the lower extremities or death in the worst case. The 
first outbreaks were reported in the early 19
th
 century in the EU and the United States. The 
number of paralytic cases increased and peaked at 21,000 cases in the United State in 1952. 
After the introduction of the polio vaccines; inactivated polio vaccine (IPV) and attenuated oral 
polio vaccine (OPV), the number of poliomyelitis decreased rapidly and the last incident of 
poliomyelitis caused by wild type PV in the United States was recorded in 1979. After a decade, 
WHO proposed a global eradication campaign for PV using OPV because of its efficiency, 
ease of administration and low cost. Since the launch of project, the number of poliomyelitis 
cases globally has declined by over 99% but approximately 1000 cases of poliomyelitis have 
been reported annually since 2000, mostly associated with zones of conflict, which questions 
the feasibility of eradication. While the number of wild type PV derived poliomyelitis cases has 
declined however, OPV virus derived poliomyelitis cases, also known as Vaccine-associated 
paralytic polio (VAPP) have become more prominent as a percentage of the overall cases. The 
vaccine strain of OPV has shown genomic instability and may evolve into VAPP in some 
instances. The use of OPV necessarily maintains virus in the environment with the potential to 
result in future outbreaks if herd immunity drops following the cessation of routine vaccination. 
In contrast to OPV, IPV does not evolve to a revertant form. However, the cost of production 
and the necessity of wild type virus culture in high security facilities, which could result in an 
accidental or intentional release, means this method of production is not feasible for a polio 
free world. As a result of such considerations, new approaches to PV vaccine development 
are required. One such approach is the development of PV empty capsid production using 
recombinant expression systems. These systems allow the production of assembled 
immunogenic viral capsids, virus-like-particles (VLP) without being infectious. In this project I 
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will investigate empty PV capsid production in selected foreign expression systems and 
address possible improvements in capsid stability that could benefit immunogenicity and 
contribute to the likely take up of this candidate vaccine. 
 
1.2 Poliovirus 
The existence of poliomyelitis was recorded on Egyptian hieroglyphic stele (Figure 1.1A) which 
date from 1580-1350 BC depicting a young man, a supposed king, with a typical leg 
characteristic of PV paralysis (Galassi et al., 2017). Similarly, mummified bodies with foot 
deformation typical of weakened limbs date back to a similar age. These historical records 
indicate that PV has been a health threat to mankind for a long period and that the outcome of 
infection, paralysis, has not changed. PV infection is normally asymptomatic or only associated 
with very slight morbidity but depending on the site of virus replication the same infection can 
give rise to life changing disease.  
PV and other members of the Picornavidae family consist of a single stranded RNA genome 
of positive polarity within a non-enveloped particle (for a review see Tuthill et al. (2010)). 
However, HAV has shown an exception with transient envelope formation on newly released 
viruses (Feng et al., 2013). Although picornavirus genomes vary in size they are typically 
between 7-9 kb and the genome structure is universally shared. The genomes encode a single 
open reading frame (ORF) with non-translated regions (NTRs or untranslated regions/UTRs) 
that flank the ORF. The ORF is translated into a single large polyprotein and is then matured 
into individual functional proteins by the action of a virus-encoded proteases reviewed in 
Racaniello (2013). The picornavirus genome is packed into an icosahedral capsid with a typical 
size of 30nm diameter and a typical PV electronmicrogram is shown in Figure 1.1B. Sixty 
copies of each viral protein 1 to 4 (VP1 to VP4), arranged as a single unit, the protomer, are 
arranged in an icosahedral lattice. VP1 to VP3 form the mature capsid exterior while the mature 
capsid interior is faced by VP4 (Hogle et al., 1985). PV is one of the most studied picornavirus, 
in fact one of the most studied animal viruses, as a result of the drive to develop poliovirus 
vaccines in the 1950s which enabled efficient poliovirus culture and subsequent molecular 







PV was first recorded as a causative agent of poliomyelitis in 1908 by Landsteiner and Popper 
(1908). The authors demonstrated the transmission of the disease and its pathology by the 
injection of a bacteria-free central nerve system (CNS) homogenate from a child showing acute 
infection into the peritoneum of a rhesus monkey. Studies of the molecular biology and 
biochemistry of PV progressed with the increase in the paralytic cases in 1950s and a notable 
milestone for PV research was the propagation of PV in vitro with the concomitant ability to 
study its replication in human cells (Enders et al., 1949). Large-scale virus growth and 
purification led to PV becoming a model virus in the field of virology with a number of major 
‘first’ studies associated with it. For example, the first animal infectious DNA clone was 
produced from poliovirus RNA (Racaniello & Baltimore, 1981) and the lack of a 5' cap structure 
in its messenger RNA (mRNA) was first found in poliovirus (Hewlett et al., 1976; Nomoto et 
al., 1977a). Amongst these studies, the high-resolution three dimensional structure of PV 
(Hogle et al., 1985) and the proteolytic processing of the precursor protein into the mature viral 
proteins (Summers & Maizel, 1968) are highly relevant to this dissertation. 
Figure 1.1. History of PV 
(A) Egyptian stele showing a king with deformed limb (GPEI, 2016) (B) Electronmicrogram of PV. The virus particle 





Most PV infection remains unapparent and asymptomatic. The transmission of PV is via the 
faecal-oral route. The virus is shed in the faeces of infected individuals, which is then ingested 
from contaminated water or foodstuffs. The initial replication of PV takes place in the pharynx 
and/or gastrointestinal tract (Bodian & Horstmann, 1965; Sabin, 1956). After local viral 
replication, the virus enters into blood stream via the cervical and mesenteric lymph nodes 
causing primary viraemia (Bodian, 1955; Ren & Racaniello, 1992; Wenner & Kamitsuka, 1957). 
At this stage of infection, PV may cause abortive poliomyelitis (4-8% of total PV infection), a 
minor mild illness including fever and gastrointestinal symptoms. The incubation period is 
about 1-3 days, however the illness may take up to 5 days to be apparent. Less frequently, 
aseptic meningitis has been reported. This is a non-paralytic, typical viral meningitis with fever 
and headache and does not involve the CNS parenchyma. The symptoms may last a few days 
to 2 weeks (Pallansch et al., 2013). In 1 in 200 (0.5%) of infection, secondary viraemia occurs 
and leads to a paralytic disease, poliomyelitis by affecting motor neurons. The incubation 
period is about 4-10 days, which is followed by 2-5 days of headache. Then the onset of 
paralysis becomes apparent. The early symptoms indicative of poliomyelitis are sensory 
complaints and shooting or aching pain in muscles, which signals virus growth in the tissue 
(McKinney et al., 1987; Pallansch et al., 2013). Depending on the site of paralysis, the outcome 
of the symptom is different. When paralysis takes place as a result of virus replication in the 
spinal cord, it is called spinal polio. The paralysis severity differs from mild weakness to the 
total loss of use of all four limbs and trunk. In 10-15% of poliomyelitis cases examined the virus 
is found in the brainstem, bulbar polio. In bulbar polio, the cranial nerves or medullary centres 
which control the respiratory and vasomotor systems are destroyed by virus replication. Cranial 
nerves IX and X are most affected. This damage causes pharyngeal and laryngeal muscle 
paralysis, which makes swallowing and talking difficult. Weakness of the face and tongue 
muscles is also caused by cranial nerve damage (cranial nerve VII for face and cranial nerve 
XII for tongue). More seriously, PV replication may affect the brainstem reticular formation 
which is involved in the control of the respiratory system. The autonomic nerve system damage 
may result in irregular sweating, urination, defecation and blood pressure (Pallansch et al., 
2013). Invasion of the central nervous system by poliovirus is an accidental diversion as there 
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is no benefit to the virus in replicating in nervous tissue. The survival of the virus depends on 
viral transmission which in turn requires efficient replication in host gut and shedding in the 
faeces. The neurological infection ends up as a dead-end for the virus as it offers no release 
portal to other hosts for a review see  Blondel et al. (2005). Figure 1.2 summaries the route of 
PV infection to reach the CNS. 
 
1.2.3 Taxonomy 
The picornaviruses are classified as viruses of the Picornavidae family, a name which comes 
from pico (meaning small) – RNA virus. There are many members and they can be pathogens 
of bacteria, animals and plants (Wagner et al., 2008). Within the family, 80 species are classed 
into 35 genera. Well-known and significant pathogens are PV, enterovirus 71/EV71 (genus 
Enterovirus), hepatitis A virus/HAV (Hepatovirus), human rhinovirus/HRV (Enterovirus) and 
foot-and-mouth-disease virus/FMDV (Aphthovirus) (Zell et al., 2017) The genus Aphthovirus 
consists of 4 species including foot-and-mouth disease virus (FMDV) and the target host is 
cloven-footed animals which are infected by FMDV primarily via the upper respiratory tract. 
Figure 1.2. PV infection route to result in poliomyelitis. 
Primary PV replicates in the oropharynx and/or alimentary mucosal surface. If PV enters the blood stream via the 
lymph nodes, primary viraemia may take place. PV travels to the organs and tissues by the blood stream. If PV 
enters the central nerve system via the blood-brain barrier, secondary viraemia may cause poliomyelitis by 
replication in and destruction of motor neurons. Depending on the PV affected area in the CNS, the symptoms vary. 
The figure is from a review by Blondel et al. (2005). 
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FMDV infects over 70 species of mammals and there are 7 identified serotypes, each of which 
are consist of numerous subtypes. The genus Enterovirus consists of 15 species; Rhinoviruses 
(RA-C) and 4 human enteroviruses (EV-A to D) and 8 animal enteroviruses (EV-E to –L) (Zell 
et al., 2017). Within the species, PV and human enteroviruses belong to group EV-C.  
The replication of these viruses takes place in the alimentary tract and the virus survives low 
pH, enabling re-infection via ingestion as reviewed in Blondel et al. (2005). PV has three 
serotypes; type 1, type 2  and type 3 (Bodian et al., 1949). Originally they were classified 
according to their ability to produce immunity after the initial paralytic infection (Bodian, 1949) 
which was shown by virus neutralisation assay (Bodian, 1951). Complete genome sequencing 
revealed that serotype differences are largely characterised by N-terminal amino acid 
sequences in the capsid proteins, which are normally buried in the capsid. However, these 
sites are displayed while the capsid conformation undergoes RNA release. Viral infectivity is 
neutralised if antibodies bind the sequences that are necessary for receptor engagement and 
virus entry into the cell via the poliovirus receptor which has been mapped as CD155, a cell 
surface protein involved in epithelial cell junctions with a wide distribution including on intestinal 
and nervous cells (for review see Racaniello (2013)). The reference virulent strains which are 
used for IPV productions are Mahoney (type 1), MEF-1 (type 2) and Saukett (type 3) (Plotkin 
et al., 1999). OPV strains are produced from the attenuated Sabin strains type 1 (LS-c, 2ab), 
type 2 (P712, Ch, 2ab) and type 3 (Leon 12ab). 
1.2.4 Genome 
The PV genome consists of 7441 nucleotides and includes 3 distinctive picornavirus regions; 
the 5’ UTR which is covalently bound to a viral genome-linked protein, VPg, a single ORF 
which is later translated into a single polyprotein and the 3’ UTR (Dorschhasler et al., 1975; 
Kitamura et al., 1981; Spector & Baltimor.D, 1974). Figure 1.3 illustrates the PV genomic 




This region of the PV genome is extensively studied for its usually long sequence. It has been 
revealed that it contains unique features for RNA replication and translation. The poliovirus 5’ 
UTR consists of 6 domains of RNA secondary structure which play roles in RNA translation 
and synthesis. The 742 nucleotide long RNA sequence and structure are highly conserved 
among the serotypes (Skinner et al., 1989; Toyoda et al., 1984). A cloverleaf structure is one 
of the 5’ UTR functioning feature and is formed by the first 88nt of the RNA and facilitates 
positive-stranded RNA synthesis (Andino et al., 1990). It also functions as a regulator of viral 
translation by masking the initiation codon from the host cell ribosomes that are seeking the 
Figure 1.3. Poliovirus serotype 1 (Mahoney) genome structure and polyprotein cleavages.  
The 5’ non-translated region of the genome contains 6 independent RNA secondary structures which form two 
functional domains; the clover leaf and the internal ribosome entry site (IRES). VPg binds to the 5’end of the NTR 
covalently. The 3’NTR consists of 2 structures and a ~60 nucleotide poly(A) tail. The open reading frame (ORF) is 
cleaved into structural protein, polyprotein 1 (P1) and non-structural proteins (P2 and P3) by virus encoded 
proteinases. The co-translationally encoded proteases, 2Apro and 3Cpro/3CDpro process the polyproteins into 
mature viral proteins. The figure is from the review by De Jesus (2007). 
 26 
AUG (Kozak, 1989). The 5’ UTR is also the site for an internal ribosome entry site (IRES). The 
IRES associates with virus modified host cell ribosomes to initiate polyprotein translation. 
Instead of binding to the canonical 7-methyl guanosine cap structure and then scanning for the 
kozak sequence, the host ribosome binds to 100 to 150nt upstream of the AUG codon (a cis-
acting element) and then scans for the AUG codon to initiate translation (Kuge et al., 1989; 
Pelletier & Sonenberg, 1988). This feature is a major difference between cellular mRNA and 
PV RNA translation which allows the virus to use host-cell shutoff to minimise cellular 
translation and favour that of the virus. The spacer regions between the cloverleaf structure 
and IRES (89-123nt) and from the IRES 3’ end to AUG codon (640-742nt) were found to be 
functional elements as the former region was shown to be involved in RNA replication (Toyoda 
et al., 2007) while RNA translation is partially regulated by the latter (Arita et al., 2004). The 
virus RNA cannot be capped as in place of the cap structure of host cell mRNA, the virus has 
the VPg protein which is a 22 amino acid long virus-encoded protein that covalently binds to 
the 5’ UTR and functions as a primer in RNA synthesis (Lee et al., 1977; Wimmer, 1982). 
3’ UTR 
The 3’UTR is 65nt long and it is highly conserved in polioviruses as well as enteroviruses 
(Toyoda et al., 1984). Its RNA secondary structure is characterised by the presence of 
pseudoknot structures which are required for negative-stranded RNA to be synthesised for 
virus replication (Jacobson et al., 1993). The RNA is terminated by a poly(A) tail which is 
included in the genome rather than post-transitionally added as seen in cellular mRNA poly(A) 
tail (Wagner et al., 2008). 
ORF 
This largest part of the genome is later translated into a single polypeptide, the polyprotein, a 
250 kDa polyprotein sub-divided into polyprotein1 (P1), P2 and P3 (Figure 1.3) and whose 
mechanism of translation is described in section 1.3.2.  
P1 is translated to the viral structural proteins while P2 and P3 are cleaved to form the viral 





translationally cleave the polyprotein into the final individual functional proteins (Pallansch et 
al., 1984). 2A protease cleaves the polyprotein at a tyrosine-glycine dipeptide at the junction 
of P1 and P2 to release the 97 kDa P1 structural precursor protein (Toyoda et al., 1986). This 
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initial proteolytic processing takes place as self-cleavage and is pre-required for P1 cleavage 
(Nicklin et al., 1987). P1 is subsequently cleaved into the viral capsid proteins (VP) 0, VP3 and 
VP1 by the 3C/3CD protease (Hanecak et al., 1982; Ypmawong et al., 1988a). VP0 cleaves 
further into VP4 and VP2 in a viral protease independent event which occurs when the viral 
structural protein matures to the procapsid and incorporates RNA (Harber et al., 1991).  
P2 and P3 are processed into the stable viral proteins; 2A
pro









 catalysis at 
glutamine-glycine dipeptides (Hanecak et al., 1982). The intermediate proteins, 2BC, 3CD and 
3AB have been reported to function in different ways from the final proteins. While 2A protein 
is essential for proteolytic processing of the polyprotein it is also required for RNA replication 
as negative strand synthesis during RNA replication was found to be stimulated by the 
presence of 2A in a cell-free replication system. Although the exact mechanism of 2A 
involvement in RNA synthesis is not known, it is speculated that 2A may influence cellular 
protein function during negative strand RNA synthesis (Jurgens et al., 2006). 2A also 
recognises a tyrosine-glycine cleavage site within the 3D sequence which produces 3C’ and 
3D’ although these are not essential for PV proliferation (Lee & Wimmeri, 1988). The other 
function of 2A is in shut-off of host cell mRNA translation (Hambidge & Sarnow, 1992). The 
small, hydrophobic, membrane-associated protein, 2B is also required for viral replication as a 
mutation in 2B led to a defect in PV RNA synthesis (Johnson & Sarnow, 1991). The 
hydrophobic region of 2B is essential for function and association with membranes where it 
oligomerises to creates a channel, which may result in mature virus release (Agirre et al., 
2002). Highly conserved 2C protein consists of membrane-, RNA- and NTP- binding regions 
(Rodrguez & Carrasco, 1995; Rodríguez & Carrasco, 1993; van Kuppeveld et al., 1997a; van 
Kuppeveld et al., 1997b) and its amino acid sequence is highly homologous with RNA 
helicases which are found in most positive stranded RNA viruses. PV 2C unwinds the 
intermediate double stranded RNA synthesised during RNA replication and guanidine 
hydrochloride (GuHCl) resistance mutations have been mapped to 2C (Pincus et al., 1986) 
consistent with the fact that GuHCl inhibits negative strand synthesis and NTPase activity 
(Pfister & Wimmer, 1999). 2C synthesis disturbs the cellular Golgi apparatus and ER structures 
to form vesicular structures similar to those produced during RNA synthesis (Aldabe & 
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Carrasco, 1995; Cho et al., 1994). 2BC is the precursor protein of 2B and 2C and some 
remains uncleaved during the infection cycle. It seems to have a role in that membrane 
association for virus release is more efficient with 2BC than with 2B only (Aldabe et al., 1996). 
3AB is a precursor for 3A and 3B (Viral Protein genome-linked/VPg) proteins (Semler et al., 
1982) and cleaved by 3CD
pro
 to release VPg and 3A (Lama et al., 1994). VPg is crucial in viral 
replication as it acts as the protein primer for viral RNA synthesis. VPg and 3D
pol 
function is 
mentioned in section 1.3.3. 3CD is a multi-functional precursor protein which cleaves to give 
the PV protease, 3C
pro 
and the RNA-dependent RNA polymerase, 3D
pol
. In spite of the 
presence of 3D, 3CD functions as only a protease. It cleaves P1 into the structural proteins 




 are also cleaved 
by 3C or 3CD (Harris et al., 1992). 3CD also plays an important role in viral RNA replication, 
as it facilitates the recruitment of uridynylated VPg and 3D
pol 
(Paul et al., 1998). The cleavage 
of structural proteins from P1 by 3C/3CD
pro 
is highly relevant to this project as the protease 
choice for recombinant expression systems is one of the key parameters for efficient synthesis 
and details of this will be discussed further in chapter 3.  
Lulla et al. (2019) reported a newly identified protein expressed from an upstream ORF (UP) 
in echovirus 7 and PV1. UP knockout viruses were attenuated indicating the association with 
late stage infection in which membrane bound UP facilitates virus release. The findings 
enabled an understanding of how UP promotes virus growth in the gut and the site of initial 
contact with susceptible hosts. The study may challenge the single-polypeptide genome 
strategy for picornaviruses.  
 
1.3 Replication cycle 
PV replicates efficiently in the host cell cytoplasm where, as any virus, it takes over cellular 
function in favour of virus replication. In brief, PV infection initiates with cell attachment via the 
CD155 receptor (De Sena & Mandel, 1977; Fenwick & Cooper, 1962; Tsang et al., 2001). After 
capsid uncoating and RNA entry into the cell, VPg is removed from the RNA (Ambros & 
Baltimore, 1980) and this molecule acts as the viral mRNA used for RNA translation and 
replication in the host cell cytoplasm. Host cell ribosomes translate the ORF to produce a single 
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polyprotein which is cleaved into capsid proteins (P1) and non-capsid proteins (P2 and P3) by 
virus coded protease, 2A
pro
 (Kräusslich et al., 1988; Lawson & Semler, 1990; Pallansch et al., 
1984). Structural proteins, VP0, VP1 and VP3 are cleaved from P1 and self-assemble into the 
capsid (Holland & Kiehn, 1968; Jacobson & Baltimore, 1968a). Non-capsid proteins are 
required for RNA genome replication in membrane vesicles. VPg accumulates in the 
membrane structures and acts as primer for negative strand production which is then used as 
template for more positive strand RNA synthesis (Barton & Flanegan, 1997). Once a copy of 
the newly synthesised RNA genome is enclosed in the capsid (Nomoto et al., 1977b; Novak & 
Kirkegaard, 1991), maturation takes place wherein VP0 cleavage into VP4 and VP2 takes 
place (Harber et al., 1991). Upon cell lysis, PV particles are released to infect new cells for 




1.3.1 Poliovirus attachment and entry 
The PV infection establishes when the PV particle interacts with the surface poliovirus 
receptor, PVR, aka cluster of differentiation 155 (CD155) of the host cell. CD155 is a 
glycoprotein which belongs to the immunoglobulin (Ig) superfamily (Mendelsohn et al., 1989) 
and consists of extracellular Ig-like domains (D1 to D3), a transmembrane domain and a 
cytoplasmic tail. D1 interacts with PV particles (Koike et al., 1991; Selinka et al., 1991) and at 
Figure 1.4. PV replication in a susceptible cell. 
Each step of replication is illustrated and numbered from virus attachment to exit of the cell. 1) PV particle 
attachment to CD155 2) Internalisation of CD155-PV complex 3) PV RNA release after capsid uncoating 4) RNA 
translation by VPg removed viral mRNA by host cell ribosomes to produce 5) Polyprotein 6) Proteolytic processing 
of polyprotein into capsid protein (P1) and non-capsid proteins (P2 and P3) 7) P2 and P3 derived proteins are used 
for RNA replication 8) VPg free RNA is recruited for membrane vesicle 9) Double stranded RNA production 10) 
Production of more positive strand RNA 11) Nascent RNA can be used for further RNA translation after VPg removal 
12) P1 cleavage into structural viral proteins (VP0, VP3 and VP1) 13) Encapsidation of RNA genome 14) VP0 
cleavage into VP4 and VP2 by capsid maturation, progeny PV virus exit after cell lysis (Flint et al., 2015a). 
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physiological temperature, the PV particle undergoes a conformational change; 160S particle 
to 135S particle (De Sena & Mandel, 1977; Fenwick & Cooper, 1962; Tsang et al., 2001) in 
which the particle becomes expanded by 4% in size and opens holes at the 2-fold and quasi 
3-fold axes. At the same time, the N terminus of VP1 and myristoylated VP4 are externalised 
(Chow et al., 1987; Curry et al., 1996; De Sena & Mandel, 1977; Fenwick & Cooper, 1962; 
Fricks & Hogle, 1990). These bind to the host cell surface membrane resulting in pore channel 
formation (Danthi et al., 2003; Fricks & Hogle, 1990 ; Tosteson et al., 2004; Tuthill et al., 2006). 
At the same time, the expanded particle is internalised into an endosome form of virus 
(Brandenburg et al., 2007) where viral RNA genome transport from the viral capsid to the host 
cell cytoplasm is suspected to occur directly through the channel (Butan et al., 2014). 
CD155 is one determinant for PV permissiveness and in the human, CD155 is expressed in a 
wide range of cells including the usual sites for PV replication (Mendelsohn et al., 1989). 
Transgenic mice engineered to express Hu CD155 are used as an infection model to test anti-
viral responses, e.g. the interferon-α/β (INF α/β) response. When Hu CD155
+
 transgenic mice 
lacking the INF α/β receptor were injected with PV, replication was seen not only in the CNS 
but also in liver, spleen and pancreas whereas in Hu CD155
+
 transgenic mice, PV replicated 
only in the CNS. The expression of IFN-stimulated genes (ISGs) in extraneural tissues was 
significantly enhanced in CD155
+
 transgenic mice but remained moderate in brain and spinal 
cord. These findings suggest that an active IFN response is a factor protecting extraneural 
tissues from PV infection, which agrees well with poliomyelitis prevalence as only 1% of total 
PV infection results in CNS invasion. Evidently, most cases of PV infection must be limited by 
the INF α/β response in non-neural tissue (Ida-Hosonuma et al., 2005).  
CD155 specific binding by PV is part of the virus host range as although PV infects mainly 
humans it can also infect Old World primates (Hsiung et al., 1964) where CD155 
homologs/orthologs are found. However, efficient PV infection is not established in these 
animals. In most mammals the amino acid sequence of the D1 domain at is not compatible 




1.3.2 Viral RNA translation 
Once the viral RNA genome is released into the cytoplasm, host cell enzymes remove the 5’ 
linked VPg (Ambros & Baltimore, 1980) to allow RNA translation resulting in the primary 
250kDa polyprotein cleaved mature proteins (Harris et al., 1992; Kitamura et al., 1981; 
Kräusslich et al., 1988; Lawson & Semler, 1990; Pallansch et al., 1984; Parsley et al., 1999). 
Translation is initiated by ribosome attachment to the internal ribosome entry site (IRES) 
(Nicholson et al., 1991; Pelletier & Sonenberg, 1988) rather than ribosomal scanning for an 
AUG codon for mRNA translation (Kozak, 1989). All picornaviruses utilise an IRES for the 
initiation of translation (Macejak & Sarnow, 1991) with the enteroviruses using a Type I IRES 
structure (Figure 1.5). The RNA secondary structure of the IRES allows 40S ribosome subunit 
recruitment  and subsequent translation from the AUG codon, although the optimal sequence 
of (ACCAUGG) is required for optimal 40S scanning to initiate the polyprotein translation 
(Kozak, 1986).  
 
 
Figure 1.5. A schematic representation of the IRES structure used in enteroviruses 
The nucleotide sequences share little conservation, but the secondary structures are important in the recruitment 
of the ribosome. Once the 40S ribosome subunit is recruited, scanning for the initiation codon occurs and then viral 
genome translation. The figure is from the review by Racaniello (2013) 
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In PV infected cells, host cellular mRNA translation is diverted to viral RNA translation. In 
eukaryotic mRNA translation, translation begins with recruitment of the 40S ribosome subunit 
and eukaryotic initiation factors (eIFs). In cellular mRNA eIF4E associates with the 5’ mRNA 
cap structure and directs the 40S ribosome subunit onto the mRNA. This is followed by 
complex formation with eIF4G, eIF3, eIF4A and eIF4E and scanning in the 5’ to 3’ direction to 
reach a correct initiation codon. Once the 40S ribosome subunit locates the AUG codon, the 
60S ribosome counterpart joins to form an 80S ribosome to commence translation (Hershey & 
Marrick, 2000; Kozak, 1989). This mechanism is hijacked in favour of the virus for its genome 
translation in virus susceptible cells as the IRES recruits the host ribosome to translate the 
viral genome without the requirement for a cap structure at the 5’ end, that is, cap-independent 
translation. In fact PV 2A
pro 
cleaves eIF4G (Hambidge & Sarnow, 1992) effectively inactivating 
host mRNA cap dependent translation whereas IRES enabled translation occurs with cleaved 
eIF4G which still forms a complex with eIF3 and eIF4A. Thus, the cleavage of eIF4G can be 
defined as a switch from host cell mRNA translation to that of the viral RNA and contributes to 
the major host cell shutoff shown by most picornaviruses. Figure 1.6 shows the eIFs required 





Figure 1.6. Schematic representation of 40S ribosome recruitment for the initiation of translation 
(Left) eIF complexes form around mRNA 5’-cap for recruitment of the 40S ribosomal subunit in eukaryotic mRNA 
translation. (Right) IRES led 40S ribosomal subunit recruitment still occurs with cleaved eIF4G and the rest of eIFs. 
PV 2A
pro 
cleaves eIF4G leading to a switch in host cell mRNA translation to the viral RNA. The diagrams were 
adapted from a review by Racaniello (2013). 
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1.3.3 RNA synthesis  
The picornavirus genome is amplified up to 50,000 copies per cell  during RNA synthesis which 
takes place on host cell intracellular membranes termed double-membrane vesicles (Beske et 
al., 2007; Egger et al., 2000; Schlegel et al., 1996). During RNA synthesis, 3 types of RNA are 
present in the infected cell. These are positive sense single stranded RNA, replicative 
intermediate (RI) and replicative form (RF). The most abundant of these are positive sense 
single stranded RNA. Figure 1.7 illustrates PV RNA synthesis. The incoming genome serves 
as the initial template for the synthesis of complementary negative strands leading to a full-
length duplex RNA called the RF. From this intermediate, several positive strands of RNA are 
synthesised either to be translated into more viral proteins or used as template to synthesise 
further negative strand RNA or packaged into virions to be released from the cell (Barton & 




Figure 1.7. PV RNA synthesis 
Negative strand synthesis initiation using the positive strand 
as a template. Once full-length negative strand is produced, 
those two strand forms duplex RNA strand (RF). The 
negative strand serves to produce multiple nascent positive 
strands. The black circle indicates the RNA-dependent RNA 
polymerase, 3D
pol





The enzyme responsible for RNA synthesis is the RNA-dependent RNA polymerase (RdRp), 
3D
pol
. This 63 kDa protein is a cleaved product from 3CD
pro
, which functions as a protease. 
The polymerase requires a poly(U) primer to elongate from the 3’ end poly(A) template and 
this is provided by uridylylated VPg (Paul et al., 1998). 
1.3.4 Encapsidation of viral RNA 
Once sufficient PV capsids are assembled and RNA synthesised, one copy of the newly 
synthesised positive-stranded RNA is packaged into the capsid for progeny virus release 
(Nomoto et al., 1977b; Novak & Kirkegaard, 1991). The exact mechanism of viral genome 
encapsidation is unknown. An early study suggested that VPg acted as a single protein marker 
which leads the RNA into the viral particle (Nomoto et al., 1977b). However, it is now known 
that the negative strand is also bound with VPg protein, yet no negative strand RNA exists in 
progeny viral particles so this mechanism is incorrect. Later study suggested encapsidation is 
controlled by multiple viral proteins including 2C
ATPase 
and VP3 which lead to RNA incorporation 
while the viral capsid is assembling. In this model, when 5 protomers form a pentamer, mature 
VPg linked positive stranded RNA attaches to it and assembly continues into the provirion 
which contains the RNA in the interior of the capsid (Liu et al., 2010). This is followed by 
maturation of the provirion into the infectious virion by VP0 cleavage into VP2 and VP4 (Harber 
et al., 1991). The detail of PV capsid assembly and structure is discussed in section 1.4. 
1.3.5 Exit of the viral particles 
Once viral particles are assembled and the genome packaged, PV undergoes extracellular 
release. PV infected cells start to show cytopathic effects such as condensation of chromatin 
and shrinkage of the entire cells and it is widely accepted that viral particle release is by final 
lysis of the host cells. Leakage from the lysosome of the host cell has been suggested to 
induce cell lysis (Guskey et al., 1970). At the same time however, non-lytic release has been 
observed without cell lysis in cultured cells (Taylor et al., 2009) and PV particles are found in 
lysed cells as well as in the media surrounding intact infected cells (Lloyd & Bovee, 1993; 
Pelletier et al., 1998). CPE is rapid and after only 3-4 hours of PV infection host cell internal 
membranes are rearranged into double-membraned vesicle (Dales et al., 1965). These 
vesicles share characteristics with cellular autophagosomes which are responsible for the 
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regulated self-destruction of unnecessary cellular components (Klionsky, 2005; Mizushima et 
al., 2002). The proteomes of PV-induced vesicles and cellular autophagosomes has shown 
that the autophagy proteins LC3 and Atg12 are reduced in PV-induced vesicles indicating that 
PV compromises the cellular autophagy pathway possibly for non-lytic release (Jackson et al., 
2005).  
  
1.4 PV capsid 
The poliovirus icosahedral capsid is composed of 60 copies each of 4 viral capsid proteins, 
VP1 (~33 kDa), VP2 (~30 kDa), VP3 (~26 kDa) and VP4 (~7.5 kDa). The capsid structure is 
conserved within all picornaviruses, albeit with slightly different capsid sizes. The capsid 
serves to protect the RNA genome from the environment and in consequence, requires a rigid 
structure. However, the structure is also required to be ready to release the RNA once it 
attaches to the receptor on a permissive cell. Therefore, the capsid is a metastable structure.  
1.4.1 Capsid assembly 
PV capsid assembly undergoes sequential steps involving intermediates identified by their 
antigenicity and sedimentation coefficient on sucrose gradients. This is illustrated in Figure 1.9. 
The process requires considerable specificity and coordination among the viral proteins. The 
assembly of the PV capsid initiates with the proteolytic processing of P1 and the production of 
the protomer which sediments at 5S and contains 1 copy of each VP0, VP3 and VP1. The 
protomer matures into a pentamer consisting of 5 copies each of VP0, VP3 and VP1, 
sedimenting at 14S (Phillips & Fennell, 1973; Watanabe et al., 1965). Pentamer stabilisation 
is maintained by protein-protein contacts as well as clustering of the myristate chain present 
at the N terminus of VP4 at the five-fold axis (Figure 1.8). Myristoylation thus provides a factor 
of PV capsid stability and assembly  (Marc et al., 1990; Moscufo et al., 1991). The gathering 
of 12 pentamers forms the empty capsid which sediments at 80S (Jacobson & Baltimore, 
1968b). This capsid has not yet gained PV RNA but does so when it finally assembles into the 
160S mature capsid (Jacobson & Baltimore, 1968a). The interchange among the 14S 
pentamer, 80S procapsid and 160S mature capsids is dynamic and the precise point at which 
RNA is incorporated remains unclear. However, cleavage of VP0 into VP4 and VP2 is 
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speculated to occur concomitant with encapsidation of the viral genome. The mature capsid 
shows elevated stability compared to the empty capsid suggesting that VP0 cleavage is 
another part of the requirement to produce a stable particle (Guttman & Baltimore, 1977). 
 
 
1.4.2 Capsid proteins 
X-ray crystallography enabled the determination of the PV structure. VP1, VP2 and VP3 were 
shown to be constructed with a common ‘core’ architecture consisting of an eight-stranded β-
barrel connected by 2 loops and flanked by C- and N- terminal extensions, termed a “β-barrel 
jelly-roll”. Figure 1.10 illustrates the b) VP1, c) VP2 and d) VP3 structures while a) represents 
the core structure arranged in a wedge-like structure. One wall of the wedge is made of 
antiparallel β sheets consisting of C, H, E, F β-strands. The other wall and floor is occupied by 
the other β sheets (B, I, D, G β-strands) which bend at the wall-floor junction. The difference 
in sequences of the β-strand connecting loops and the N- and C- terminal extensions gives 
VP1, VP2 and VP3 their conformational distinction. By contrast VP4 has a distinctive structure 
with its extended conformation resembling the N-termini of VP1 and VP3 (Hogle et al., 1985). 
Figure 1.8. Myristate position in the capsid 
At the 5 fold axis, five N termini of VP3 assemble into a parallel β sheet structure which interacts with another β 
sheet structure produced by VP4 and VP1 via the myristate group. Myristoylation is a post-translation addition to 
VP4. Until proteolytic processing of VP0 into VP4 and VP2 completes, the internal structure is not fully assembled. 
The figure is from Flint et al. (2015b) 
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Figure 1.9. PV capsid assembly and sedimentation coefficient on sucrose gradient 
The series of 4 images at the top of page illustrates the polyprotein precursor translation by ribosomes through to 
assembly of 5S protomer consisting of VP1, VP2 and VP0. 5 of protomers self-assemble into pentamers, 14S, and 
12 pentamers may form the empty capsid of 80S. Encapsidation of RNA turns the empty capsid into a provirion, 
150S and VP0 cleavage into VP4 and VP2 completes the maturation and produces the virion, 160S. The figures 
are modified from a review by Racaniello (2013). 
 
 







1.4.3 External capsid surface 
The external surface of the capsid is constructed by a network of VP1, VP2 and VP2 C-termini 
and loops connecting the β-sheets. These are arranged into surface features which include a 
star-shaped structure called the “mesa” seen at the 5-fold axes and a 3-bladed “propeller”-
shaped structure at the 3-fold axes (Figure 1.11a). The features are isolated by a groove 
surrounding the mesa and a depression separating the 3-fold axes structures and 2-fold axes 
(Hogle et al., 1985). A key feature called the “canyon” is formed by the joining of the groove 
Figure 1.10. Poliovirus capsid protein schematic representation 
(a) The ‘core’ structure of the viral capsid proteins arranged in an eight-stranded wedged-shape antiparallel β barrel. 
The β strands are given letters B to I (in N to C terminus order). Four (B, I, D and G) strands forms a β-sheet in the 
front of structure. The back of the structure consists of the C,H,E and F β-sheet. The loops connecting these two 
sheets are denoted by the strands which is the loop connects (i.e. GH loop). The structurally conserved α-helices 
are represented by cylinders. (b) VP1, (c) VP2 and (d) VP3 share a ‘core’ structure with different loop length and C 
and N termini. The long loop end of the VP1 is arranged into a 5 fold axes. The end of VP2 and the VP3 β-barrel 
are packed on the 3-fold axes. The figures are from Hogle et al. (1985). 
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around the mesa. This is the site for receptor attachment, its recessed nature shielding it from 
the generation of neutralising antibodies (Belnap et al., 2000; He et al., 2000; Xing et al., 2000).  
The external surface of the capsid presents the major neutralising antigenic sites. For PV, 
these sites are located in VP1, VP2 and VP3 regions of the sequence (Minor et al., 1986). As 
conformational change occurs as the PV capsid undergoes particle attachment to the receptor, 
those sites are exposed and neutralising antibody can bind them. 
1.4.4 Internal capsid surface 
The internal surface of the capsid is decorated with the N-terminal extensions of VP2, VP3 and 
VP1 and with VP4. Protein-protein interactions function to stabilise the capsid (Figure 1.11b) 
and include a plug for a channel consisting of 5 copies of VP3, found on the inner side of the 
5-fold axes. The plug is formed by 5 copies of the intertwisted N-termini of VP3, called a twisted 
parallel β-tube. The structure is surrounded by 5 copies of a 3-stranded β sheet formed by the 
myristoylated VP4 N-termini and residues from the VP1 N-terminus (Figure 1.11c). The 
structure stabilises the structure as it is maturing from protomer to pentamer (Hogle et al., 
1985). The other internal shell feature is a 7-stranded β-sheet formed by a 2-stranded β hairpin 
from the N-terminus of VP2 sandwiched by a 4-stranded CHEF sheet (C, H, E and F β-sheet 
as seen in Figure 1.10) of VP3 and a peptide from the N-terminus of VP1, both of which are 
from the neighbouring pentamer. The structure cements neighbouring pentamers together to 
achieve stabilisation of the overall PV icosahedral structure (Figure 1.11d) (Filman et al., 
1989). 
The interior of the capsid is partially filled with a 1500 nucleotide long RNA which may also 
contribute to capsid stability. CAV20 and PV chimeric virus particle showed an interaction 
among 2C and VP3 (Liu et al., 2010) and VP1 (Wang et al., 2012a) suggesting a contribution 
to capsid assembly and encapsidation of newly synthesised RNA.  
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1.4.5 VP1 hydrophobic pocket 
Many picornavirus capsids have a hydrophobic space in the core of VP1, beneath the canyon 
as indicated in Figure 1.12A, the cleft revealed by atomic structures where the receptor, CD155 
in the case of poliovirus, binds. This space is termed the hydrophobic pocket and there are a 
total of 60 pockets as indicated in yellow in Figure 1.12B in an assembled picornavirus capsid, 
corresponding to the number of VP1 proteins. In the available atomic structures for most 
enteroviruses these pockets are found to contain lipids derived from the host cell called 'pocket 
factors' (Filman et al., 1989). The pocket factor is not a unique molecule as analysis of bovine 
enterovirus virions has shown mixed types of lipids, although palmitic acid and myristic acid 
represent the majority (Smyth et al., 2003). In poliovirus type 1 and type 3, the pocket is filled 
with sphingosine. Those fatty acids being determined from the electron density features of the 
Figure 1.11. The PV capsid features 
(a) The radical-depth cued model of poliovirus capsid (Right). The numbers indicate the locations of the icosahedral 
axes. The ribbon presentation shows a protomer (Left). The viral capsid proteins are colour coded; blue for VP1, 
yellow for VP2, red for VP3 and green for VP4. (b) The inner shell network of poliovirus depicted by VP4 and N-
termini of VP1, VP2 and VP3 (c) The ‘plug’ structure at the 5-fold axes is formed by the N-terminal peptides of VP3, 
VP4 and VP1 (d) The sandwich structure consist of 2 neighbouring pentamers. The upper 4 strands from the CHEF 
sheet of VP3 sits on the neighbouring α-hairpin of VP2. The VP1 strand sites in the bottom of the complex. Modified 
from Levy et al. (2010). 
d c b 
a 
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crystallographic study (Filman et al., 1989). During receptor binding in the canyon, a 
depression of the canyon floor results in deformation of the PV1 pocket and ejection of the 
pocket factor. In consequence, the capsid conformation changes and uncoating occurs, 
leading ultimately to the release of the RNA genome into a new cell. However, this 
conformational change is prevented when hydrophobic antiviral drugs such as WIN 
compounds, shown in Figure 1.12C and discussed in detail in 1.6.1, are present in the pocket 
as they are designed to bind tightly, lock the cavity and counteract canyon depression which 
then prevents virus entry by inhibiting the capsid conformation changes that occur after 
receptor binding (Grant et al., 1994; Muckelbauer et al., 1995; Rossmann, 1994; Smith et al., 
1986). This is the functional basis of their antiviral activity. When a pocket factor is dislodged, 
capsid destabilisation leads to the externalisation of the N termini of VP4 and VP1. These 
orchestrate genome release across the 2-fold axis and into the host cell most likely via a pore 
formed from VP4 (Tuthill et al., 2006). Thus, in viral capsid uncoating, the pocket factor plays 
a role as a picornavirus infection initiation switch (Plevka et al., 2013) and it follows that this 
switch might be fixed in an off conformation, pocket locked, by manipulating the VP1 cavity 
and so act to control virion thermal stability (Filman et al., 1989; Macadam et al., 1989). 
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1.5 PV infection control 
PV infection was rare until the 20
th
 century. At that time PV was in general circulation and 
infants encountered it within 6-12 month of age when they were still under maternal antibody 
protection. This resulted in mild infections and PV immunity development. Following the 




Figure 1.12. Images for VP1 pocket in PV 
(A) A sketch of the picornavirus icosahedral capsid with canyon at the 5-fold axes. The hydrophobic pocket location 
in the canyon is illustrated, as is a cross section of the hydrophobic pocket with WIN compound (Oliveira et al., 
1993). (B) A radial depth-cued representation of poliovirus with a pocket binding WIN compound (R78206) indicated 
in yellow. The imaging method demonstrates dimensional depth by colouring the atoms closer to the core of PV 
particle with a deeper blue colour. White/pale blue colour indicates that the atoms are projecting away from the 
capsid. (C) A cross section of a pocket with pocket compound (WIN52084) bound. The original lipid in the pocket 
was replaced by this compound which inhibits infectivity. The image shows residues facing into the pocket. Although 
mostly from VP1, one residue of VP3 also contributes to the structure. The images B and C were from the review 
by Racaniello (2013). 
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improved. This delayed the first PV contact with infants. These unprotected infants then 
became susceptible to PV infection (Nathanson & Kew, 2010) and the increase in PV naïve 
infants led to poliomyelitis epidemics (Centers for Disease Control and Prevention, 2012). The 
growing number of poliomyelitis cases led the development of PV vaccines which are currently 
still used world-wide. The early success of those vaccines led to the WHO campaign for WT 
PV eradication and while that has been very effective, vaccine revertant poliomyelitis has 
become prominent as the total number of cases dropped. In the case of a wholly PV naïve 
population, an endemic outbreak would be predicted and because of this possibility, an 
infection management plan is necessary for the post-eradication future even though WT PV 
eradication has not been achieved yet for all serotypes.  
1.5.1 Current vaccines 
Jonas Salk produced inactivated PV vaccine (IPV) and its introduction achieved a reduction in 
paralytic poliomyelitis cases from 13.9 cases in 100,000 in 1954 to 0.5 cases in 100,000 in 
1961 (Centers for Disease Control and Prevention, 2012). Virulent WT PV, inactivated by 
formalin, is administrated by intramuscular injection (Salk, 1960). In 1961, live attenuated oral 
PV vaccine (OPV) was proven to be effective by Albert Sabin and the current OPV is named 
Sabin after the inventor. Monovalent OPVs were licensed prior to trivalent OPV which was 
licensed in 1963. Since then, OPV has replaced IPV because of the ease of administration 
(the droplet alone or on a sugar cube), the induction of mucosal immunity and the public health 
benefit of some live vaccine virus spreading from immunised to non-immunised individuals 
(Sabin, 1985). Sufficient OPV replication in the alimentary tract imitates natural PV infection 
which elicits neutralising antibodies, serum antibodies and secretory immunoglobulin A (IgA), 
resulting in the induction of local intestinal mucosal immunity and terminating PV shedding in 
healthy individuals (Ghendon & Robertson, 1994; Hird & Grassly, 2012; Ogra  et al., 1968; 
Valtanen et al., 2000). The spread of the attenuated virus among close contacts of the 
vaccinated individuals resulted in prevention of WT PV transmission which normally takes a 
faecal-oral route of infection (Nomoto & Arita, 2002). These benefits of OPV were considered 
to be sufficient advantage to tolerate a low level of vaccine-associated paralytic poliomyelitis 
(VAPP) which is caused by a low level of reversion of the vaccine virus at the peak of the 
epidemic. VAPP cases occur at 1 every 2 to 3 million doses of OPV. However, from 1980 to 
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1999, this revertant infection became responsible for 95% of the paralytic poliomyelitis cases 
in the United States as wild-type circulating PV infection declined. Further studies showed 
recombination between PV serotypes (Romanova et al., 1980; Tolskaya et al., 1983) and 3 
Sabin vaccine strains in vaccine recipients (Cammack et al., 1988; Cherkasova et al., 2005). 
These data confirmed the evolution of OPV into circulating vaccine-derived poliovirus (cVDPV) 
and after the last case of WT PV poliomyelitis in the United States in the 1970s, VAPP could 
no longer be overlooked, regardless of the low number of cases it produced. Soon after, an 
‘enhanced-potency’ IPV was shown to be effective to induce comparable immunity to OPV and 
the occurrence of VAPP and the availability of the new IPV influenced the OPV administration 
policy in the United States and led to the exclusive use of the improved IPV immunisation from 
2000. The switch from OPV and IPV has also been seen in most western countries (Centers 
for Disease Control and Prevention, 2012). Although improved IPV appears to be a superior 
vaccine to OPV, IPV has to be noted for differences from OPV; the cost is relatively high when 
compared to OPV and there is a requirement for healthcare professional training for 
intramuscular injection (Ehrenfeld et al., 2009). In addition, levels of protective immunity are 
remarkably distinctive. In contrast to OPV intestinal mucosal immunity, IPV induces only serum 
antibodies rather than secretory IgA (Ogra  et al., 1968) which translates to only limited 
resistance to PV infection in the intestine (Henry et al., 1966). In addition, as IPV is effective 
only for IPV-vaccinated individuals, the community herd immunity required to be maintained to 
achieve prevention of PV transmission via the faecal-oral route is lost (Nomoto & Arita, 2002). 
In 2015, WT type 2 PV eradication was announced and trivalent OPV was switched to divalent 
OPV by the removal of type 2 OPV. The type 2 OPV component has been estimated to be 
responsible for up to 38% of VAPP so the use of type 1 and type 3 divalent OPV is not only 
part of the trajectory for OPV withdraw but should also lead to a cessation of VAPP caused by 
type 2 OPV (The Global Polio Eradication Intiative, 2015). 
1.5.2 PV eradication and its difficulties 
The effective administration of OPV led to the end of WT PV transmission in 1979 in the United 
States. The global eradication of smallpox accelerated the idea of the global eradication of a 
major human disease and in 1988 the World Health Organisation (WHO) announced the 
Global Polio Eradication Initiative (GPEI) aiming at global WT PV eradication by 2000. It is 
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proposed that breaking WT PV transmission will be necessary to achieve this goal. In the 
United States, in 1960s, national immunisation days were launched to immunise children under 
5 with OPV whether or not they had been previously immunised. This strategy was successful 
and eliminated PV from susceptible populations and reduced WT PV circulation and the same 
strategy was applied to the global eradication project. OPV was chosen as the means of 
vaccination because of its immune response and the ease of administration. A great reduction 
in poliomyelitis cases was seen immediately after the start of project. However, ~1000 cases 
of WT PV infection per annum in the world were still reported by the time the project limit had 
reached 2000 (Ehrenfeld et al., 2009). Since then a low number of WT PV derived cases have 
been regularly reported meaning that the disease is still not eradicated (i.e. less than 100 cases 
since 2015) (WHO, 2017). If WT PV eradication is successful, complete poliomyelitis 
eradication will be the ultimate goal and in order to achieve it, a number of factors must be 
considered that prevent eradication. There have been outbreaks of paralytic poliomyelitis 
associated with VDPV in Haiti and the Dominican Republic and the responsible virus was found 
to be a recombinant between type 1 OPV and an unidentified enterovirus. This outbreak 
indicated that VDPV had the ability to transmit (Kew et al., 2002). Another outbreak in northern 
Nigeria in 2006 was caused by a revertant of type 2 OPV. In the area concerned, there was a 
year without PV immunisation which increased the population of PV naïve individuals. The 
reintroduction of immunisation then caused a rapid spread of the vaccine virus which allowed 
it to evolve to be a pathogenic VDPV (Adu et al., 2007; CDC, 2007).  Thus, when herd immunity 
declines, there is a tendency of the vaccine virus to evolve towards VDPV which suggests that 
vaccination has to be continued at a high level for some years after eradication. In addition, 
there is a chronic environmental source of VDPV. Individuals, normally with B cell deficiency, 
can be chronically infected with the vaccine virus resulting in constant shedding of progeny 
VDPV years after OPV immunisation. The virus evolves by acquiring mutations to be a more 
virulent VDPV within the host (Blomqvist et al., 2004; Shulman et al., 2006) and demonstrates 
that the use of OPV cannot ever achieve the ultimate goal of poliomyelitis eradication. 
Inadequate immunisation coverage is another factor delaying the eradication. Most areas 
which remain endemic are regions of military conflict where health workers cannot easily reach 
the target population. Alternatively, they are regions with political or cultural disbelief in vaccine 
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safety or general resistance against large health campaigns. These obstacles demonstrate the 
limitations to the poliomyelitis eradication campaign and question the current strategy by WHO 
to cease OPV vaccination 3 years after the last case of poliomyelitis. The rational for this plan 
is to prevent VAPP and OPV evolution to a more virulent VDPV. However, OPV termination 
leaves a PV susceptible population (Ehrenfeld et al., 2009) and these findings suggest the 
necessity to sustainably protect the entire population and, in turn, the need for a new 
generation of vaccines.  
1.5.3 Post-PV eradication world and vaccination 
Although OPV has contributed to the eradication of WT PV, OPV vaccine is the source for 
VAPP cases and circulating VDPV which may result in outbreaks as noted in 1.5.2. After WT 
PV eradication, the protection benefit of OPV becomes less than the risk of poliomyelitis cases. 
It is therefore inevitable that OPV is discontinued to achieve the eradication of poliomyelitis 
(Dowdle et al., 2003). A computer model of PV introduction into a PV naïve population has 
suggested that a PV outbreak is unavoidable (Thompson et al., 2008). Historically, the 
population immunity to PV was high due to the circulation of wild strains which enabled children 
to develop immunity (in the pre-industrialisation era) or via effective vaccination schemes. But 
the cessation of immunisation in isolated communities followed by outbreaks of usual severity 
has shown what would happen following PV re-introduction to an immunologically susceptible 
population, such as after eradication (Adu et al., 2007; CDC, 2007; Ehrenfeld et al., 2009). It 
is an unfortunate but foreseeable fact too that accidental PV release from research or vaccine 
production establishments or intentional release of virulent PV as a bioterrorism weapon could 
have severe consequences in low herd immunity populations (Collett et al., 2008; Nomoto & 
Arita, 2002).  
In order to maintain a polio-free world, the whole population has to be protected continuously 
and this could be achieved by indefinite PV immunisation with a suitable vaccine that did not 
suffer from the accepted limitations of IPV and OPV. A number of new PV immunisation 
strategies have been proposed for a polio-free world including use of the enhanced-potency 
IPV as in the shift from OPV to IPV in high income countries. However, a world-wide switch to 
IPV is prevented by difficulties such as the production cost, the administration route and the 
production size required to meet global demand. In addition, IPV vaccines are formulated using 
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virulent viruses which poses PV containment and safety issues for the manufacturing facilities 
(Ehrenfeld et al., 2009). It is debatable whether WT PV could be considered as truly eradicated 
while a vaccine was produced using WT PV (Chumakov & Ehrenfeld, 2008). Other IPV 
improvement approaches have been also investigated. IPV production from OPV/Sabin strain 
is one such approach as this is proposed to be safer as the current OPV vaccine viruses will 
be used for the inactivation. Another approach has investigated the production of IPV derived 
from a stable attenuated PV strain but with the virulent IPV reference strain capsid (Ehrenfeld 
et al., 2009). This new IPV is expected to achieve a lower cost than current IPV, avoid virulent 
PV release but to have equal or enhanced immunogenicity (Ehrenfeld et al., 2009). As the 
biosecurity of production is less, the cost should be lowered which could result in being able 
to supply the vaccine demand for the world. However, as discussed, as it is IPV mucosal 
immunity will not be induced and the production methods still relate to the earlier debate by 
Chumakov and Ehrenfeld (2008) on whether PV could be considered as truly eradicated while 
producing a vaccine using replicating PV. For the post-eradication world, ideally antigens 
would be produced without any PV live culture and this could be offered by recombinant 
vaccines technologies which approaches immunogen production from a different angle. 
 
1.6 Thermal stability 
Further to current vaccine issues related to VAPP for OPV and IPV inability to induce intestinal 
mucosal immunity, which does not contribute to the herd immunity, as well as bio security 
concerns for the production of vaccines involving live PV culture both vaccines exhibit an 
instability which is one of the worst amongst common childhood vaccines. It is essential for the 
vaccines to be transported in a temperature controlled environment. However, this cold-chain 
requirement is not always easy for logistical and economic reasons (Pipkin & Minor, 1998; 
WHO, 2006).  
The PV immunogenicity loss is caused by heating and was originally observed by antigen 
complement fixation assays (Hummeler & Hamparian, 1958; Mayer et al., 1957) where, on 
heating, immunogenic antigen is converted to non-immunogenic antigen. Hummeler and 
Hamparian (1958) called the immunogenic antigen N (Native) antigen and the non-
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immunogenic antigen H (Heated). Conversely, Mayer et al. (1957) labelled the immunogenic 
antigen as D and the non-immunogenic antigen C based on their sedimentation position in 
gradients; fractions from a sucrose gradient were collected from the top of the tube and named 
A, B and so on. The authors showed that C antigen reacts with acute human sera while 
convalescent sera reacted with D antigen. In addition, C antigenic particles were found to have 
lost their RNA when the capsid conformation changed from the D antigenic form (Breindl, 
1971).  
The addition of compounds isolated as antipicornaviral drugs, such as the oxazolinyl 
isoxazoles (the so-called WIN compounds) developed by Sterling-Winthrop Inc, (McSharry et 
al., 1979) and the pyridazinamines, developed by Janssen (Andries et al., 1992) were shown 
to maintain capsid conformation and improve stability, preventing capsid denaturation or 
conformation change on heating.  
While the thermostability is an issue for PV vaccines, PV shed from infants who had received 
OPV indicated that PV could overcome this sensitivity which was later found to be due to an 
acquired point mutation in the case of PV3 virus (Minor, 2012). Additional mutations were also 
identified to supress the temperature sensitivity by culturing Sabin type 3 vaccine at elevated 
temperature. This method of identifying mutation was then applied to find thermal stabilising 
mutations for each serotype. PV empty capsids, formed by infection of such viruses in the 
presence of guanidine chloride showed that improved stability was retained, as was  
immunogenicity (Fox et al., 2017). With this rational, current vaccine issues discussed in 1.5 
may be resolvable as it is clear that WT empty capsids are unstable and change their 
conformation to the H form readily (Basavappa et al., 1994). Thermostable mutations in PV1 
virus were selected similarly and a number of mutations, located mostly at intersubunit 
interfaces, were identified and these viruses produced N conformation thermostable empty 
capsids (Adeyemi et al., 2017) which could be applied for VLP production.  
From the mutations identified by the studies of Fox et al. (2017) and Adeyemi et al. (2017) 
subunit interfaces seem to contribute to the thermostability of empty capsids. These regions 
are also closely associated with capsid conformation change during uncoating as shown by 
resolving 135S (Butan et al., 2014) and 80S (Levy et al., 2010) structures.  
 50 
In the following chapters, some of the thermostabilising methods such as VP1 pocket 
manipulation by pocket factor binding or pocket filling mutations, introduction of 
thermostabilising mutations and the potential contribution of capsid uncoating are investigated 
to attempt to produce a high level of N conformation VLPs. 
1.6.1 Antipicornavirus compounds 
Small molecules such as antiviral ‘WIN’ compounds that inhibit the viral capsid conformational 
change bind the pocket and regulate viral infection (Rossmann, 1994). When these 
compounds bind to the PV pocket, the natural pocket factors are replaced and capsid 
conformational change is limited to a minimum (Smith et al., 1986). The precise effects of the 
compounds differ in individual viruses. In HRV14, the binding of these compounds induces a 
capsid conformational change so that the virus particle fails to attach to the receptor (Pevear 
et al., 1989). In PV, the WIN compounds showed inhibition of capsid uncoating but not the 
attachment to the host receptor (Rossmann, 1994). The relationship between the residues that 
line the pocket and the action of pocket factors has been demonstrated by PV mutants which 
are dependent on the WIN compounds for viral replication. Without the WIN compound these 
mutants were of the H conformation at 37 °C and missing VP4 (Mosser & Rueckert, 1993) 
which can now be interpreted as the result of externalisation of VP4 during capsid uncoating 
and the conformation change from 135S to 80S (Butan et al., 2014). Thus, pocket factors are 
integral to capsid stability and polioviruses with these compounds are more stable.  
1.6.2 Thermostable PV mutants 
The successful identification of thermostable mutations in the Sabin type 3 vaccine strain 
showed VP3 residue 91 changed to phenylalanine from serine (Minor, 2012). The mutation is 
at the interface of the protomers (Filman et al., 1989) explaining how it contributes to the 
temperature sensitivity of virus growth and capsid assembly (Macadam et al., 1991).  
Similar mutations could improve empty PV capsids, enabling robust production in foreign 
expression systems. For thermostable Saukett empty capsids, mutations identified in Sabin 
type 3 were introduced into strains Leon and Saukett resulting in 8 amino acid changes from 
IPV Saukett which is now called Saukett SC8 (Fox et al., 2017). When this sequence was used 
for plant expression studies, one of the candidate foreign expression platforms used for VLP 
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assembly, both wt Saukett and Saukett SC8 VLPs were purified and visualised under TEM but 
those of Saukett SC8 were better formed. Antigenicity analysis showed that the SC8 VLPs had 
an N conformation and its ability to produce protective immunity was confirmed by transgenic 
mice immunisation and challenge with Saukett virus (Marsian et al., 2017). The study indicated 
that a combination of thermostability engineering and foreign expression could produce PV 
VLP that were a potential candidate vaccine. 
Mahoney thermostabilising mutations were also identified by Fox et al. (2017) and Mahoney 
SC6b (Fox et al. unpublished data) was found to be most thermostable mutant to produce 
empty capsid rather than Mahoney SC7 described in Fox et al. (2017). Table 1.1 shows the 
list of mutations introduced in the thermostable mutants. The study was running concurrently 
to our project as a part of consortium. Therefore, thermostable mutants became available in 
the middle of project and were adopted at that time, as noted in the following chapters.  
 
Table 1.1. List of mutants for thermostable Saukett SC8 (Fox et al., 2017) and Mahoney SC6b (Fox et al. 
unpublished data) 










1.6.3 Capsid stabilising region 
Studies of 135S (Butan et al., 2014) and 80S (Levy et al., 2010) suggested a capsid uncoating 
mechanism which involves dynamic change in the structure. Figure 1.13 shows the suggested 
conformation change on one protomer. When the mature PV capsid is altered to the 135S 
capsid, the N-terminus of VP1 associates with a hole at the 2-fold axis produced by capsid 
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rearrangement and a further change produces another bigger hole at the quasi-3-fold axis. 
The N-terminus moves to the bigger hole, promoted by capsid change and later it is 
externalised to bind to the tip of VP2 propeller, a feature on the capsid surface which occurs 
at the junction of two protomers. VP4 is also involved in the uncoating reaction by translocating 
from the inner surface of the capsid, where it may help mature virion stability (Hogle et al., 
1985), to the outer surface. The N-terminus of VP4 is known to be myristoylated which is 
believed to be essential for protomer association and pentamer formation (Ansardi et al., 
1992). The formation of an EV71 80S-like VLP without VP4 and its potency as a vaccine (Wang 
et al., 2018) has since cast doubt of the contribution of VP4 to VLP assembly, it may simply be 




1.7 Recombinant VLP vaccines 
Recombinant vaccines are a type of vaccine produced by combining recombinant DNA 
technology with foreign gene expression systems. The target viral gene is transferred into non-
pathogenic viruses, bacteria, yeasts, insect cells, plant cells or mammalian cells to express the 
immunogenic protein(s) as reviewed in Flint et al. (2015c). Recombinant virus-like-particle 
(VLP) vaccines are one of the recombinant vaccine production approaches as the capsid 
Figure 1.13. Hypothetical mechanism of capsid (protomer) rearrangement during the uncoating process. A protomer 
is colour coded for each viral protein, VP1 (blue), VP3 (red) and VP2 (yellow).  
(A) 160S mature capsid before the uncoating. The rigid structure is provided by the C terminus and GH loop of VP1 
(Navy line) binding in the VP2 propeller structure proximity. The quasi-3-fold hole is filled with coiled VP3 GH loop 
(red line). N terminus of VP1 (light blue line) stays beneath the inner capsid across VP1 to VP3. (B) The expanded 
virion during breathing of PV capsid. The N terminus of VP1 is externalised through a newly formed 2-fold hole. (C) 
VP1 extension moves to quasi-3-fold hole from the 2-fold hole. (D) GH loop of VP3 changes to form hairpin structure 
which results in opening of the quasi-3-fold hole and prepares the binding site for the externalised VP1 to bind. At 
this point, VP4 is already lost while RNA is still present in the capsid. (E) The C terminus and GH loop of VP1 (Navy) 
become disordered. (F) The N terminus of VP1 extends from the tip of the VP2 propeller structure. (G) The extended 
N terminus of VP1 reaches to the host membrane, the beginning of a virus-host connection. (H) After complete or 
partial loss of RNA, 135S turns into an 80S expanded empty capsid with the quasi-3-hole and 2-fold hole. The N 
terminus of VP1 returns to the inside of the capsid (Garriga et al., 2012; Lin et al., 2011; Wang et al., 2012b). The 
C terminus and GH loop of VP1 remain disordered for PV. The figure is from Butan et al. (2014).  
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proteins of non-enveloped and some enveloped viruses assemble to a capsid structure on 
their own as long as they are producing in sufficient quantity. The assembled capsid structure 
is identical or near identical to native virus particles so conformational epitopes are maintained 
to induce neutralising antibodies and a protective immune response. The obvious difference 
in viral particles and VLPs is the content of the capsids. VLPs contain no viral genetic material 
so are non-infectious, and do not need inactivation (Chackerian, 2007). This is another 
advantage of VLPs because chemical inactivation can contribute to conformational epitope 
change and if this occurs vaccine efficiency is lowered. VLP vaccines for the human market 
are already in use for hepatitis B virus (HBV) and human papilloma virus (HPV). The HBV 
vaccine prevents HBV chronic infection which can otherwise lead to liver cirrhosis and 
hepatocellular carcinoma. The vaccine consists of the HBV surface antigen which self-
assemble into a VLP like structure. The licensed vaccine expression is done in yeast cells. 
HPV vaccines consist of VLPs made using sequences of strains 6, 11, 16 and 18 which are 
the main strains causing cervical cancer in women. The major capsid protein, L1 of HPV is 
known to assemble on its own to form VLPs even though the natural capsid also contains a 
small amount of a second protein, VP2. The current licenced HPV vaccines contain VLPs 
produced either in yeast cells or in insect cells for a review see Mohsen et al. (2017).  
VLP vaccine development for picornaviruses has been demonstrated for EV71 in foreign 
expression systems such as the baculovirus expression system (Chung et al., 2006) and yeast, 
Saccharomyces cerevisiae (Li et al., 2013). As EV71 and PV both belong to the enteroviruses, 
the technologies developed for EV71 should be transferable to PV. Indeed, PV VLP production 
has been attempted previously in various expression systems. Immunogenic PV empty 
capsids were produced by recombinant baculovirus expression following the insertion of the 
complete ORF and poly(A) tail sequence into the baculovirus genome (Urakawa et al., 1989) 
although yields were very low. Later, Jore et al. (1994) showed PV empty capsid production in 
S. cerevisiae although these capsids were not immunogenic unless a pocket binding 
compound was added, in which case the immunogenicity was altered to a form that induced 
neutralising antibodies (Rombaut & Jore, 1997). Despite these successes, the production of 
PV VLP vaccines has not progressed. Possibly the baculovirus production method could have 
been seen as over labour-intensive at the time of the study and for PV empty capsid production 
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in S. cerevisiae, the pleconaril requirement may have been seen as a prohibitive increase in 
cost. With the current requirement for new PV vaccines for use after eradication, PV VLP 
vaccines need to be revisited, a member of the project consortium associated with the work 
described here produced good levels of immunogenic empty PV capsid from plants (Marsian 
et al., 2017) using the thermostable mutants described by Fox et al. (2017). Recently, 
thermostable immunogenic PV VLPs were also produced using baculovirus expression 
systems (Xu et al., 2019). With the excellent track records of both baculovirus and yeast 
expression system for current marketed VLP vaccines, those expression systems required re-
investigation as methods to produce immunogenic PV empty capsids.  
 
1.8 Baculovirus expression system 
Expression systems are regarded as recombinant protein production platforms which offers 
high-level expression especially for complex and biologically active proteins (Stern & Wiley, 
1992). The successful production of commercialised vaccines for HBV and HPV in such 
systems demonstrates their potential in commercial manufacturing. Baculoviruses are lethal 
pathogens for lepidopteran, dipteran and hymenopteran larvae. Baculoviruses are ingested 
daily but as they do not replicate in vertebrates they are not considered a risk (Heimpel et al., 
1973). Normally baculovirus expression work is carried out in biosafety level 1 containment 
laboratories and the safety required is minimal (O'Reilly et al., 1992). The term ‘baculo’ refers 
to the rod-shape capsids which are 40-50nm in diameter and 200-400nm in length. The 
genomes are double-stranded, circular and covalently closed molecules of ~80-200kb 
(Burgess, 1977). The extendable capsid is capable of accommodating large DNA inserts which 
is a useful character for the recombinant protein expression platform (Fraser, 1986). Several 
well-characterised insect cell lines are widely available for laboratory use. Spodoptera 
frugiperda (Sf9 and Sf21) cells originating from the fall armyworm are the most widely used 
(Vaughn et al., 1977) but Trichoplusia ni (T. ni, commercially known as High Five™) (Granados 
et al., 1994; Wickham & Nemerow, 1993) and Tnao38 cells (Hashimoto et al., 2010) from the 
cabbage looper are alternate expression hosts. All insect cell lines grow well in suspension 
culture at 27ºC and this can be beneficial for the expression of temperature sensitive functional 
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proteins which cannot tolerate 37ºC (Reynisdóttir et al., 1990). The expression system was 
first described for the production of human IFN- !  in insect cells using a recombinant 
baculovirus in which the highly active polyhedrin promoter was used for the expression of the 
foreign gene (Smith et al., 1983). Later, another late baculovirus promoter, for the p10 gene, 
was found to be equally powerful and both these promoters have been used for numerous 
recombinant protein expression examples. Expression in insect cells exhibits most of the post-
translational modification characteristics of other eukaryotic cells, such as mammalian cells 
and this may influence the functional activity and immunogenicity of some expressed proteins 
(Luckow & Summers, 1988; O'Reilly et al., 1992).  
1.8.1 Baculovirus 
Two baculoviruses are commonly used for the foreign gene expression; Autogapha californica 
multi-nuclear polyhedrosis virus (AcMNPV) and Bombyx mori nuclear polyhedrosis virus 
(BmNPV). Both genomes are ~130kb and are found complexed with the nucleoprotein as a 
nucleocapsid. Two forms of virus exist in infected cells, budded viruses which are enveloped 
with a loose membrane studded with surface projections, aka peplomers, on one apex and 
occluded virus, which lack the surface structures and is found in crystalline arrays in the 
nucleus of infected cells. In nuclearpolyhedrosis viruses (NPVs) such as AcMNPV, the 
polyhedral occlusion bodies are known as polyhedra and contain multiply embedded 
nucleocapsids (Van der Beek et al., 1980). The virus budded from the plasma membrane, 
budded virus (BV), is responsible for cell to cell spread within the infected insect while the 
occlusion derived virus (ODV) is responsible for transmission between hosts, the occlusion 
structure providing protection from desiccation and UV damage (O'Reilly et al., 1992). The 
peplomers which is a key difference in the BV and ODV forms of virus is the presence of the 
viral-encoded glycoprotein, gp64 which is only found in BV. Gp64 functions for cell entry via 
adsorptive endocytosis followed by membrane fusion (Volkman & Goldsmith, 1983). Natural 
infection in the wild is via the ODV form which is ingested by browsing larvae. When it reaches 
the midgut, the crystalline polyhedrin matrix is solubilised by the alkaline environment and the 
embedded virions are released to enter midgut cells. The BV form of virus produced is released 
into the larvae’s open circulatory system which allows the BV to spread throughout the body 
and the larvae becomes a sac filled with baculovirus virions. Eventually it ruptures to release 
 57 
ODV and start the cycle in a new host. Figure 1.14 shows the baculovirus replication cycle in 
nature from ingestion of occlusion body, through virus replication in the midgut producing 2 
forms of viruses to release from the host cell to a new host. 
 
 
In insect cell culture, baculovirus replication undergoes 3 phases: early, late and very late.  
In cell culture entry by adsorptive endocytosis releases the nucleocapsid which travels from 
the cytoplasm to the nucleus where early transcription begins (Chisholm & Henner, 1988). 
Within 6 hours post infection (h pi), the virus enters viral DNA replication, the host cell loses its 
chromatin structure and is enlarged. Early proteins from the early viral promoters, expressed 
Figure 1.14. Baculovirus infection cycle in nature 
Baculovirus occlusion body enters a susceptible larva by ingestion. Alkalinity in gut disturbs the occlusion body and 
releases occlusion derived virus, a form of baculovirus and initiates virus replicates in the midgut. DNA replication 
takes place in host cell nucleus and is packed into budded virus (BV), the other form of baculovirus for internal 
infection. Meanwhile, occlusion derived virus is packed into occlusion body which is packed with polyhedrin. 
Eventually the host cell dies and releases the new occlusion bodies into the environment and the cycle restarts. 
The figure is from OET (2019)   
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by the host RNA polymerase on nuclear entry, establish the conditions for DNA replication to 
begin (Charlton & Volkman, 1991). 
In the late phase, the viral DNA replicates, late proteins are expressed and BVs are assembled. 
This period lasts from 6h to 24 h pi and BV production is logarithmic at 12-20 h pi but declines 
thereafter (Knudson & Harrap, 1976; Lee & Miller, 1979). During this period, nucleocapsids 
assembled in the nucleus travel to the plasma membrane where they incorporate gp64 during 
the budding process. An important point to note is that an entire replication cycle can be 
completed without the requirement of the ODV phase, a fundamental property of the 
recombinant baculovirus system. 
In the very late phase, occlusion-specific protein expression and morphogenesis take place 
and by the end of this phase, the infected cell nucleus is filled with occlusion bodies. In cell 
culture conditions cell lysis begins around 60 h pi and protein synthesis has effectively ceased 
by 72 h pi as it enters cell death or lysis. The very late phase lasts ~two days and is 
characterised by the synthesis of polyhedrin and p10 both of which are produced from specific 
very late promoters. As ODV forms of virus are not required for the tissue culture replication, 
these very late genes can be deleted, or replaced with genes of interest. The resulting 
recombinant virus is still able to establish a productive cycle in culture but now expresses the 
target gene product during the very late phase of expression. The use of very late promoters 
and the lack of the ODV form of virus are therefore key features of the recombinant baculovirus 
expression system.  
1.8.2 Baculovirus expression vector 
Although Smith et al. (1983) showed the high-level expression of a foreign gene product by 
replacing the polh gene in the baculovirus genome the system did not spread widely as it was 
not as a convenient platform as bacterial or yeast expression systems. An early difficulty was 
the low rate of recombinant baculovirus production which was in the order of 0.1-1% of the 
progeny virus. At this time, distinguishing the recombinant virus from wild type virus was based 
on loss of the ODV phenotype as observed by light microscopy and many rounds of plaque 
assay were required to isolate a pure recombinant virus. Later this was vastly simplified by the 
use of linearised baculovirus DNA in place of the circular form during transfection. A unique 
restriction site was inserted in the polh locus (Kitts et al., 1990). Linear DNA is not infectious 
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unless rescued to the circular form by recombination with the transfer vector and with this 
implementation the rate of recombinant baculovirus formation rose to ~30%. Further 
modifications included the deletion of orf1629 which is an essential gene adjacent to the polh 
locus. As before correction of this deletion was achieved by recombination with the transfer 
vector, which restored infectivity at the same time as incorporating the gene of interest giving 
up to 97-98% recombinant formation (Kitts & Possee, 1993). In parallel, a method was 
developed which used the baculovirus genome cloning into a bacterial artificial chromosome 
(bac) in Escherichia coli (E. coli). A transfer vector is still use but site specific transposition is 
used to incorporate the gene of interest into the bac in E. coli (Luckow et al., 1993). This 
technology, commercialised as the Bac-to-Bac system is widely used as the transposition 
event is done entirely using plate genetics with appropriate antibiotic selection. While the 
various technical improvements increased the yield of recombinant baculovirus a background 
of wild type virus was still encountered, requiring a plaque assay to prevent outgrowth of the 
wild type virus during recombinant amplification (van Oers et al., 2015). A later improvement 
combined the bacmid and linearisation approaches by mutating ORF 1629 by gene knockout 
so that even circular DNA was non-infectious until recombined. This modification achieved 
100% recombinant baculovirus production (Zhao et al., 2003). A similar strategy was applied 
for a commercially available bacmid DNA, flashBAC™ by Oxford Expression Technologies 
(King et al., 2007) and is the method used in the work described here. In addition, flashBAC™ 
DNA is deleted for two non-essential gene encoding a cathepsin like protease and a chitinase 
which are normally used for cell lysis but have been shown to lessen overall recombinant 
protein yields (Hitchman et al., 2011; Lu et al., 2002; Possee et al., 1999; Thomas et al., 1998).  
1.8.3 Transfection 
The delivery of both flashBAC GOLD DNA and the purified transfer vector are achieved by 
liposome based transfection. Positively charged liposomes and negatively charged DNA bind 
each other to form a complex that enters cells (Felgner et al., 1994). Once the DNA is 
internalised a proportion undergoes recombination in the nucleus restoring the circular 
baculovirus genome and allowing early gene expression to occur. A full replication cycle 
ensues resulting in the harvest of a recombinant virus which expresses the recombinant gene 
in the very late phase of the cycle. 
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1.8.4 Post-translational modification 
One of the advantageous characteristics of the baculovirus expression system is the typically 
eukaryotic post-translational modifications, which include phosphorylation, glycosylation, 
acylation, disulphide bond formation and proteolytic processing (Miller, 1988). In the case of 
PV expression, the N terminus of VP4 is modified by N-myristoylation by N-myristoyl 
transferase (NMT) which does not occur in bacteria but has been reported as essential to 
assembly (Ansardi et al., 1992). However, NMT functions in insect cells so VP4 is myristoylated 
as required for VLP assembly. To this extent post-translational modification is essential for the 
assembly of authentic empty capsids to elicit an effective immune response as a VLP vaccine. 
Protein folding 
VLPs consist of multiple proteins that require correct folding of each protein for assembly to 
occur (Liu et al., 2013). The insect cell cytoplasm is equipped with chaperons and foldases 
such as Hsp70 to fold and assemble polypeptides without forming aggregates (Ailor & 
Betenbaugh, 1999; Sokolenko et al., 2012). The efficiency of foreign protein folding in insect 
cells compared to mammalian cells is not fully known and may differ for different proteins 
depending on their complexity. 
Glycosylation 
The one post translational modification that does differ between insect and mammalian cell is 
glycosylation (Chen et al., 2010). The baculovirus expression system produces glycoproteins 
and is widely used for this purpose for recombinant proteins as efficiency can exceed the 
production possible in mammalian cells. However, while glycosylation starts similarly for both 
insect and mammalian cells, the subsequent processing in insect cells is much more limited. 
Insect cells cannot produce complex mammalian style N-glycans, instead producing high 
mannose glycans unless used with engineered insect cell lines aimed at mimicking mammalian 
processing (Altmann et al., 1999; Jarvis, 2003). In the case of PV VLPs however glycosylation 
differences should not be a concern as none of the capsid proteins are glycosylated.   
1.8.5 Purification of VLPs  
For pharmaceutical and scientific use, baculovirus-insect cell origin proteins are required to be 
free from baculovirus particles due to their adjuvant activity as agonists of Toll-like receptor 9 
(TLR9) (Abe et al., 2005). If it is not removed physically or biochemically, the immunogenic 
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response to the VLP may be jeopardised or there may be an unacceptable inflammatory 
reaction at the site of immunisation (Vicente et al., 2011). When synthesised recombinant 
proteins and baculovirus particles have similar properties, the separation process may be 
complicated and this is the case for the purification of VLPs. Traditional velocity or density 
gradient ultracentrifugation is capable of separating VLPs from baculovirus particles or 
nucleocapsids but it is labour intensive, time consuming and scale limiting and its productivity 
for the final product is questionable as it still contains impurities (Huhti et al., 2010; Liu et al., 
2013). As a result simpler stepwise operations were also widely used, for example, low speed 
centrifugation, precipitation and ultrafiltration or diafiltration have been employed (Maranga et 
al., 2002). Chromatography may be also added after filtration or precipitation, with size 
exclusion chromatography acting to polish the final product after filtration (Peixoto et al., 2007). 
For example, norovirus VLPs were purified by polyethylene glycol precipitation followed by 
anion exchange chromatography (Koho et al., 2012; Lin et al., 2015). Although chemical 
inactivation of baculovirus infectivity is possible, for example by formaldehyde, VLP antigenicity 
may be affected by the treatment (Liu et al., 2013; Vicente et al., 2011). A novel development, 
rather than relying on biophysical and biochemical methods, has been the introduction of an 
engineered baculovirus to ease the purification. Deletion of the vp80 gene in baculovirus 
genome produces recombinant baculovirus which cannot form either BVs or ODVs, without 
affecting the level of foreign gene expression (Marek et al., 2011). The recombinant is grown 
in a helper cell line which provides this function in trans but non helper cells are used for the 
protein expression phase. This application simplifies the purification method particularly for 
secreted proteins which are harvested from the supernatant of infected cells, which would 
include VLPs produced in insect cells (Lin et al., 2015) although this particular method has not 
been reported for the production of VLPs.  
1.8.6 Baculovirus expression system application for this project 
The expression system was used throughout this project as the default eukaryotic platform for 
PV gene expression with 1) high yield and 2) post-translational modification. These two 
characteristics suit an examination of the system for PV VLP based vaccine production. VLP 
conformation is critical to obtain an immunogenicity that is as good as or better than OPV or 
IPV. The high expression rate is driven by the strong very late baculovirus promoters which 
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has the potential to make baculovirus-insect cells derived VLPs a cost effective product. 
Nevertheless, another expression system was tested as part of this project. 
 
1.9 Yeast expression system 
The yeast system similarly offers the higher eukaryotic cell characteristics but combines this 
with the advantages of mass microbial cultivation. Although prokaryotic expression systems 
such as E. coli have been successful for many simple products, recombinant protein 
localisation in inclusion bodies is a frequently encountered problem and for complicated 
proteins such as VLPs bacteria have proved problematic (Porro et al., 2005; Sorensen, 2010). 
Where it has been investigated, picornavirus assembly to the fully assembled capsid has failed 
(Goodwin et al., 2009) although recently the apparent assembly of FMDV in E. coli was 
reported (Puckette et al., 2017). Yeast cells however, retain the simplicity of bacterial culture: 
high growth rate and low cost while offering eukaryotic post-translational modification (Porro 
et al., 2011). The availability of yeast molecular and genetic resources is another advantage 
that can be applied for a VLP vaccine production platform (Goffeau et al., 1996). Using these 
benefits, vaccines for HBV and HPV have been approved for human use (Bill, 2015) and by 
their adoption, yeast cell expressed products have shown their safety and immunogenicity.  
Currently, baker’s yeast, Saccharomyces cerevisiae (S. cerevisiae) is the most commonly 
used strain for expression systems and is used in the production of licensed vaccines. Other 
yeasts such as Pichia pastoris (P. pastoris) are also used widely in research laboratories. Their 
potential cannot be neglected as they offer different expression rates and expression 
conditions and may contribute to solving some expression difficulties such as 
hyperglycosylation and protein retention in the periplasm which results in partially degraded 
proteins along with proper conformational proteins (Romanos et al., 1992). The variety of host 
cell characteristics is one of the reasons to choose yeast as an expression system and yeast 
host cell choice is still increasing for specific expression requirements of individual recombinant 
proteins.  
For recombinant protein production, the desired heterologous gene is transformed into the 
yeast cells where it may integrate into the yeast genome or exist as a freely replicating episome. 
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In order to obtain a high yield of the heterologous protein, a highly transcribed promoter is 
essential and the choice of promoter may require the use of a specific host cell, as is the case 
for expressing using the methanol inducible promoter AOX in P. pastoris (Macauley-Patrick et 
al., 2005). After the recombinant protein is produced, the purification method will differ 
depending on protein location and will need to be determined for each heterologous protein, 
as it is for any other expression system. 
1.9.1 Transformation of heterologous genes 
Following cloning a heterologous gene sequence into a yeast expression plasmid (see below) 
the gene is introduced into yeast by transformation in one in main 3 methods, spheroplast 
preparation, lithium acetate (LiAc) method or electroporation (Porro et al., 2005). Spheroplast 
preparation is achieved by disturbing the yeast cell wall using 2-mecaptoethanol and delivering 
the heterologous gene containing plasmid DNA with carrier DNA. The LiAc method is similar 
to spheroplasts preparation but includes 5 elements: LiAc, polyethylene glycol (PEG), heat 
shock at 42°C, single-stranded carrier DNA, and use of intact mid-log phase cells, all of which 
contribute to a higher transformation efficiency. Electroporation has also been investigated for 
yeast cell transformation and its initial low transformation rate was improved by supporting the 
electrically compromised cell in a buffer with 1M sorbitol (Kawai et al., 2010). The 
improvements in each transformation method have resulted in all being used with some 
preferred for individual host cells or the size of transforming material e.g. yeast artificial 
chromosomes. However, for simplicity and easy preparation the LiAc method is an obvious 
choice for yeast cell transformation and was the method used here.  
1.9.2 Yeast cell selection markers 
To select transformed yeast cells auxotrophic markers are commonly used although later 
vectors make use of novel antibiotic selection, e.g. zeocin. As a result of the large repertoire 
of yeast mutants engineered yeast cells with critical enzyme deficiencies can survive by taking 
up a heterologous vector carrying a compensatory gene along with the desired heterologous 
DNA sequence. In theory, only the successful transformant survives in selective media which 
is lacking the specific biosynthesis product. For example, URA3 gene which encodes orotidine-
5’-phosphate decarboxylase is involved in pyrimidine biosynthesis while HIS3 (L-histidine 
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synthesis), LEU2 (L-leucine), TRP1 (L-tryptophan) and MET15 (L-methionine) are all 
employed as auxotrophic markers (Pronk, 2002). To overcome the cross-feeding possible 
when plating high density culture, engineered cells may include other auxotrophic markers to 
ensure a clean selection (Porro et al., 2005). For example, for the URA3 maker gene the 
essential biosynthetic intermediate uridine 5’-monophosphate of S. cerevisiae can be 
produced by 2 pathways, via the URA3 gene product or by pyrimidine conversion to uracil by 
uracil phosphoribosyl-transferase (FUR1). Yeast cells with both mutations (∆URA3 and 
∆FUR1) enable a plasmid-origin URA3 gene as a selection marker even in uracil-containing 
culture as the double mutants are lethal (Pronk, 2002).  
1.9.3 Transformation vectors for yeast cells  
Cloning of the desired DNA is normally carried out in E. coli using a shuttle plasmid capable of 
replication in both yeast and bacteria for ease of gene manipulation. Transformation vectors 
are available as integrative vectors and extrachromosomal vectors based on autonomous 
plasmids and episomal plasmids (Singh & Heinemann, 1997). The integrative plasmids rely on 
recombination into the yeast chromosomal DNA for foreign gene expression and to enable this 
the plasmid has to contain DNA homologous to a specific yeast locus, although random 
recombination may also occur (Porro et al., 2005). The method is known for low foreign gene 
transfer frequency but, if the correct integration takes place it is very stable when cultured in 
selective medium. Extrachromosomal vectors replicate in yeast cells as they contain a yeast 
origin of replication, an autonomous replication sequence (ARS) such as the naturally 
occurring 2µ circle. This facilitates high heterologous gene carriage but with lower stability 
although this is improved by introduction of centromeric sequence at the expense of a lower 
copy number. Episomal plasmids offers the most suitable characteristics overall for yeast 
expression vectors but are not available for all possible host yeasts. At present, there is no 
universal transformation vector which offers stability of foreign gene and high copy number 
limiting to some degree the host cells that are chosen.  
1.9.4 Promoters 
Transcription efficiency for any heterologous gene relies on the promoter in use and a wide 
variety of promoters are available, including homologous or heterologous, inducible or 
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constitutive (Porro et al., 2005). Yeast promoters typically consist of 3 domains, an upstream 
activation sequence, TATA elements and initiator elements and are often over 500bp in length. 
Glycolytic enzyme promoters including alcoholic dehydrogenase I (ADH1), phosphoglycerate 
kinase and glyceraldehyde-3-phosphate dehydrogenase (GAP or GAPDH) are powerful 
promoters that are widely used. Highly inducible promoters such as GAL1 are also used with 
addition of galactose for induction and glucose for suppression. Inorganic phosphates, 
temperature and metal ions have also been used for inducing promoters (Berlec & Strukelj, 
2013). Inducibility is useful when a foreign protein is toxic but for higher expression efficiency, 
constitutive promoters are preferred and the GAP promoter is used in the work described here 
(Porro et al., 2005).  
1.9.5 Heterologous protein purification 
The location of any recombinant protein in yeast cells alters the downstream process of 
extraction; cytoplasmic proteins offer very high expression level but difficult extraction whereas 
secreted proteins are much easier to purify. As yeast cell walls are robust structure, high 
pressure homogenization is necessary to access the cytosolic contents and during this process, 
some loss of the expressed protein is inevitable. In the case of VLPs the lysis procedure also 
has be compatible with maintenance of the capsid structure. It is notable that for the HBV 
vaccine the surface antigen is extracted from yeast cells in a denaturing protocol and renatured 
post-purification (Yamazaki, 1988). Such a strategy would not be compliant with a multi-protein 
VLP such as a picornavirus capsid.  Although secretion would be useful there are few universal 
rules for secretion from yeast make this currently unworkable for capsids expression.  
The encouraging data on the use of yeast as an expression host for PV VLPs is the previous 
experience with PV in S. cerevisiae, albeit at low levels (Jore et al., 1994; Rombaut & Jore, 
1997) and the more recent data on the production of enterovirus 71 VLPs in both S. cerevisiae 
and P. pastoris (Li et al., 2013; Zhang et al., 2015). In these reports, P1 and its protease 3CD 
were employed to produce the individual viral proteins VP1, VP3 and VP0. While co-
transformation of P1 and 3CD plasmids produced VLPs (Zhao et al., 2013) the yield was low 
when compared to P1 and 3CD combined on a single expression plasmid (Zhang et al., 2015; 
Zhou et al., 2016). It is clear that the expression strategy made a difference in VLP yield and 
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these findings, control over the balance of viral proteins expressed, suggest that a similar 
strategy for PV could be beneficial (Kim & Kim, 2017).  
 
1.10  Aims of the project 
The aims of this project are to investigate the assembly, characterisation and development of 
recombinant PV capsids using the baculovirus and yeast expression systems. While PV is a 
candidate for the third virus ever to be eradicated from the world, the feasibility of achieving 
this remains in debate. There are two types of vaccine currently available; OPV and IPV. OPV, 
whilst proving the greatest immune response, could give rise to revertants that could serve as 
a source of the wild virus in the population even after incidents of disease have ended. IPV 
does not generate revertants but large scale growth of the live virus under level 3 containment 
is required. Therefore, new concepts for PV vaccines are required for the post-polio world. The 
project will use technology developed at the University of Reading to assemble empty 
picornavirus capsids in insect cells and to apply this also to yeast. Such capsids trigger an 
immune response without being infectious and represent a novel candidate polio vaccine. 
Further engineering, which would not be feasible with infectious virus, such as improved 
stability, is also possible. 
The project will utilise the following approaches for assembly, characterisation and 
development of recombinant PV capsids: 
 
1) PV VLP production in baculovirus and yeast expression systems 
Picornavirus 3C
pro
 cytopathic effects, which jeopardises natural host cell function, have 
suggested the need for an adjustment in 3C activity to serve as an appropriate P1-2A 
processing protease in the baculovirus expression system. Dual control of 3C
pro 
resulted in 
FMDV VLP expression in which suitable P1-2A and 3C
pro
 molar ratios were met by the 
inclusion of a human immunodeficiency virus (HIV) frameshift and mutating 3C
pro
 itself (Porta 
et al., 2013). Similarly, for the successful expression of EV71 VLPs the EV71 3Cpro included a 
mutation at the conserved residue involved in substrate recognition, S128A, which lowered the 
enzymatic activity significantly (Cui et al., 2011). As a result, in this work a genetic construct 
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optimised for FMDV expression was adapted for PV VLP production by replacing the P1 region 
with PV P1 and the 3C
pro
 region with EV71 3C
pro
 containing the S128A mutation. The use of 
the EV71 3C
pro 
for processing PV structural proteins has not been previously reported. 
Improvements in VLP purification methods will be also discussed as part of the optimisation of 
production. 
 
2) Improvement of PV capsid stability 
IPV has shown instability at elevated temperatures and in some chemical conditions (Plotkin, 
1991; 1997). The poliovirus uncoating mechanism was visualised to show externalisation of 
the N termini of VP1 and VP4 (Bostina et al., 2011; Butan et al., 2014; Lin et al., 2011). This 
finding indicates that molecular engineering at these sites could be used to prevent premature 
opening and achieve a more stable capsid. Such mutations may be lethal for the virus as it 
would be unable to uncoat but this is not applicable when empty capsids are used.  
 
3) Capsid conformation status alteration 
PV VLPs originating from S. cerevisiae are found not to be conformation inducing protective 
immunity (H-form). Addition of VP1 pocket binding drug in the culture and purification 
procedure changed the VLPs into immunogenic conformation (N-form) (Rombaut & Jore, 
1997). To follow this up the same P1-3C
pro
 cassettes developed for insect cell expression will 
be assessed for yeast PV VLP expression. Alteration of the conformational status will be 
attempted with the addition of pleconaril and another capsid binding drug, GPV13 (De Colibus 
et al., 2014) and an assessment of the H/N-form of VLPs made.
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  Materials and General Methods 
In this section, routinely used general methods for this project are explained. When stated 
commercially available kits were used following the manufacturers’ protocols.  
2.1 Materials 
2.1.1 Chemical reagents, enzymes and columns  
Chemical reagents, enzymes and columns used in this project is listed in the table below 
 
Manufacturers/distributers Chemicals 
ThermoFisher scientific, US Ethanol, Methanol, glucose, sucrose, sodium chloride 
(NaCl), sodium acetate, Ethylenediaminetetraacetic acid 
(EDTA), Tris, Tween™ 20, bacteriological agar, potassium 
chloride (KCl), sodium phosphate dibasic (Na2HPO4), 
potassium phosphate monobasic (KH2PO4), 5M 
hydrochloric acid (HCl), 10 M sodium hydroxide (NaOH), 
FastDigest restriction enzymes, T4 DNA ligase, Zeba 7K 
MWCO spin column, Immobilon-P transfer membrane, 
protein-free T20 (TBS) blocking buffer (Thermo Scientific), 
clear flat-bottom nonsterile 96-well plate, Bolt™ 4-12 % 
Bia-Tris Plus gels, Novex™ sharp pre-stained protein 




Lipofectin Transfection Reagent, Bolt™ Bis-Tris Plus Gels, 
10-well, Bolt™ LDS sample buffer, SilverQuest™ Silver 
staining kit  
Merck Millipore, US 
(through ThermoFisher 
scientific, US) 
Amicon Ultra 100K MWCO 0.5, 4 and 15 mL 
  
Table 2.1. List of materials with the manufacturer 
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Sigma-Aldrich, US (Merck 
Millipore, US) 
Lithium acetate, salmon sperm DNA, polyethylene glycol, 
Nonidet™ P-40, Benzonase®, cOmplete ULTRA EDTA-
free tablets, DL-Dithiothreitol (DTT), D-sorbitol, HEPES 
sodium salt, glycerol, bromophenol blue, 2-
Mercaptoethanol, guanidine chloride, bovine serum 
albumin (BSA), sulfuric acid (H2SO4), yeast nitrogen base 
without amino acid, yeast synthetic drop-out medium 
supplement without uracil, ampicillin sodium salt, 
pleconaril, PEG-8000 (P2139), Rupintrivir, poliomyelitis 
vaccine (inactivated) BRP, lithium acetate (LiAc), Salmon 
sperm DNA, Polyethylene glycol, bovine serum albumin 
(BSA), Nycodenz, Phenylmethylsulfonyl fluoride (PMSF), 
Coomassie Brilliant Blue R250, sodium carbonate 
(Na2CO3), sodium bicarbonate (NaHCO3), dimethyl 
sulfoxide (DMSO), foetal calf serum (FCS) 
New England Biolabs, US Phusion® High-Fidelity PCR Master Mix with HF Buffer 
Local supermarket Dried milk 
BD bioscience, US Fixation/Permeabilization solution kit 
Geneflow, UK ChemiFast Western blot detection agent 
National Diagnostic, US 
(through Geneflow, UK) 
20 % sodium dodecyl sulphate solution (SDS), 50X Tris-
acetate-EDTA (TAE), 10X Tris-Glycine SDS PAGE buffer, 
Tris-buffered saline buffer (TBS) and 10X Tris-glycine 
Electroblotting buffer 
AGCT, UK 
(through Geneflow, UK) 
Agarose 
AMS Biotechnology, UK Zymolyase 100T 
GE Healthcare Life science, 
US 
Whatman™ 3MM Chromatography Paper  





Beckman Coulter, US Ultra-Clear Thinwall tube for SW40 (13.2ml) and  
Ultra-Clear Thinwall tube for SW32 Ti (38.5ml) 
MatTek, US poly-D-lysine glass-bottom 35 mm sterile dish  
Agar scientific, UK Uranyl acetate, Formvar/Carbon 300 Mesh Copper grid 
Bio-Rad Laboratories, US Mini-PROTEAN® TGX™ Gel,10 well, 30 μl  
National institute for 
biological standards and 
control (NIBSC) 
PV standard for IPV 
 
2.1.2 Specialised equipment 
 
Manufacturers/distributers Equipment 
Lifetechnologies, US Countess® Automated Cell Counter 
Bio-Rad laboratories, US BioLogic LP 
Stanstead Fluid Power Ltd, UK Lab Homogenizer Cell Disruptor 
MP Biomedicals, US FastPrep®-24 Classic Instrument 
Parr Instrument Company, US N2 cavitation vessel (40 ml capacity) 
ThermoFisher Scientific, US EVOS FL Cell Imaging System 
Eppendorf, Germany Bench top centrifuge (5418) 
Bechman coulter, US Optima™ L-90K Ultracentifuge 
Eppendorf, Germany Biophotometer 
BioComp Instruments Gradient Master Base Unit 
ATTO, Japan HorizBLOT 
Syngene, UK G: Box imager 
Tecan, Swizerland Infinite 200 Microplate Fluorescence Reader 
Leica, Germany gSTED microscope 
Joel, Japan 2100Plus TEM 




In this project, a cassette system was used for expression in insect and yeast cells. The 
cassette consists of P1, the first 10 amino acids of PV 2A, a HIV-1 framshift sequence and an 
EV71 origin 3C protease sequence which carries a S128A mutation (3CEV71). The vector is 
based on pOPINE (Berrow et al., 2007), itself a modification of pTriEx1.1 (EMD Chemicals Inc, 
2011). 
 
Vector Description Source 
pOPINE EV71 P1-2A_FS_3CEV71 pOPINE vector contains EV71 
cassette 
Cone (2015) 
pOPINE Mahoney P1_2A_FS_3CEV71  
 
pOPINE vector contains PV 
Mahoney cassette 
This work 
pOPINE MEF-1 P1_2A_FS_3CEV71 pOPINE vector contains PV 
MEF-1 cassette 
This work 
pOPINE Saukett SC8 P1_2A_FS_3CEV71 pOPINE vector contains PV 
Saukett with SC8 mutation 
cassette 
This work 
pTriEx1.1 Mahoney P1 pTriEx1.1 vector contains PV 
Mahoney P1 sequence 
This work 
pTriEx1.1 GFP pTriEx1.1 vector contains GFP 
sequence 
Host lab 
pET15b-3CDμ10 3CDΔ sequence source. Serine 
insertion at the junction of PV 
wild type 3C and 3D prevents 
3CD cleavage 
NIBSC 
pOPINE Mahoney P1_2A_3CDWT pOPINE vector contains 
Mahoney P1, first 10 aa of 2A 
and PV wild type 3CD 
sequence 
This work 
Table 2.3. List of expression vectors 
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pOPINE Mahoney P1_2A_3CDΔ pOPINE vector contains 
Mahoney P1, first 10 aa of 2A 






P1_2A_3CDWT with FS 
sequence between 2A and 3CD 
This work 
pOPINE Mahoney P1_2A_FS_3CDΔFS pOPINE Mahoney 
P1_2A_3CDΔ with FS 
sequence between 2A and 3CD 
This work 
pKT10 pKT10, a yeast 2μ expression 





pKT10 Mahoney P1_2A_FS_3CEV71 pKT10 inserted with PV 
Mahoney cassette 
This work 
pKT10 Saukett SC8 P1_2A_FS_3CEV71 pKT10 inserted with PV Saukett 
SC8 cassette 
This work 
pOPINE Mahoney P1_2A_FS_3CEV71 - 
M132L, M132W, M132W-H207W, M132W-
F237W, H207W-F237W, M132W-H207W-F237W 
(Triple), Y159W, Y159W-Y205W, Y205W, 
H207W, F237W 
pOPINE vector contains PV 
Mahoney cassette with VP1 
mutation at the specific 
locations 
This work 
pKT10 Mahoney P1_2A_FS_3CEV71 - 
M132L, M132W, Y159W, Y205W and M132W-
Y207W-F237W (Triple) 
pKT10 vector contains PV 
Mahoney cassette with VP1 
mutation at the specific 
locations 
This work 
pOPINE Mahoney SC6b 
P1_2A_FS_3CEV71 
pOPINE vector contains PV 




pOPINE Mahoney SC6b P1 Ex10, Ex15 
and Ex20, _2A_FS_3CEV71 
pOPINE vector contains PV 
Mahoney SC6b mutation 
cassette with various degree of 
HIV matrix protein p17 inserted 
at VP4 N-terminus 
This work 
pOPINE Mahoney SC6b P1 VP1_1, 
VP1_2 and VP1_3, _2A_FS_3CEV71 
pOPINE vector contains PV 
Mahoney SC6b mutation 
cassette with GS linker inserted 
at VP1 N-terminus  
This work 
 
2.1.4 Recombinant baculovirus strains 
 
Virus Vector used Description 
Bac-PV1P1-3C pOPINE Mahoney 
P1_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express PV 
Mahoney (PV1) viral proteins 
Bac-PV2P1-3C pOPINE MEF-1 
P1_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express PV MEF-
1 (PV2) viral proteins 
Bac-PV3P1-3C pOPINE Saukett SC8 
P1_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express 
thermostable PV Saukett 
(PV3) SC8 viral proteins 
Bac-PV1P1 pTriEx1.1 Mahoney P1 Recombinant baculovirus 
produced to express PV 
Mahoney (PV1) P1 
Bac-GFP pTriEx1.1 GFP Recombinant baculovirus 
produced to express GFP 
Table 2.4. List of recombinant baculovirus strains 
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Bac-PV1P1-3CDWT pOPINE Mahoney 
P1_2A_3CDWT 
Recombinant baculovirus 
produced to express Mahoney 
VPs by PV wild type 3CD 
cleavage 
Bac-PV1P1-3CD∆ pOPINE Mahoney 
P1_2A_3CDΔ 
Recombinant baculovirus 
produced to express Mahoney 
VPs by PV mutated 3CD 
cleavage 
Bac-PV1P1-3CDWTFS pOPINE Mahoney 
P1_2A_FS_3CDWTFS 
Recombinant baculovirus 
produced to express Mahoney 
VPs by FS down regulated PV 
wild type 3CD 
Bac-PV1P1-3CD∆FS pOPINE Mahoney 
P1_2A_FS_3CDΔFS 
Recombinant baculovirus 
produce to express Mahoney 
VPs by FS down regulated PV 
mutated 3CD 







Y159W, Y159W-Y205W,  




produced to express PV 
Mahoney (PV1) viral proteins 
with the VP1 mutations shown 
Bac-PV1SC6bP1-3C pOPINE Mahoney SC6b 
P1_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express 
thermostable PV Mahoney 
(PV1) SC6b viral proteins 
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Bac-PV1SC6bP1Ex10, 
Ex15 and Ex20 
pOPINE Mahoney SC6b P1 
Ex10, Ex15 and Ex20, 
_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express PV 
Mahoney (PV1) SC6b viral 
proteins with VP4 N-terminus 
mutants 
Bac-PV1SC6bP1VP1_1, 
VP1_2 and VP1_3 
pOPINE Mahoney SC6b P1 
VP1_1, VP1_2 and VP1_3, 
_2A_FS_3CEV71 
Recombinant baculovirus 
produced to express PV 
Mahoney (PV1) SC6b viral 
proteins with VP1 N-terminus 
mutants 
 
2.1.5 Recombinant yeasts 
 
Yeast  Vector used Description 
RAY3A-D-PV1-3C pKT10 Mahoney 
P1_2A_FS_3CEV71 
Recombinant RAY3A-D 
engineered to express PV 
Mahoney (PV1) viral proteins 
RAY3A-D-PV3SC8-3C pKT10 Saukett SC8 
P1_2A_FS_3CEV71 
Recombinant RAY3A-D 
engineered to express PV 
Saukette SC8 (PV3) viral 
proteins 
RAY3A-D-PV1-3C - 










engineered to express PV 
Mahoney (PV1) viral proteins 
with desired VP1 mutations 
Table 2.5. List of recombinant yeasts 
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2.1.6 Cell lines 
 
Cell line Description Source 
Sf9 A clonal derivative of Sf21 (IPLB-SF21-AE) cell line 
derived from pupal ovarian tissues of the fall 
armyworm, Spodoptera frugiperda. They are 
susceptible to baculovirus infection. Sf9 cells are 
more uniform in sizes than Sf21 cells which helps the 
identification of plaques. Doubling time: 24 hours 
ThermoFisher, US 
High Five™ BTI-Tn-5B1-4 cell line originated from the ovarian 
cells of cabbage looper, Trichoplusia ni. The 
recombinant protein yield is higher than Sf9 cells. The 
cell line contains TNCLV, an alphanodavirus. 
Doubling time: 18 hours 
ThermoFisher, US 
Tnao38 BTI-Tnao38 cell line originated from a clonal isolate of 
the High Five™ (BTI-Tn-5B1-4) cell line. The 
recombinant protein yield is at the same level as High 
Five™ cells. TNCLV is absent. Doubling time: 20 
hours (Hashimoto et al., 2012) 
Blissard lab, US 
Stellar cells Chemically competent E. coli HST08 strain for high 
efficiency transformation 
Clontech, US 
RAY3A-D S. cerevisiae laboratory adapted auxotrophic mutant 
strain (MATa/α ura3/ura3 his3/his3 leu2/leu2 
trp1/trp1) (Ruggieri et al., 1989) 
Dr Yuko Morikawa, 
Japan 




Antibody Use Manufacturer 
Anti-poliovirus Blend Ab, 
MAB8566 
Detection of PV VP1 for all 
serotypes 
Millipore, Germany 
Rabbit anti-VP0 sera, Day 
39 
Detection of PV VP2 for all 
serotypes  
Reading 
Rabbit anti-VP3 sera Detection of PV VP1 for all 
serotypes 
Host lab collaborator 
Rabbit anti-PVP1 sera Detection of PV P1 for all 
serotypes 
Host lab collaborator 
Mouse anti-baculovirus p39 
sera 
 
Detection of baculovirus 
major baculovirus structural 
protein 
Host lab collaborator 




conjugated with HRP 
Dako, Denmark 




conjugated with HRP 
Dako, Denmark 
Oregon green 488 Fluorophore conjugated 
anti-mouse Ab 
ThermoFisher Scientific, US 
STAR440SXP Fluorophore conjugated 
anti-rabbit Ab 
Abberior GmbH, Germany 
SH16 for PV1 PV1 capture Ab for N/H 
ELISA 
NIBSC, UK 
R Skt live PV3 capture Ab for N/H 
ELISA 
NIBSC, UK 
Table 2.7. List of antibodies 
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234 PV1 N specific Ab for N/H 
ELISA 
NIBSC, UK 
520 PV3 N specific Ab for N/H 
ELISA 
NIBSC, UK 
1588 PV1 H specific Ab for N/H 
ELISA 
NIBSC, UK 




2.1.8 Buffers, solutions and media 
 
Buffer / solution Description Manufacturer 
PBS 137 mM NaCl 
2.7 mM KCl 
10 mM NA2HPO4 
1.8 mM KH2PO4  
Central school 
service (CSS) in the 
University 
TBS 50 mM Tris base 
150 mM NaCl 
adjust to pH 7.5 with HCl 
CSS or purchased 
from National 
Diagnostics 
Lonza InsectXPRESS with 
L-Glutamine 
Commercial media supports the 
growth of insect cell lines such as Sf9 
Lonza, Switzerland 
 
Softening medium 100 mM Hepes-KOH, pH9.4 
10 mM dithiothretiol (DTT) 
25 mM EDTA 
Host lab modifying 
from Odorizzi 
(2003) 
Spheroplasting medium 2 % glucose 
50 mM Hepes-KOH, pH 7.2 
1 M Sorbitol 
1 mM EDTA 
Host lab, modifying 
from Odorizzi 
(2003) 
Table 2.8. List of buffers, solutions and media 
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Break buffer PBS pH 7.2 
1 % NP40 
1.7 mM EDTA 
cOmplete ULTRA EDTA-free tablet 
Host lab, based on 
Kim et al. (2010) 
Homogenization buffer 250 mM sucrose 
10 mM Hepes pH7.2 
1 mM EDTA 
1 mM DTT 
cOmplete ULTRA EDTA-free tablet 
Host lab, modifying 
from Wang et al. 
(2014) 
YPD media 20 g Bacto peptone 
10 g Yeast extract 
in diH2O to 950 mL for autoclave 
20 % sterile glucose was added to be 
2 % final concentration after autoclave 
CSS 
YPD media agar YPD media 
High grade agar 
CSS 
TE buffer 10 mM Tris base 
1 mM EDTA 
adjusted to pH 8.0 with HCl 
Reading 
LiAc mix 100 mM LiAc in TE buffer Host lab referred 
from Herskowitz 
(2012) 
PEG mix 40 % PEG in 100 mM LiAc mix Host lab referred 
from Herskowitz 
(2012) 
Synthetic dropout (SD) 
media for pKT10 
Yeast nitrogen base without amino 
acids 




50 % sterile glucose 
SD media agar for pKT10 Yeast nitrogen base without amino 
acids 
Yeast synthetic dropout medium 
supplement 
High grade agar (without uracil) 
50 % sterile glucose 
CSS 
Buffer 1  1X PBS 
1 mM CaCl2 
0.5 mM MgCl2 
Host lab 
Blocking/wash buffer for 
gSTED sample preparation 
1X PBS 
2 % BSA 
Host lab 
2XSDS loading buffer 125 mM Tris-HCl pH 6.8 
25 mM EDTA 
4 % SDS 
20 % Glycerol 
0.4 % Bromophenol Blue 
286 mM 2-Mercaptoethanol 
Host lab 
10X Tris-Glycine SDS PAGE 
Buffer 
0.25 M Tris base 
1.92 M Glycine 
1 % (w/v) SDS 
National 
Diagnostics, US 
20X Bolt™ MES SDS 
running buffer 
Exact content is not known. 








Coomassie stain 250 mg Coomassie Brilliant Blue 
R250 
10 % Glacial acetic acid 
10 % Methanol 




0.25 M Tris base 




TBST 1X TBS 
0.2 % (v/v) Tween™ 20 
Host lab 
WB blocking buffer 5 % (w/v) dried skimmed milk  
TBST 
Host lab 
Renaturing buffer 20 mM Tris-HCl 
1 mM EDTA 
0.5 mol/L NaCl 
0.05 % Tween™ 20 
1 M Guanidine hydrochloride 
 5 % dried skimmed milk 
Host lab referred 
from Jia et al. (2013)  
Carbonate coating buffer 15 mM sodium carbonate 
35 mM sodium bicarbonate 
Host lab 
PBST 1X PBS 
0.1 % Tween™ 20 
Host lab 
blocking solution for western 
blot 
PBST  
1 % BSA 
Host lab 
assay diluent 1X PBS 





2.1.9 Commercial Kits  
 
Kit Manufacturer 
Gel extraction and MinElute kits QIAGEN, Germany 
In-Fusion cloning kit Clotech, US 
QIAprep Spin Miniprep kit QIAGEN, Germany 
QIAquick PCR Purification kit QIAGEN, Germany 
Yeast Plasmid Isolation kit Clontech, US 
GeneJET Gel Extraction and DNA Cleanup 
Micro Kit 
ThermoFisher Scientific, US 
GeneJET Plasmid Miniprep Kit ThermoFisher Scientific, US 
SilverQuest™ Silver staining kit Invitrogen, US 
 
2.2 Cloning 
2.2.1 Construction of expression vector for insect cell expression system 
This section explains the construction of the PV1 (Mahoney) expression vector for insect cell. 
All subsequent studies are based on this expression vector. 
Insect cell transfer vectors  
The PV1 expression vector (pOPINE Mahoney P1_2A_FS_3CEV71) was constructed based on 
the existing EV71 expression vector which had already shown expression of EV71 capsid 
proteins that assembled into empty capsids (Cone, 2015). The EV71 expression vector was 
produced by inserting the capsid polyprotein (P1) sequence, first 10 amino acid sequence 
derived from 2A, HIV frameshift sequence and 3C protease with the S128A mutation into the 
base pOPINE expression vector. These 4 features (P1-2A-FS-3C) in the expression cassette, 
were introduced downstream of the p10 promoter by In-Fusion cloning (Clontech, US) (Berrow 
et al., 2007). In-Fusion cloning is a method that allows the introduction of DNA fragments into 
any vector following unique primer design. The 5’ end of the primer contains 15 nucleotides 
which are homologous to the linearised vector. The 3’ end also requires an analogous 
homologous sequence in the insert. The total length of sequence added is around 40 
Table 2.9. List of commercial Kits 
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nucleotides. Linearised vector and PCR product are recognised by In-Fusion Cloning enzyme 
and the activity fuses the homologous sites to produce a new transfer vector. During this 
process unique restriction sites were added to the cassette system; a BstEII site at position 0 
of the P1 sequence and a NotI site at the junction between 2A and the FS. A Bsu36I site was 
placed at the end of 3C sequence. Figure 2.1 illustrates the transfer vector and its details. 
These sites allow the swapping of a P1-2A sequence for the resident EV71 sequence. A PV 
P1-2A synthetic gene with unique BstEII and NotI sites was produced by Lifetechnologies 
(US). Both EV71 expression vector and the synthetic vector were digested with BstEII and 
NotI, and then isolated by gel extraction (MinElute Gel Extraction kit and QIAquick Gel 
Extraction Kit, QIAGEN, Germay). The linearised EV71 transfer vector and PV P1-2A fragment 
were ligated by T4 DNA ligase (Thermo scientific, US) and then transformed into Stellar E. coli 
chemically competent cells. After antibiotic selection, plasmid DNA was prepared using 
plasmid preparation kits (QIAprep Spin Miniprep Kit or EndoFree Plasmid Maxi Kit, QIAGEN, 
Germany) and screened with ScaI digest, a marker for the PV sequence. Positives were 
verified by DNA sequencing (Source BioScience, UK). For expression of MEF-1, Saukette SC8 
and Mahoney SC6b the sequences were gifted by Andrew Macadam, NIBSC and synthetic 
DNA for P1 region of all clones were synthesised as GeneArt Strings (ThermoFisher, US) 
which contained BstEII site at 5’ and NotI at the 3’ end. Those P1 regions replaced the resident 
PV1 region at the restriction sites in the backbone vector. Following ligation, transformation 
and DNA sequencing, pOPINE MEF-1 P1_2A_FS_3CEV71, pOPINE Saukett SC8 





Figure 2.1. Schematic representation of the PV transfer vector 
The vector was constructed based on the pOPINE vector which has insect cell p10 promoter. Unique restriction 
sites, BstEII and Bsu36I were introduced to transpose the cassette system.  P1+2A and frameshifted 3C is 
separated by a NotI site to allow replacement of P1. (B) Annotated ORF of the cassette with frameshift. HIV FS 
regulates the ribosome progression to 3C (C) Detailed HIV frameshift sequence. The figure was modified from Porta 
et al., 2013b. 
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pTriEx1.1 Mahoney P1 
pTriEx1.1 Mahoney P1 was produced by ligation cloning. pTriEx was digested with either XhoI 
and NcoI to linearise. The linearised vector was cleaned by GeneJET Gel Extraction and DNA 
Cleanup Micro Kit (ThermoFisher Scientific, US). Mahoney P1 region including franking 
restriction sites, XhoI and NcoI were amplified by PCR using Phusion® High-Fidelity DNA 
polymerase master mix (NEB, US) which is described below. The transformation, plasmid 
preparation and sequencing of newly produced plasmid were performed as explained above. 
pOPINE Mahoney_3CD 
pOPINE Mahoney P1_2A_FS_3CEV71 was modified to accommodate the 3CD sequences. 
3CDWT and 3CDWTFS were cloned from the authentic virus sequence, a gift from Toby 
Tuthill. pET15b-3CDμ10 expression plasmid contains an extra serine at the 3C-3D junction to 
prevent auto-cleaving (Parsley et al., 1999) and was used as the source of the 3CD sequence 
for 3CD∆ and 3CD∆FS. The 3CD fragment was amplified following the same method as 
section 2.2.2 using primers which contain the cassette system unique restriction sites, NotI 
and Bsu36I to replace the resident 3C. Two types of forward primers were designed, 3CDF 
and 3CDFSF. 3CDF was designed for constructs that do not contain the frameshift sequence, 
which are 3CDWT and 3CD∆. 3CDFSF was used to introduce the HIV frameshift sequence 
into both 3CDWTFS and 3CD∆FS. The PCR product and the PV1 parental vectors were 
digested with NotI and Bsu36I. Following the ligation of 3CD fragment with the backbone vector 
and transfection into E. coli competent cells, newly constructed plasmids were purified and 
sequenced as explained above.  
Yeast cell expression vector 
The cassette consists of the P1-2A-FS-3CEV71 from the insect cell expression vector was 
amplified by PCR as per 2.2.2. Restriction site substitutions were included in the priming 
oligonucleotides (BstEII to EcoRI and Bsu36I to StuI) to facilitate cloning into the yeast vector 
pKT10. The PCR product was cleaned with GeneJET Gel extraction and DNA Cleanup Micro 
Kit (ThermoFisher, US). pKT10 was digested by EcoRI which was followed by the reaction 
cleanup using the same GeneJET kit. The purified PCR product was inserted into the linearised 
pKT10 by In-Fusion cloning (Clontech, Japan). The newly formed vector was transformed into 
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E. coli competent cells. The plasmid was purified using GeneJET Plasmid Miniprep Kit and 
verified by DNA sequencing (Source Bioscience, UK) prior to transformation of yeast. 
VP1 mutant expression vectors 
The mutations were inserted by overlap site-directed mutagenesis (Ho et al., 1989) in the 
baculovirus expression vector (pOPINE Mahoney P1_2A_FS_3CEV71) followed by re-cloning 
via the restriction digest and ligation method. By site-directed mutagenesis, primers carrying 
the desired mutation were used for PCR to introduce the mutation in the product and re-amplify 
the full-length product. Following the procedure, AgeI and NotI double digest was carried out 
for both PCR product and the parental vector. The ligation with PCR product with newly 
introduced mutation and the double-digested pOPINE Mahoney P1_2A_FS_3CEV71 produced 
the baculovirus vector with the desired mutation. For the yeast expression vector, the AgeI and 
NotI fragment which ultimately contained the mutation, were cloned into the exact restriction 
sites of pKT10 Mahoney P1_2A_FS_3CEV71. 
2.2.2 Polymerase chain reaction (PCR) 
Phusion® High-Fidelity DNA polymerase master mix (NEB, US) was chosen for all 
amplifications for its low error rate in DNA amplification. 
The PCR is performed following the manufacturer’s protocol. The reaction mixture is prepared 
to contain 0.5 μM forward and reverse primers, template DNA (5ng), 1X Phusion® High-Fidelity 
PCR Master Mix with HF Buffer (NEB, US) and Nuclease-free water to make up to the final 
volume. After the reaction mixture is placed in a thermocycler and the following condition is 
applied; initial denaturation at 98 °C for 30 seconds and then 30-35 cycles of 98 °C for 10 
seconds (denaturation), 45-72 °C for 30 seconds (annealing) and 72 °C extension, whose time 
was adjusted according to the product size, and 1 cycle of final extension at 72 °C for 10 
minutes. The PCR product was visualised by agarose gel electrophoresis to ensure the purity. 




2.3 Insect cell culture 
Sf9 cells, High Five cells and Tnao38 cells are insect origin cells. They were used in routine 
virus passage and/or expression. In order to minimise the contamination to these cells, they 
were handled under sterile condition in a laminar flow hood. Insect cells were grown in Insect-
XPRESS™ Media (Lonza, Switzerland). The suspension cultures were placed in a 28 °C 




 day of passage, a cell count 
was obtained using a Countess® Automated Cell Counter (Lifetechnologies, US) to decide the 
cell dilution for next passage. Sf9 cells and T.ni cells were adapted to grow in serum free insect 
media. Tnao38 cell was culture in insect media with 2% FCS. 
2.3.1 Transfection and recombinant baculovirus production 
Sf9 cell were transfected with flashBAC GOLD (Oxford Expression Technologies, UK), using 
lipofectin (Invitrogen, US), the transfer vector and nuclease free water. Each well of 6 well dish 
was seeded with 1X10
6 Sf9 cells (50 % confluence). The transfection mixture was incubated 
for 15 minutes at room temperature and transferred into the well with 1ml of serum free insect 
media. The 6 well dish was incubated in a 28 °C incubator and the following day, the media 
was changed to 2 ml of media containing 2 % FCS. On 7
th
 day from transfection, the 
recombinant virus was harvested by centrifugation at 13000 rpm for 3 minutes. The 
supernatant, which contains recombinant virus, was passaged to fresh cells settled in 6 well 
dishes. Subsequent passages were followed every 4 or 5 days until virus titre was so high that 
CPE become visible under a microscope.   
2.3.2 Recombinant protein expression 
Small-scale infection 
Once a recombinant virus was produced, a small size infection using a 6 well dish was set up 
to assess the recombinant protein expression. Each well was seeded with the cell type of 
choice (for the first test, normally the Sf9 cells) at 50 % confluence (1X10
6
). 200 µL of the virus 
stock (10 % of total infection size) was added and the infection progress was monitored under 
an inverted microscope. At 3 days post infection the infected cells were harvested by gentle 
pipetting and centrifuged at 13000 rpm for 3 minutes to separate cell pellet and supernatant. 
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The pellet was re-suspended with PBS at 1/20 volume of the original infection volume (i.e. 2 
ml infection = 100µL). 
Rupintrivir 3C protease inhibition  
Six well dish small-scale infections using the PV1 recombinant baculovirus were set up. At 3 
hours p.i., 10-fold serial dilutions of Rupintrivir in insect cell media starting at 330 nm to 0.33 
nm were added to the individual wells. Two days later, the infected cells were harvested and 
the cell pellet was re-suspended in the same manner as described above. 
2.3.3 Protein expression scale up 
A large volume of recombinant virus is required to scale up the protein expression to obtain 
purified VLP. Monolayer cultures were used for amplification of the virus stock. Cell culture 
flasks were seeded with a suitable number of Sf9 cells to achieve 50% confluence. Once 
recombinant virus was added, the flask was incubated in 28°C incubator. On the 7
th
 day, CPE 
was easily observed. The cells were lifted by gentle tapping and collected and then centrifuged 
at 4500 rpm, 20 minutes at 4 °C. The supernatant containing recombinant baculovirus was 
pooled and stored at 4 °C. When a sufficient amount of recombinant virus is obtained, a 
suspension culture was prepared to be 1x10
6 
cells/ml to commence the infection. 10 % of total 
infection volume of virus stock representing an MOI of ~3 was added to the cell culture and 
placed in the incubator for 3 or 4 days until its viability reached 30-40%. The infected cells 
were harvested by centrifugation at 4500 rpm, 20 minutes at 4°C. The pellet was stored at -
80°C. 
 
2.4 Yeast cell culture 
RAY3A-D (MATa/a ura3/ura3 his3/his3 leu2/leu2 trp1/trp1), a strain of Saccharomyces 
cerevisiae was used for PV VLP production. The strain was kindly gifted by Dr Yuko Morikawa, 
Kitasato University, Tokyo, Japan. For RAY3A-D and recombinant yeast expression culture, 
YPD media was used. During the transformation, synthetic dropout (SD) media was utilised. 
The expression vector has a uracil marker. Therefore, SD media lacking uracil was used. For 
parental yeast growth, culture was prepared at 250 rpm shaking at 30 °C overnight. For the 
expression, the temperature was lowered to 20 °C for slower yeast growth. 
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2.4.1 Yeast cell transformation and its confirmation 
pKT10 with the PV cassette expression vectors were transformed into S. cerevisiae using the 
lithium acetate (LiAc) protocol described by Herskowitz (2012). RAY3A-D was grown in YPD 
media over night to reach saturation. The following day, the saturated cells were diluted in the 
fresh 100 ml media at an OD600 reading of 0.2 and grown to reach OD600 0.5-0.7 at 30°C, 250 
rpm. The cultures were harvested at 3000 rpm for 5 minutes. The cell pellet was washed in 5 
ml LiAc mix (100 mM LiAc in TE buffer) and recovered by centrifugation. 1 ml of LiAc mix was 
added to the pellet and 100 μL aliquots were taken per transformation. 1 μg pKT10 expression 
vector with the PV cassette, 50 μg salmon sperm DNA as a carrier and 0.7 ml PEG mix (40 % 
PEG in LiAc mix) were added and vortexed. The cells were incubated at 30 °C for 30 minutes 
and then heat-shocked at 42 °C for 20 minutes. The cells were then centrifuged at 3000 rpm 
for 30 seconds. The pellet was dispersed in 200 μL sterile diH2O and plated out onto SD media 
agar. For RAY3A-D transformed cells, uracil lacking media was utilised. The plate was 
incubated at 30 °C for 3-4 days. Once the colonies were observed on the plate, a glycerol 
stock for the transformed yeast cells were prepared. The colonies were resuspended in 0.5 ml 
of the synthetic dropout media, sterile glycerol to 25 % was added and was kept in a -80 °C 
freezer for the future use. At the same time, the transformed plasmid was re-isolated to confirm 
successful transformation using a yeast plasmid isolation kit (Clontech, US). The purified 
plasmid was transformed back into Steller E. coli cells (Clontech, US). pKT10 plasmid has the 
bacterial origin of replication and an antibiotic resistant marker therefore it can be recovered 
into E. coli cells. After growing the inoculation overnight, the plasmid was purified from the 
E.coli cells and DNA sequencing verified the transformation as described in section 2.2.1. The 
steps from the transformation to the confirmation of the presence of the expression vector are 
summarised in Figure 2.2. 
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2.4.2 PV VLP expression by S. cerevisiae 
For each culture preparation, transformed yeast cell glycerol stocks were streaked on SD 
media agar for the start culture. The culture was prepared by incubating scraped yeast cells 
from the plate at 30 °C overnight at 250 rpm. The following day, the saturated media were 
transferred to seed YPD medium for the expression phase. The expression medium at starting 
OD600 of 0.2 was incubated at 20 °C overnight at 250 rpm and left to grow to the desired 
density. The culture was harvested by centrifugation at 5000 rpm for 20 minutes at 4°C. If it 
was not required immediately, the pellet was stored at -80°C.
Figure 2.2. Schematic representation of yeast expression vector transformation and its confirmation flow 
Once the expression vector is constructed, it was transformed into S. cerevisiae cells by LiAc transformation 
method. Then the selection of the cells combined with the expression vector carrying URA3 gene was carried out 
on the SD media lacking uracil. For the confirmation of positive transformation, the expression vector was purified 
from the yeast cells and transformed back into competent E. coli cells to purify the plasmid. The vector was 
prepared from the E. coli cells and then sequenced to confirm its identity. 
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2.5 Purification of recombinant PV empty capsid 
The method described in this chapter especially for yeast cell derived VLPs was later improved. 
The changes will be described in chapter 5. 
2.5.1 Cell lysis 
Insect cell  
For VLP purification from the insect cells, the pellet was re-suspended with 10X volume of PBS 
for the pellet weight. Afterwards, a total concentration of 1 % Nonidet® P40 (Fluka, US) in PBS 
and 20 units/ml Benzonase® nuclease (Sigma-Aldrich, US) and 1 cOmplete™ ULTRA 
protease inhibitor tablet (Roche, Switzerland) were added and incubated in ice for 60 minutes. 
Clarifying by centrifugation removed unbroken cells and nuclei leaving the supernatant which 
contained the PV VLP. 
Yeast cell lysis by cell disruptor 
The harvested PV VLP yeast cells were resuspended in ice cold buffer 1 supplemented with 1 
tablet of cOmplete™ ULTRA protease inhibitor (Roche, Switzerland). First, the cell disruptor 
cooling system equipped with glycerol was switched on 30 minutes prior to the operation. The 
system was purged with ice cold diH2O and then ice-cold buffer 1 (without protease inhibitor). 
The pressure was set to 2.5 bar (280 MPa). The sample was loaded onto the system. The 
sample consistency was checked to be free from clumps or high viscosity and 10 ml sample 
volumes were pressurised in one press. The sample temperature was monitored for PV VLP 
stability. 
2.5.2 Ultracentrifugation 
The ultracentrifugation condition, including medium, centrifuge speed, time, and gradient was 
changed through the project to improve the yield. Here, the basic procedure is described. The 
condition for each ultracentrifugation will be noted later where appropriate.  
Two types of ultracentrifugation; velocity centrifugation and isopycnic centrifugation have been 
used. The first type separates the particles into distinct zones on the basis of the size and 
shape (which contribute to the sedimentation rate). Normally sucrose is chosen to form a 
gradient. In the second type, the particles undergo separation by differences in their buoyant 
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density. Once the centrifugation starts, the particles migrates to the equilibrium point where 
the particle’s buoyant density and the gradient density are the same. At this point, the 
isodensity level, the sample does not migrate any further (Mazzone, 1998). A sucrose cushion 
is a simple form of pre-gradient (Dijkstra & Jager, 1998). In our project, 30 % sucrose was used 
because assembled capsids can migrate through this sucrose layer to reach the bottom of the 
centrifuge tube. Any other smaller substances cannot enter the layer, hence, they are 
separated. This process is used as a first selection step before the final gradient step. 
After the cell lysis or supernatant concentration, debris was removed by clarification 
centrifugation at 15,000 rpm, 30 minutes at 4°C. The clarified supernatant was loaded onto the 
30% sucrose layer and centrifuged at 30,000 rpm for 16 hours at 4 °C. Depending on the 
supernatant size, it was loaded into Thinwall Ultra-Clear tubes for either the SW32 Ti rotor 
(38.5ml capacity) or SW40 rotor (13.2 ml). The formed pellet at the bottom of tube was 
resuspended in a small volume (~800 μL) of appropriate buffer. The resuspension was 
centrifuged at 15,000 rpm, 30 minutes at 4 °C in a refrigerated bench top centrifuge to remove 
insoluble aggregates and the supernatant was removed from the tube and stored on ice. The 
newly formed pellet was resuspended in a small volume of buffer and centrifuged again. The 
combined supernatant was then loaded onto the sucrose gradient consisting of a 20-60 % 
discontinuous sucrose gradient with 5 % increments or a linear 15-45 % sucrose gradient 
produced by a gradient master base unit (BioComp Instrument, Canada). The gradient maker 
prepares a linear gradient of the media automatically by mixing the most and least 
concentrated media at a specific angle, with a specific rotation and length of time. 
Ultracentrifugation at 30,000 rpm or 21,000 rpm at 4 °C for 16 hours separated the VLPs into 
different zones and the sample was fractionated from the top of the gradient. 
Occasionally, a 2
nd
 ultracentrifugation was done to improve the VLP purity. Following the 
analysis of 1
st
 gradient, the chosen fractions were pooled and diluted to remove the sucrose 
or passed through a Zeba 7K MWCO desalting spin column. Once the removal of sucrose was 
completed, the eluate was concentrated using an Amicon Ultra 4 ml or 15 ml cassette to lay a 
small volume on top of the 2
nd
 sucrose gradient and ultracentrifuged as described above.
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2.6 SDS-PAGE and Western blot assay 
Samples for western blot were prepared by adding 2X SDS loading buffer (2.1.8) or 4X Bolt™ 
LDS sample buffer (Invitrogen, US) containing 2-mercaptoethanol. For insect cells from a 
small-scale infection, 5x10
4 
cells were loaded per well. In order to denature the sample 
completely, they were vortexed for 30 seconds, centrifuged briefly at maximum speed and 
boiled for 10 minutes at 100 °C. The samples were then blended for 30 seconds to reduce 
viscosity with a vortex and centrifuged again for 5 minutes at 13000 rpm. Sodium dodecyl 
sulphate gel electrophoresis (SDS-PAGE) was run to separate the denatured protein samples 
using a Mini-PROTEAN® TGX™ Gel, 10 well, 30μl (Bio-Rad Laboratories, US) with 1X Tris-
Glycine SDS PAGE buffer (National Diagnostics, US) or Bolt™ Bis-Tris Plus Gels, 10-well 
(Invitrogen, US) with 1x Bolt™ MES SDS running buffer (Invitrogen, US). Once the gels 
finished running, they were either stained for visualisation by coomassie staining (2.1.8) or 
silver stained by the SilverQuest™ Silver staining kit (Invitrogen, US) or transferred for western 
blot. For western blot, the gel was then transferred onto an Immobilon-P transfer membrane 
(Merck Millipore, US) by semi-dry transfer. The transfer membrane and Whatman™ 3MM 
Chromatography Paper (GE healthcare, US) were soaked in 1X Tris-glycine electroblotting 
buffer (National Diagnostics, US) supplemented with methanol. The transfer sandwich (3 
layers of chromatography paper, membrane layer and another 3 layers of chromatography 
paper) was prepared on a HorizBLOT (Atto, Japan). After the transfer, the membrane was 
incubated in either Western blot (WB) blocking buffer, Protein-free T20 (TBS) blocking buffer 
(Thermo Scientific Pierce, US) or at 4 °C or renaturing buffer at RT overnight. The membrane 
was incubated with TBST (2.1.8) 3 times (5 minutes each) to wash off any excess carry over 
from the previous step. The membrane was then incubated with primary antibody for 1hour 
together with the same buffer used in the blocking step except in the cases of renaturing buffer. 
For membrane blocked with renaturing buffer, Protein-free T20 (TBS) blocking buffer was used 
for antibody incubation. On completion, membranes were washed 3X 5 minutes in TBST. 
When the primary antibody is not conjugated with horseradish peroxidase (HRP), a secondary 
antibody conjugated with HRP was incubated to probe for the primary antibody. Typical Ab 
combinations for a particular antigen detection are listed in Table 2.10.  
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ChemiFast (Syngene, UK) was used as a chemiluminescent detection agent to react with HRP. 
The antigen was detected by G:Box imager (Syngene, UK) to produce a digital image. 
 
  D  Detection  Primary Ab HRP conjugated secondary Ab 
VP1 detection 
Anti-poliovirus Blend Ab 
(MAB8566, Millipore at 
1:5000) 
Polyclonal Goat Anti-mouse 
Immunoglobulins/HRP (P0447, 
Dako at 1:2000) 
VP0 detection 
Rabbit anti-VP0 sera 
(Day 39, Host lab at 
1:2000) 
Polyclonal Goat Anti-rabbit 
Immunoglobulins/HRP (P0448, 
Dako at 1:2000) 
VP3 detection 
Rabbit anti-VP3 sera 
(Collaborator at 1:2000) 
Polyclonal Goat Anti-rabbit 
Immunoglobulins/HRP (P0448, 
Dako at 1:2000) 
P1 detection 
Rabbit anti-PVP1 sera 
(Collaborator at 1:2000) 
Polyclonal Goat Anti-rabbit 
Immunoglobulins/HRP (P0448, 




(Collaborator at 1:2000) 
Polyclonal Goat Anti-mouse 
Immunoglobulins/HRP (P0447, 
Dako at 1:2000) 
 
2.6.1 Rapid analysis of VP expression in Yeast 
This procedure enabled rapid analysis for the recombinant protein extraction from S. cerevisiae 
(Kushnirov, 2000). For the expression analysis of PV VPs, colonies grown on YPD agar were 
scraped off and resuspended in 100μL distilled water. Alternately, a fraction of liquid culture 
(2.5 OD600U/ml) which provided roughly 2.3 mg of yeast pellet in wet weight, was resuspended 
in distilled water. Then, 100 μL of 0.2 M NaOH was added and incubated for 5 minutes at room 
temperature. After pelleting in the bench top centrifuge at 14000 rpm for 5 minutes, the sample 
was resuspended in 50 μL 1X SDS loading buffer, boiled for 3 minutes, then pelleted. The 
Table 2.10. Combination of primary and secondary antibodies for a particular detection in WB analysis.  
The detail of the antibodies are listed on Table 2.7 
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prepared samples were analysed by WB following the SDS-PAGE and semi-dry transfer as 
described in section 2.6.  
 
2.7 Microscopy 
Two types of imaging were utilised for this project to visualise PV VLP. Gated-Stimulated 
Emission Depletion (gSTED) microscopy situated at the Research Complex at Harwell. Dr 
Christopher Tynan helped to operate the microscope. Transmission Electron Microscopy, Joel 
TEM available at The University of Reading. Dr Peter Harris and Miss Amanpreet Kaur gave 
technical training.   
2.7.1 Gated-Stimulated Emission Depletion (gSTED) microscopy 
gSTED microscopy produces high resolution images utilising improved fluorescence confocal 
imaging and is especially user friendly for live cell imaging. STED microscopy generates the 
images by using two different beams, excitation laser beam and STED beam. The excitation 
beam strikes the sample conjugated with fluorophore whereupon the fluorophore emits Stoke’s 
shifted emission photon. It scans the fluorophore in a section of interest pixel by pixel. The 
STED beam defines the excitation strike spot by surrounding it. With two beams, the central 
area of STED beam fluorescence detection is enhanced to produce the final image (Vega, 
2014).  
Small scale infection with recombinant baculovirus was carried out in poly-D-lysine coated 
glass-bottom 35 mm sterile dishes (MatTek, US) following section 2.3.2. After 2 days infection, 
the virus and media was discarded from the dish. Infected cells were fixed and permeabilized 
using a Fixation/Permeabilization kit (BD Bioscience, US). The solution was washed off with 
blocking/wash buffer, PBS with 2 % BSA. Then the specimen was blocked in blocking/wash 
buffer for 1h. After aspirating the buffer, the primary antibody against the target protein was 
diluted in the same buffer and incubated for 1h. The fixed sample was washed with the 
blocking/wash buffer 3 times, 5 minutes incubation each. Fluorophore conjugated secondary 
antibody was diluted in the same buffer and used to incubated the specimen in the dark for 1h. 
After a 2
nd
 wash, the sample was sealed with parafilm and kept in dark until the specimen 
observation. The standard operation manual was followed for imaging. The choice of imaging 
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wavelength according to the fluorophore is important for high resolution image. For Oregon 
green 488, manufacturer recommends to detect the wavelength around 514 nm. At the same 
time, STED beam intensity was adjusted to improve the resolution.  
2.7.2 Transmission Electron Microscopy  
Once samples were adjusted for correct concentration in a buffer for TEM imaging, a couple 
of microliter was laid on a piece of parafilm. Two droplets of diH2O were placed next to the 
sample. These are flowed by two droplets of 0.45 µm filtered 2 % uranyl acetate. Once all the 
solutions were prepared on the parafilm, formvar/carbon 300 mesh copper grid was floated on 
with shiny side facing the sample. After 5 minutes incubation, any excess sample on the grid 
was removed by filter paper. The grid was transferred onto the first diH2O and moved to 
second. The excess solution was blotted with the filter paper. Then the grid was placed on the 
uranyl acetate for 5 minutes. Then moved to second droplet and the excess was removed by 
filter paper. After preparing the grid, it was stored in a grid box. The TEM was operated 
following a standard protocol. For PV VLP visualisation, high tension was set for 200 kV. 
Typically, PV VLP images were obtained around X27,500 magnification. Higher magnification 
is desired for PV VLP particle size.  
 
2.8 N/H ELISA 
This ELISA protocol was modified from the original protocol offered by the National Institute 
for Biological Standards and Control (NIBSC).  
A clear flat-bottom immune nonsterile 96-well plate (Thermofisher, US) was coated with 
poliovirus capture antibody (SH16 for PV1 at 1:500 and R Skt live for PV3 at 1:2000) diluted 
in carbonate coating buffer (2.1.8) for at least 16 hours prior to the assay. Once the plate is 
coated, the plate was sealed and placed in a lunch box with a humidified atmosphere. The box 
was stored in 4 °C. The following day, the plate was washed with PBST (2.1.8) 3 times. Then 
the plate was incubated in blocking solution (2.1.8) for 30 minutes at room temperature.  
In the meantime, sample dilutions were prepared. The European PV standard was diluted in 
assay diluent to 1:20 for the start dilution (2.1.8). The dilutions of the purified samples from the 
expression systems varied on each occasion. Duplicate of samples were prepared for N and 
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H specific antigen analysis. Columns 1 to 5 was used for N specific ELISA and columns 7 to 
11 for H specific ELISA. The samples were added in column 1 and 7. From the columns, 5 
series of 1:2 dilutions were made. One row was added with assay diluent to serve as a blank. 
The plate was sealed and placed in the humidified atmosphere lunch box. It was incubated at 
room temperature for 2h.  
After the incubation, the plate was washed with PBST 3 times. Then diluted monoclonal 
antibodies for N and H were then added to the wells. N specific antibodies (234 for PV1 and 
520 for PV3) were diluted in 1:200 in assay diluent. The same dilutions were used for H specific 
antibodies (1588 for PV1 and 517.3 for PV3). The plate was placed in the same box and 
incubated at room temperature for 1h. 
After the plate was washed 3 times with PBST, goat anti-mouse HRP conjugated antibody 
(2.1.7) at 1:1000 in assay diluent was added to the wells. The plate was incubated in the same 
manner as above, which was followed by a 3 plate washes with PBST. 
For detection, TMB Stable (Thermofisher, US) was added to the well and incubated up to 30 
minutes at room temperature. In order to stop the TMB stable reaction with HRP, 0.25 M H2SO4 
was added. The optical density at 420 nm was read by a Tecan plate reader, with Magellan 6 
software. The result was exported from the programme to an excel sheet and OD vs serial 
dilution graphs were plotted.
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  Capsid protein expression and assembly in insect 
cells 
3.1 Introduction 
3.1.1 VLP production in insect cells 
Previous studies on the expression of FMDV empty capsids in insect cells defined the minimal 
proteins required; the structural polyprotein (P1), the self-cleaving 2A peptide and the 3C 
protease (Lewis et al., 1991; Roosien et al., 1990). Using these components, a P1-2A construct 
synthesised the FMDV structural polyprotein but a P1-2A-3C cassette failed in the expression 
of significant amounts of the individual structural proteins. The study suggested that the 3C 
protease activity led to 3C cleavage of host cell proteins as well as P1 precursor cleavage 
(Porta et al., 2013). To overcome this, it was suggested that 3C protease activity down 
regulation would be required for the efficient synthesis of the mature viral structural proteins 
and this was achieved by the addition of two 3C regulators. The first regulation was done by 
the introduction of a mutation in the 3C enzyme shown to reduce activity in vitro (Sweeney et 
al., 2007). The second level of regulation was the addition of a HIV-1 ribosomal frameshift 
signal between P1-2A and 3C. The signal consists of two distinctive structural features. A 
hexameric ‘slippery site’ consisting of 6T nucleotides followed downstream by a stem-loop, an 
RNA secondary structure thought to cause ribosomal pausing (Dinman et al., 2002). These 
two elements are linked by a spacer sequence (2A first 10 amino acids) and together they 
facilitate ribosome slip back by one base in the 5’ direction, and then start a new reading frame 
from the -1 frame codon. The level of slippage of the HIV frameshift is reported to be about 1 
in 20 translation events (Wilson et al., 1988). A schematic representation of the HIV-1 
frameshift is shown in Figure 3.1. The use of this signal acts to translate P1-2A as the majority 
product and P1-2A-FS-3C as the minority product, effectively reducing the level of 3C 
compared to the level of P1. The combined use of these regulators effectively reduces 3C 
toxicity and allows the build-up of sufficient cleaved mature picornavirus capsid proteins for 
empty capsid assembly to occur (Porta et al., 2013).  
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An analogous mutation affecting 3C activity, serine 128 to alanine, has been shown for EV71, 
another member of the Picornavirus family (Cui et al., 2011) suggesting a similar strategy could 
work for empty capsid production for enterovirus members. Indeed, previous work in the host 
laboratory showed that EV71 capsids could be assembled in insect cells using the same 
cassette design as that described for FMDV (Cone, 2015). As the sequences of the EV71 3C 
and that of poliovirus 3C are very similar as shown in Figure 3.3, the modified EV71 3C 
sequence was used for the construction of equivalent cassettes for the expression of PV empty 
capsids. For the structural P1 region, IPV virulent reference strain sequences of the three PVs, 
Mahoney/PV1, MEF-1/PV2 and Saukett/PV3 were chosen for the initial production of PV VLP. 
However, during the course of the work, viruses with improved stability were described (Fox 
et al., 2017) and VLPs made in plants using a the same, improved, sequence from PV3 Saukett 
were shown to be more stable than the WT sequences (Marsian et al., 2017). Therefore, in 
later experiments a sequence variant, Saukett SC8, was used for insect cell expression rather 
than the wild type sequence.  
 
Figure 3.1. Schematic presentation of PV viral proteins expression cassette showing controls for 3CEV71 
P1 region is coloured in blue and is followed by the first 10 amino acids of 2A in green. The HIV-1 frameshift is 
shown in orange connected to the 3C grey region. The orange area focuses on the nucleotide sequence at the 
frameshift slipping site. The majority of expression terminates after the host cell ribosome drops off from ORF1 but 
a minority of the ribosomes continue translating in the -1 frame after the frameshift sequence (Wilson et al., 1988). 
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3.1.2 Protease for P1 processing 
The difference in the roles of 3C and 3CD
pol 
in the proteolytic processing of P1 has been 
previously investigated. In the picornaviral replication cycle, 3C is one of the proteases which 
is responsible for cleavage of the polyprotein at a Gln-Gly junction into functional mature 
protein products (Kuo et al., 2008), including temporary intermediate products (Lawson & 
Semler, 1990). These intermediate products have functions which are different from the final 
cleaved products. One of such products is the viral polyprotein 3CD as discussed in 1.2.4. 
Comparative studies using poliovirus 3C and 3CD protease showed that 3CD protease cleaves 
more efficiently than 3C, although 3C contains the enzymatic active site (Andino et al., 1993; 
Harris et al., 1994; Jore et al., 1988; Mosimann et al., 1997; Ypmawong et al., 1988a; 
Ypmawong et al., 1988b). These data suggested that certain 3D regions act as a 3C activity 
enhancer. While the mechanistic details are poorly understood, the necessity for 3D in P1 
cleavage was shown in several studies (Jore et al., 1988; Parsley et al., 1999; Ypmawong et 
al., 1988b). A 3CD construct which contains a serine insertion at the junction between 3C and 
3D to eliminate the auto-cleavage of 3C and 3D showed enhanced cleavage of PV viral 
proteins produced by bacterial expression (Parsley et al., 1999). These historical findings led 
to the use of 3CD in recombinant expression systems to produce empty PV capsids using P1 
and 3C/3CD. Ansardi et al. (1991) showed co-infection of one recombinant vaccinia virus 
expressing P1 and the other 3CD resulted in PV viral proteins expression in HeLa cells. The 
Figure 3.2. BLAST result of 3CEV71 and 3CPV 
The result aligned 3CPV and 3CEV71 to find the amino acid sequence homology. The result was produced by UniProt. 
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sucrose gradient fractionation pattern was found to be consistent with sedimentation of PV 
empty capsids and electron microscopy showed empty capsids with a capsid centre 
penetrated by stain and of suitable size and shape. Similarly PV VLP production in 
Saccharomyces cerevisiae used P1 and 3CD expression vectors (Rombaut & Jore, 1997). 
However, the host laboratory has shown that FMDV and EV71 VLPs are produced in insect 
cell expression system using a single transfer vector with a regulated 3C rather than co-
expression of P1 and 3CD. These findings suggest that there is a need to study the preferred 
protease in the insect cell system for the expression of PV empty capsids via a single 
expression cassette.  
In this chapter, the synthesis of PV viral proteins by the recombinant baculovirus expression 
system and their assembly to PV VLPs is investigated. Optimisation experiments include an 
investigation of PV VLP production by the preferred protease, 3C or 3CD.  
3.2 The expression of viral proteins for PV1, PV2 and PV3 
3.2.1 Construction of insect cell expression vector 
The expression vector construction was carried out as per 2.2.1. Figure 3.3 summarised the 
cassette system used for all the PV serotypes. Using existing expression vectors that had 
previously shown EV71 VLPs assembly in insect cells (Cone, 2015) the sequence of P1EV71 
and first 10 amino acids of 2A was removed from the vector pOPINE EV71 P1_2A_FS_3C 
and replaced by PV P1 (Mahoney/PV1, MEF-1/PV2 and Saukett/PV3) and the first 10 amino 
acids of 2A to construct equivalent insect cell expression vectors with the potential to assemble 
PV VLPs following baculovirus expression. The vectors produced were pOPINE Mahoney 
P1_2A_FS_3CEV71, pOPINE MEF-1 P1_2A_FS_3CEV71, and pOPINE Saukett SC8 
P1_2A_FS_3CEV71. In addition, to provide a suitable control for the non-cleaved polyprotein, 
pTriEx1.1 Mahoney P1 was also produced for the expression of PV P1 only. The method is 
detailed in 2.2.1.  
3.2.2 Synthesis of VP0, VP3 and VP1 by 3CEV71 
Expression vector transfection and recombinant baculovirus production, followed by small-
scale infections and WB to examine protein expression and cleavage were carried out as 
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described in 2.3.1, 2.3.2 and 2.6. Recombinant baculoviruses, Bac-PV1P1-3C, Bac-PV2P1-
3C, Bac-PV3P1-3C, Bac-PV1P1 and Bac-GFP (expression control) were produced following 
the transfection of the relevant expression vectors and virus passage to generate high titre 
stock.  
 
To assess the genetic cassette design for the expression of PV proteins, a time-course of 
infection was carried out using Bac-PV1P1-3C infection of Sf9 cells. A six well dish was seeded 
with ~10
6
 Sf9 cells per well and infected with 0.1mLs of the PV1 recombinant baculovirus stock 
for 1 hr at room temperature. The inoculum was then removed and replaced with 2mls of 
culture medium. A single well of the infection was harvested each day. The baculovirus 
inoculum had a titre of ~5 x 10
7
 pfu/ml giving an MOI of ~5 for this and subsequent experiments. 
Approximately 1/20
th
 of the harvested well, that is ~5x10
4
 insect cells were analysed per well 
of a precast Bolt™ Bis-Tris Plus 4-12% gels (Invitrogen, US). VP1 detection was carried out 
by WB using a mixture of monoclonal antibodies, MAB8566, to all 3 PV serotypes (Millipore) 
(Figure 3.4). A ~32 kDa band, which was identical to the calculated VP1 MW, was visible in 
the infected insect cells from day 1 to day 4 with the intensity peaking at day 3. A minor 
intermediate band was visible at ~57 kDa, possibly representing VP3-VP1, and a high MW 
band, possible an aggregate of protein and DNA, was also present near the slot. No discreet 
Figure 3.3. The expression cassette designs for all three serotypes of PV.  
The colour scheme was maintained the same as Figure 3.1. 
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band of P1 was apparent suggesting complete polyprotein processing.  Some non-specific 
binding of the anti-VP1 Ab was seen to non-infected Sf9 cells but the band intensities were 
very low and the cross reaction did not obscure the VP1 band present in the test lanes. This 
result confirmed that the expression vector functioned as designed and that VP1 is produced 
by P1 proteolytic processing. It also showed that a 3
 
days infection was optimum for the 
detection of PV viral proteins, a time course typical of baculovirus expression driven by very 
late promoters (O'Reilly et al., 1992). 
 
To confirm that the expression of PV1 VP1 was typical of all the serotypes constructed, small-
scale 3 day infections by Bac-PV1P1-3C, Bac-PV2P1-3C and Bac-PV3P1-3C were also 
prepared in Sf9 cells. In addition, to assess the role of the host cell line on expressed protein 
yield, High Five cells and Tnao38 cells both originally from T.ni were also infected in an 
identical format. Infection by the Bac-GFP recombinant and insect cells only acted as infection 
and mock controls. At 3 day p.i. the cells were harvested and processed for WB as before. In 
these assays, in addition to the use of a VP1 specific antibody, polyvalent sera specific for VP0 
Figure 3.4. WB analysis for VP1 presence following a time course (1-4 days) small-scale Sf9 cells infection of Bac-
PV1-P1-3C 
The reactivity at 32kDa band increased to 3
rd
 d.p.i. and slightly declined on 4
th
 d.p.i. Sf9 cells were included as a 
negative control (far right). Protein molecular markers are shown to the left of the gel (M) and are in kilodaltons. 
Mini-PROTEAN TGX Any kD gel (BIO-RAD) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used.     
VP1 
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and VP3 (gifted by Dr Jane Cardosa, Universiti Sains Malaysia) were also used as primary 
antibodies. The WB analysis showed efficient PV1 P1 cleavage into VP1 (Figure 3.5A1) as 
before but also the presence of VP3 (Figure 3.5B1) and VP0 (Figure 3.5C1) as expected of 
authentic 3C mediated maturation of PV1 (Figure 3.5 left panels, column 1). In addition, the 
equivalent constructs for PV2 (Figure 3.5 middle panels, column 2) and PV3 (Figure 3.5 right 
panels, column 3) showed that these serotypes too are expressed and cleaved into their 
requisite mature viral proteins. When the signal intensity of the test tracks (lanes 2-4) was 
compared it was found that the yields of PV proteins were in the order Tnao38≥High Five>>Sf9, 
irrespective of the serotype used. When the different serotypes were compared it was evident 
that PV2 expression (middle panels) was lower than either PV1 or PV3. 
In the case of PV2 expression of VP1 (Figure 3.5A2) it was possible that the lower intensity is 
in part due to the MAB8566 mixture (anti-VP1 Ab) as the MEF-1 VP1 sequence at residue 295 
is different from the Sabin type 2 sequence which was used for production of the mAb (Gary 
et al., 1997). However a lower yield from PV2 was also apparent on the blots probed by VP3 
(B) or VP0 (C) blots, the latter being barely detectable, suggesting that the PV2 sequence is 
generally more poorly expressed. The reasons for this are unclear. The patterns of antigen 
expression revealed by the blots were generally similar although in the case of VP1 detection 
for PV3 (Figure 3.5A3) a slightly smaller band was detected in addition to the VP1 band. This 
might suggest some altered processing in different cell lines but could also reflect the affinity 
of the antibodies in the polyclonal sera for certain breakdown products. As the sera have not 
been formally epitope mapped this cannot be confirmed by inspection of the epitope 
sequences. The Anti-VP3 sera bound a major band at molecular weight 27 kDa for PV1, PV2 
and PV3 consistent with predicted MW of VP3. (Figure 3.5B1-3). The VP3 antiserum also 
showed a high background binding to GFP in the expression control lanes. In contrast the VP0 
serum had a low background and bound specifically to a 40kDa band as predicted for the MW 
of the VP0 product (Figure 3.5C1 and C3). A range of background bands were present on the 
blots but their origin is not known. Figure 3.5D showed that the baculovirus capsid protein p39 
was detected at similar rates in all infections suggesting equivalent rates of infection thus 
supporting the conclusions concerning different levels of PV antigen expression based on 
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serotype and cell line. Higher molecular weight bands in PV lanes, which are visible in (A), (B) 
and (C) may represent unprocessed or partially processed P1. 
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VP1 (A) 
   
VP3 (B) 
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3.2.3 Confirmation of P1 cleavage by the 3CEV71 protease 
The data in Figure 3.5 indicated that the P1 precursor of all PV serotypes can be processed 
by the 3CEV71 protease. To confirm that this specificity was the result of 3C protease activity 
alone, the processing in insect cell was assessed following infection by Bac-PV1P1 (without 
3CEV71), which expresses unprocessed P1 and Bac-PV1P1-3C (with 3CEV71), which produced 
cleaved viral proteins. The expressed PV proteins were detected by WB as before. Both High 
Five and Sf9 cells infections were analysed, along with insect cells only as mock infection and 
infection by Bac-GFP as infection control. Cells were harvested and processed at 3 days p.i.  
WB analysis presented in Figure 3.6 shows that the anti-VP1 mAb detected P1 in both Sf9 and 
High Five lanes at the predicted molecular weight of 100kDa (lanes at left of gel). When the 
3CEV71 protease is present however, P1 is cleaved into VP1 (Figure 3.6A lanes at right of gel). 
The p39 image (Figure 3.6B) indicates that baculovirus infection was somewhat less for the 
3C expressing viruses although this does not detract from the conclusion that PV P1 
processing is the result of co-expression with P1 of the EV71 3C protease.  
 
Figure 3.5. WB analysis showing PV P1 cleavage into viral proteins using 3CEV71 in Sf9, High Five and Tnao38 
cells.  
3 d.p.i. of Bac-PV1P1-3C, Bac-PV2P1-3C and Bac-PV3P1-3C (Skt SC8) infected cells were analysed for proteolytic 
processing. The WB for PV1 (A-D1), PV2 (A-D2) and PV3 (A-D3) contain identical samples and were probed using 
different primary antibodies; MAB 8566 for VP1 detection (A), anti-VP3 for VP3 detection (B), anti-VP0 detection 
(C) anti-p39 for p39 detection (D). Primary antibodies were detected with horseradish peroxidase-conjugated 
secondary antibodies (Polyclonal Goat Anti-mouse Immunoglobulins/HRP, P0447 for A and D and Polyclonal Goat 
Anti-rabbit Immunoglobulins/HRP, P0448 for B and C) and detected by chemiluminescence, ChemiFast. The white 
area apparent in the 32kDa band in blot (A) indicates the antigen detection is over the exposure limit. Protein 
molecular makers are shown to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels 
(ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used.     
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Figure 3.6. WB analysis demonstrating Ab specificity with Sf9 and High Five cells infection with Bac-PV1P1, Bac-PV1P1-3C and Bac-GFP (3 d.p.i) 
(A) VP1 detection. Bac-PV1P1-3C lane, MAB8566 showed a faint 100 kDa band which corresponds to the expected size of P1. In Bac_PV1P1 High 
Five lane, a higher intensity 100 kDa band was observed as well as a faint ~32 kDa band which is consistent with the theoretical VP1 size. Bac-PV1P1-
3C High Five lane showed a high intensity ~32 kDa band. Bac-PV1P1-3C also indicated antigen detection at ~32 kDa at lesser intensity than one in 
High Five cells.  Bac-GFP Sf9, Bac-GFP High Five, Sf9 and High Five lanes showed minimum non-specific binding.  (B) p39 detection indicating the 
baculovirus infection level. Protein molecular makers are shown to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels 
(ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used.   
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To confirm further the role of EV71 3C protease in PV P1 cleavage, WB antigen detection was 
used to assess expression of P1 and P1 + EV71 3C protease in the presence of the inhibitor 
Rupintrivir (formally AG7088). This compound binds irreversibly to the cysteine in the 3C active 
site. Rupintrivir is effective for all HRV strains (Binford et al., 2007; Dragovich et al., 1998) and 
for is also effective for EV71 due to 3C sequence homology with rhinovirus 3C (Binford et al., 
2005). In vitro study with mammalian cell expression has shown that the 3C inhibition occurs 
without cytotoxicity (Lee et al., 2008) suggesting that similar concentrations of drug can be 
used to investigate the 3CEV71 activity inhibition by Rupintrivir during PV P1 proteolytic cleavage 
in insect cells. Accordingly, small-scale infection using Bac-PV1P1-3C in the presence of 
various concentrations of Rupintrivir were prepared and the infected Sf9 cells were analysed 
by VP1 and P1 detection on WB at 3 days post infection as described in 2.3.2.  
WB of the samples showed the highest reactivity to unprocessed P1 at 330nM Rupintrivir, 
decreasing to no detectable P1 at 0nM of drug. A 75kDa band may indicate partial P1 cleavage 
by a cellular protease at all Rupintrivir concentrations (Figure 3.7A). In contrast, the anti-VP1 
image (Figure 3.7B) showed no VP1 detection in the 330nM and 33nM Rupintrivir lanes. As 
Figure 3.6 showed the anti-VP1 mAb binding ability to P1, 33nM Rupintrivir or higher may be 
cytotoxic for insect cells unlike in mammalian cells. VP1 was present at Rupintrivir 
concentrations lower than 3.3nM. These data confirm that PV P1 proteolytic processing into 
mature viral proteins is 3CEV71 dependent in insect cells.   
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3.3 PV VLP assembly  
Following PV viral protein expression in all insect cell types, the self-assembly of those viral 
proteins was analysed using well-characterised methods in order to identify assembled virus-
like particles. In this project, ultracentrifugation, imaging by super resolution confocal 
microscopy, gSTED, and transmission electron microscope (TEM) were employed.  
3.3.1 Ultracentrifugation 
In order to investigate PV VLP assembly in the insect cells, velocity ultra-centrifugation in which 
sucrose is used as a medium was used to identify the assembled, 80S-like empty PV capsid, 
if present. The insect cell culture size was scaled-up to 1L and infection done with the Bac-
PV1P1-3C as per 2.3.3. It was followed by non-ionic detergent based cell lysis and a 2 step 
ultracentrifugation process; a 30% sucrose cushion to remove impurities which are smaller 
than the PV VLPs, and 15%-45% sucrose gradient to band VLPs at the expected sucrose 
Figure 3.7. WB analysis for presence of P1 and VP1 of Bac-PV1P1-3C infected Sf9 cells (3 d.p.i) in various 
Rupintrivir concentration.  
(A) Rabbit anti-PVP1 sera detected P1. The reactivity was highest at 330nM Rupintrivir and lowest at no Rupintrivir 
present. Reactivity at ~75kDa  was seen though the serial dilution. (B) MAB8566 mAb detection of VP1 was poor 
at the concentration of 330nM and 33nM Rupintrivir. At the concentration of 3.3nM and lower, VP1 was detected. 
Markers to the left (M) of the gels are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye 
Pre-Stained Protein Ladder (Geneflow) were used.   
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concentration away from other molecules (section 2.5). After 16h centrifugation, 1ml fractions 
from the top of the gradient were taken and 30µL of each fraction was mixed with SDS loading 
buffer for SDS-PAGE, followed by transfer to the PVDF membrane and analysis by VP1 
detecting WB (section 2.6). The aggregate found at the bottom of the tube was resuspended 
in a volume of PBS equal to the lysate load. 
Figure 3.8 shows that a VP1 band was present in lanes from the 30%-35% sucrose 
concentration which is the characteristic of naturally occurring PV empty capsid migration 
following sucrose velocity separation. A faint VP1 band was observed in the 20% and 25% 
sucrose fractions which could represent non-fully assembled VLPs i.e. PV protomers or 
pentamers. The faint VP1 band in the 40% zone may be the result of aggregation at the bottom 
of the tube which was visible in lane P. Together the data in Figure 3.8 suggested the assembly 
of the PV VLP in insect cells using baculovirus expression system. 
  
Figure 3.8. WB analysis using VP1 antibody for sucrose velocity separation (linear 15-45% sucrose gradient) 
fractions from Bac-PV1P1-3C infected High Five cells culture 
Fractions containing top of gradient (15% sucrose) to the bottom of gradient (45% sucrose) were run across 2 gels. 
The result image is composite of the gels. VP1 band (~32 kDa) appeared from 30% sucrose to 35% (indicated) 
sucrose concentration. Faint VP1 bands occur in the 20%, 25%, 40% sucrose and lane P (pellet resuspension) 
lane were visible. Lane L is for insect cell lysate load for this ultracentrifugation. Protein molecular markers (lane 
M) are shown to the left of the gel and are in kilodaltons. Mini-PROTEAN TGX Any kD gel (BIO-RAD) and BLUeye 
Pre-Stained Protein Ladder (Geneflow) were used.   
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3.3.2 gSTED imaging of VLPs and P1 in insect cells 
Following the WB gradient result suggesting PV VLP assembly (Figure 3.8), visual 
confirmation of the assembled VLPs was desirable. Super resolution gSTED microscopy 
achieves a magnification and resolution suited for imaging particles within a single insect cell. 
For the imaging, High Five cell infections with Bac-PV1P1-3C and Bac-PV1P1 were prepared 
in glass-bottomed 35mm sterile dishes as before. The sample preparation is detailed in 2.7.1. 
At 2 days post infection the Bac-PV1P1-3C and Bac-PV1P1 infected cells were fixed and 
processed for immunolabelling with anti-VP1 antibody and anti-P1 serum respectively. Primary 
antibody binding was detected by fluorophore conjugated secondary antibodies. Anti-mouse 
Oregon green 488 antibody was used for anti-VP1 antibody and anti-rabbit antibody, 
STAR440SXP for anti-P1 sera. 
Figure 3.9 revealed an enlarged nucleus in the centre of the insect cells which is a typical 
cytopathic effect among baculovirus infected cells and abundant globular particles scattered 
in the cytosol for Figure 3.9A and linear filamentous or aggregated signal for Figure 3.9B. 
Judging from the distinctive imaging patterns, the globular 488 florescence is likely to represent 
PV VLPs and the filamentous aggregate unassembled P1 PV polyproteins. The substantial 
change in image based on the presence or absence of the 3C protease in the expressing 
construct suggested that the gSTED images also support the self-assembly of the viral proteins 
into the VLPs within expressing insect cells.
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3.3.3 TEM imaging 
TEM imaging is traditionally used for virus visualisation as images can show the size and state 
of particles, for example if they are regular assemblies. Empty capsids and virus particles have 
a distinguishing appearance which again supports the fact of capsid assembly in this study. 
Direct imaging of the peak fractions from the gradient (Figure 3.8) would confirm the presence 
of empty PV capsid. The pooled peak fractions were concentrated for EM grid preparation as 
described in 2.7.2. Figure 3.10 showed one PV empty particle and unknown structures smaller 
than the particle, possibly polymerised actin. The particle size of ~36nm is somewhat large for 
PV VLPs (expected size 30nm) but the particle could be “expanded” and the stain penetration 
gives the characteristic appearance of a PV empty capsid suggesting VLP production. In 
chapter 5, improved PV VLPs purification methods are discussed which reduce background 
and boost yields to visualise more PV VLPs.  
 
Figure 3.9. gSTED images for single High Five cells infected with (A) Bac-PV1P1-3C and (B) Bac-PV1P1 which 
are labelled with the fluorophores 
(A) The cell was immunolabelled with MAB8566 and then Oregon Green 488. In the cytosol, numerous fluorophore 
labelled globular structures were found. (B) anti-P1 rabbit sera and STAR440SXP was used for P1 imaging. 
Filamentous or aggregated structures were immunolabelled. Both cells showed enlarged nuclei as a result of the 
baculovirus infection.  
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3.4  VLP yield optimisation 
3.4.1 Cleavage efficiency enhancement in transfer vector 
Figure 3.10 indicated the presence of the PV VLP, however the yield was low. In order to 
increase the VLP production, the optimum protease choice for the transfer vector was 
investigated. As the protease used for P1 proteolytic processing has been largely 3CD 
historically, the function in the host lab setup (baculovirus expression system with single 
transfer vector to express P1 and its protease which is 3CEV71 rather 3CPV) was tested. Four 
different expression vectors pOPINE Mahoney P1_2A_3CDWT, pOPINE Mahoney 
P1_2A_3CDΔ, pOPINE Mahoney P1_2A_FS_3CDWTFS and pOPINE Mahoney 
P1_2A_FS_3CDΔFS were constructed following the method described in 2.2.1. These 
constructs append the PV 3CD protease to the P1 polyprotein either as the WT or non-
processed forms and with or without an intervening frameshift sequence. Figure 3.11 shows 
cartoons of the cassettes used in the expression vectors. After their transfection and 
production of recombinant baculovirus as described, small scale infection using Sf9 cells were 
carried out (2.3.2) and the expression products at 2 days post infection analysed by WB for 
VP1 and P1 as before and as described in 2.6.  
Figure 3.10. TEM image of concentrated sucrose gradient fractions (40% sucrose zone from Figure 3.8) 
White arrow indicates the VLP sized 36nm with negative staining. Fragmented structures which are smaller than 




WB analysis of the Sf9 cells infected with Bac-PV1-3CDWT, Bac-PV1-3CD∆, Bac-PV1P1-
3CDWTFS, Bac-PV1P1-3CD∆FS and Bac-PV1P1-3C (positive control) were carried out along 
with Sf9 cells (negative control) using VP1 antibody (Figure 3.12A) and P1 sera (Figure 
3.12B). Figure 3.12A showed a ~32kDa band which is likely to be VP1 visible for Bac-PV1-
3CDWT and Bac-PV1-3CD∆. The intensity is much lower than VP1 reactivity in infections by 
the previously described Bac-PV1P1-3C. The lanes also showed reactivity at 100kDa band 
which is possibly P1, ~42 kDa, ~50kDa and ~26kDa. The latter 3 reactivities do not fit to the 
size of 3CD partially processed P1 and are possibly cellular protease degradation products. 
The reactivity at both P1 and VP1 indicated that 3CD is acting as a protease capable of 
processing P1 to some degree but the efficiency is much lower than that observed with the 
modified 3CEV71. There was no obvious reactivity for Bac-PV1P1-3CDWTFS or Bac-PV1P1-
3CD∆FS. WB analysis for P1 (Figure 3.12B) showed a similar detection pattern although 
reactivity for processed VP1 was lower than with use of the VP1 serum in Figure 3.12A. The 
distinctive difference was reactivity at ~155kDa which fits with the predicted P1+3CD size for 
Bac-PV1-3CDWT, Bac-PV1-3CD∆, Bac-PV1P1-3CDWTFS and Bac-PV1P1-3CD∆FS. The 
results suggested that use of the PV 3CD protease or its non-cleaved variant with this 
Figure 3.11. Schematic representation for 3CD transfer vector cassettes 
The serine insertion for at 3C-3D junction is denoted with Δ. The colour scheme was maintained the same as for 
Figure 3.1 and Figure 3.3. 
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particular configuration of P1 and protease did not improve the level of VP1 synthesis and in 
turn would not increase the PV VLP yield although it should be noted that none of samples 
were purified and visualised. The choice of the protease for further chapters therefore remains 
3CEV71 with a down regulation mutation S128A preceded by the HIV-1 frameshift.  
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Figure 3.12. WB analysis by (A) VP1 antibody (MAB8566) and (B) P1 sera (Rabbit sera) for 3 d.p.i. of Sf9 cells infected with Bac-PV1P1-3CDWT, Bac-PV1P1-3CD∆, Bac-PV1P1-3CDWTFS 
or Bac-PV1P1-3CD∆FS  
(A) Bac-PV1P1-3CDWT and Bac-PV1P1-3CD∆ showed a similar pattern and level of expression. Bands corresponding to the expected size of uncleaved P1 (~100kDa) and its processed 
products, VP1 (~32kDa) were visible as well as ~55 kDa, ~50kDa and ~26kDa reactivity. The VP1 band intensity in Bac-PV1P1-3CDWT and Bac-PV1P1-3CD∆ was much lower than Bac-
PV1P1-3C indicating lower protease activity. There was no evident band for Bac-PV1P1-3CDWTFS, Bac-PV1P1-3CD∆FS and Sf9. (B) Reactivities at ~42 kDa, ~50 kDa and ~100 kDa (P1) 
occur in Bac-PV1P1-3CDWT and Bac-PV1P1-3CD∆ at similar intensity as (A). A band at ~26kDa appears on the lanes, but the intensity is lower. In addition, there was reactivity at ~150 kDa 
(P1+3CD) in the lanes. The reactivity also occurred in Bac-PV1P1-3CDWTFS and Bac-PV1P1-3CD∆FS lanes indicating inefficient protease cleavage. Protein molecular markers are shown to 
the left of the gel (M)  and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used.   
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3.5 Discussion 
The minimal picornavirus components necessary for capsid assembly, as described by others, 
were used here in a single transfer vector consisting of P1, 2A and modified 3C, designed to 
provide equimolar expression of each mature viral protein and lead to the self-assembly of the 
VLPs in insect cells. The balanced expression of PV P1 and a functional protease, EV71 3C, 
ensured the equimolar expression of mature viral proteins and is achieved by the presence of 
the HIV-1 frameshift signal and a mutation in 3C (S128A). The HIV-1 frameshift controls 
ribosome translation efficiency and while most of the translation products terminate after P1-
2A translation, 5% of ribosomes are able to translate the full of P1-2A-FS-3C sequence 
resulting in protease production. The introduced mutation at S128A for 3CEV71 was shown 
previously to lower toxicity without compromising the P1 processing function (Figure 3.1). The 
homology between 3CEV71 and 3CPV as shown in Figure 3.2 also supports its use to cleave 
mature PV viral proteins from the P1 precursor. Three reference strains (but a thermostable 
mutant for PV3 Skt SC8 as described in chapter 1) of PV P1 were introduced into the existing 
EV71 expression cassette (Figure 3.3) and all shown to cleave P1 into VP0, VP3 and VP1 
(Figure 3.4 and Figure 3.5) although there were differences in the expression levels observed. 
3CEV71 processing was investigated by comparing P1 expression alone with that of P1-3C and 
Figure 3.6 showed that, without the protease, P1 remained as an unprocessed protein. Further, 
the addition of Rupintrivir, a broad picornavirus 3C inhibitor, inhibited P1 cleavage (Figure 3.7). 
These data confirmed the ability of 3CEV71 to process PV P1 in the insect cell expression system.  
The self-assembly of cleaved viral proteins into PV empty capsids was also investigated. WB 
analysis of fractionated lysates obtained following ultracentrifugation showed VP1 reactivity in 
the 30-40% sucrose part of the gradient (Figure 3.8). As naturally occurring empty PV particles 
sediment in similar sucrose concentrations, these were likely to be self-assembled into empty 
PV capsids, and this was supported further by gSTED imaging of single insect cells infected 
with Bac-PV1P1-3C which showed distinctive punctate loci in the cytosol (Figure 3.9). Cells 
infected with Bac-PV1P1 showed only diffuse staining consistent with unprocessed antigen. 
Figure 3.9 indicates that the viral proteins self-assembly to the VLPs with the distinctive images. 
Figure 3.10 showed only one particle with the typical stain penetration appearance and a 
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measured diameter of 36nm, somewhat large for a PV VLP. However, picornavirus particles 
can undergo expansion in the procapsid (Cifuente et al., 2013) or post receptor binding state 
(Belnap et al., 2000) leading to the conclusion that this could be a single example of bona fide 
PV VLP.  Clearly further preparations with better yield will be needed to improve this. As part 
of such improvements, VLP yield improvement through the use of an alternate protease, the 
PV 3CD protease, was investigated.  PV 3CDprol has been widely used for recombinant PV 
empty capsid expression, although not in the context of the cassette system used here. Wild 
type PV protease 3CD (3CDWT) and a mutated 3CDpro, which prevents 3C-3D autocleavage 
(3CDΔ), were tested. In addition, to mimic the cassette in use, the HIV frameshift sequence 
was added to both proteases (3CDWTFS and 3CDΔFS). Although the expression study 
analysis by WB using the antibody against VP1 showed some P1 cleavage into VP1 (32kDa) 
in Bac-PV1P1-3CDWT and Bac-PV1P1-3CD∆ infected cells, reactivity was much less than the 
Bac-PV1P1-3C (the EV71 3C carrying S128A) expressed VP1. For Bac-PV1P1-3CDWTFS 
and Bac-PV1P1-3CD∆FS, there was no visible reactivity (Figure 3.12A). This result suggested 
that 3CDWT or 3CDΔ were not as efficient as proteases as the regulated 3CEV71 in the insect 
cell expression, at least not in the genetic configuration used here. When WB was done with 
a rabbit serum detecting P1 a band consistent with the expected molecular weight of P1+3CD 
was present in Bac-PV1P1-3CDWT and Bac-PV1P1-3CD∆ infection in addition to the bands 
detected by the VP1 serum. However, in Bac-PV1P1-3CDWTFS and Bac-PV1P1-3CDΔFS 
infected cells only P1+3CD was detected (Figure 3.12B). The results may suggest that 3CD 
levels were too low in this case to ensure further processing despite the equivalent cassette 
allowing efficient protease processing in the case of P1 and 3CEV71. The protease origin, EV71 
vs PV, could have a role in this difference or perhaps the large 3CD enzyme needs to be made 
at a higher level to be active. In a particular timeframe, less 3CD protease is available for P1 
proteolytic processing compared to 3CEV71, simply as translation takes longer. Whatever the 
reason, these results indicate that the regulated 3CEV71 was the most suitable protease for 
future infection experiments.  
In conclusion, novel constructs were designed for PV VLP production in the insect cell 
expression system. The chapter demonstrated the synthesis of viral proteins and their self-
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assembly into PV VLPs. Although gSTED imaging indicated abundant PV VLP production, 
further improvement in the purification protocols are needed to obtain higher PV VLPs yields.
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  Poliovirus capsid protein expression and assembly in 
Saccharomyces cerevisiae 
4.1 Introduction 
Mature PV viral protein (VP0, VP1 and VP3) synthesis and their self-assembly into VLPs in 
insect cells was shown in chapter 3. The expression was achieved by the single baculovirus 
expression vector which harbours the structural polyprotein, P1, a linker sequence derived 
from 2A, a unique HIV-1 frameshift sequence and a modified protease, 3CEV71. The production 
of EV71 VLP (Cone, 2015) and PV VLP in insect cells demonstrated that P1-2A-FS-3CEV71 
cassette system did not show cellular toxicity as it was seen in FMDV VLP production without 
3C down regulation and brought about equimolar amounts of each viral protein by equivalent 
cleavage at each mature protein junction, resulting in PV VLP assembly. However, even 
though a variety of purification methods were attempted there was some difficulty to repeatedly 
purify VLPs and often no or low numbers of particles were visible under TEM. The presence 
of baculovirus nucleocapsids was also a confounding factor. As a result, it was of interest to 
search for other expression platforms for VLP production, particularly those that did not depend 
on the use of a virus vector. Yeast cell expression systems offer the combined benefits of 
eukaryotic and prokaryotic expression system. This system still has the simplicity of bacterial 
culture preparation and low cost but does not have the disadvantages of eukaryotic cell culture: 
inconvenience, low yield and high maintenance. In addition, expression in yeast cells is able 
to produce recombinant proteins with post-translational modifications which may be essential 
to produce functional proteins. For example, the binding of eukaryotic chaperones such as 
HSP90 and GSH has been suggested to be important for some picornavirus assembly (Jiang 
et al., 2014). The benefits of yeast cell expression for vaccine production has been 
demonstrated by the success of products for HBV and HPV, both of which have been approved 
for human use (Bill, 2015). Accordingly, Saccharomyces cerevisiae is an attractive expression 
system for VLP products.  
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The concept of empty PV capsids as a vaccine drew researchers’ attention in the early 1990s 
when PV VLPs were produced in mammalian cells (Ansardi et al., 1991), insect cells (Urakawa 
et al., 1989) but also yeast cells (Jore et al., 1994). Jore et al. (1994) demonstrated the 
assembly of PV VLPs in S. cerevisiae by co-expression of a P1 vector and a 3CD vector, both 
cloned into yeast replicating vectors, also known as autonomously replicating sequence (ARS) 
vectors. The vector contained the inducible GAL promotor and following induction, VP0, PV1 
and VP3 were shown to be produced and self-assemble into empty particles. However, when 
competition immunoprecipitation assay was done, it showed that the produced VLPs were of 
the H (Heated) conformation of capsid which is unsuitable for vaccine use. It is important to 
note that the sequences used for all expression studies at that time were wild type. There was 
no data on the selection of more stable variants or the use of structure based mutants that 
might alter conformation. In a subsequent study, Rombaut and Jore (1997) succeeded to 
produce the N (Native) conformation of empty capsid by supplementation with the antiviral 
compound, Pirodavir, to the yeast culture and throughout the purification steps, allowed the 
conversion of the H antigenic VLPs to N antigenic VLPs, with the level of conversion related 
to the level of drug added. Immunisation of mice demonstrated that yeast origin VLPs purified 
in the presence of Pirodavir elicited anti-N antibodies in neutralisation assays.  
In this chapter, the yeast expression experiment was revisited using the same expression 
cassette that produced VLPs in insect cells (chapter 3). Following an investigation of PV VLP 
synthesis in yeast cells, a number of lysis and purification techniques were assessed; including 
a cell disruptor and sucrose gradient banding. Any VLP present were assessed by antigen 
distribution on sucrose gradients by WB and by visualisation under TEM. 
 
4.2 Yeast expression system 
For this study, Dr Yuko Morikawa, Kitasato University, Japan gifted a strain of S. cerevisiae, 
RAY3A-D (MATa/α ura3/ura3 his3/his3 leu2/leu2 trp1/trp1) and a yeast expression vector 
pKT10 as this combination of vector and host had proved successful for the expression of HIV 
VLPs (Sakuragi et al., 2002).  
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4.2.1 RAY3A-D 
S. cerevisiae RAY3A-D (MATa/α ura3/ura3 his3/his3 leu2/leu2 trp1/trp1) was first used by 
Ruggieri et al. (1989) and has since been used as the host strain for recombinant protein 
expression. The genotype indicates the dominant (upper case) and recessive (lower case) 
genes in the yeast strain (Tropp, 2012). For instance, RAY3A-D has MATa/α gene, however it 
lacks URA3, HIS3, Leu2 and TRP1 genes. MATa/α is the mating type of the yeast cells. The 
propagation of S. ceresiviae has two modes; vegetative budding and mating. The former mode 
is used by haploid cells containing either MATa or MATα. The mating types are controlled by 
2 different alleles of mating type (MAT) locus. MATa and MATα fuse together to produce 
MATa/α diploid cells when mating. S. cerevisiae is normally found as stable diploid cells. In 
nature, the diploid cells are produced in response to the low nutrition environment when cells 
carrying opposite mating type aggregate and stick together. Haploid budding is arrested and 
finger-like tips are extended from the opposite mating type cell to fuse (Landry et al., 2006; 
Tropp, 2012).  
The rest of the genotype indicates the common genes used for selection. Yeast expression in 
S. cerevisiae has historically used auxotrophic selection rather than the antibiotic selection 
used in bacteria because of a high frequency of antibiotic resistant mutations and low antibiotic 
efficacy in some strains of yeast. ‘Auxotrophy’ is defined as the incapability of an organism to 
produce an essential component of their nutrient requirement (Patrick, 2014). This deficiency 
in the synthesis is due to the lack of the genes which encode the necessary enzymes. Typical 
genes used for selection in S. cerevisiae are URA3, HIS3, Leu2 and TRP1. The designation 
and numbers indicate the particular genetic locus (Tropp, 2012). The URA3 gene encodes 
orotidine-5-phosphate decarboxylase, an enzyme which contributes to pyrimidine 
ribonucleotide synthesis (Saccharomyces Genome Database, 2016; Umezu et al., 1971). The 
other genes similarly encode for the enzymes involves in the synthesis of amino acids; HIS3 
(L-histidine), Leu2 (L-leucine) and TRP1 (L-methionine) (Pronk, 2002). With the lack of those 
genes, the auxotrophic strains of yeast fail to grow in simple media unless a copy of a functional 
gene is added to restore the ability to encode the biosynthetic enzyme. If the host cell acquires 
an expression vector with a relevant gene, the recombinant yeast cell is now able to synthesise 
the nutrient and can survive in a medium lacking that particular nutrient. Host cells without the 
 125 
relevant gene cannot grow (Patrick, 2014). For RAY3A-D, the genotype indicates that it lacks 
4 genes, therefore it grows only when the media is supplemented with uracil, histidine, leucine 
and methionine or in rich media, such as YPD. 
4.2.2 pKT10 
pKT10 has a URA3 gene as a selective marker, the 2μ plasmid for replication and a constitutive 
promoter and terminator derived from the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene (Morikawa et al., 2007; Tanaka et al., 1990) as shown in Figure 4.1. pKT10 is 
classified as a YEp (yeast episomal plasmid) vector and also contains bacterial plasmid DNA 
for DNA manipulation and plasmid purification in E. coli (Curran & Bugeja, 2000). The URA3 
gene acts as the auxotrophic marker and restores ODCase activity to synthesise uracil. 
Transformed yeast are selected in media without uracil allowing positive selection against 
yeast cells which have not gained the expression vector (Jones, 1992; Saccharomyces 
Genome Database, 2016). Due to its 2μ backbone, pKT10 is maintained at 50 to 100 copies 
per haploid genome in yeast cells (Berlec & Strukelj, 2013; Maloy, 2004) providing some gene 
dosage effect. The GAPDH gene promoter is chosen for pKT10 because of its high level of 
constitutive activity, a factor in vector efficiency (Curran & Bugeja, 2000). Heterologous 
termination sequences are often not recognised by S. cerevisiae resulting in unstable 
extremely long mRNAs and to avoid this issue a yeast terminator, the termination sequence of 




4.2.3 Yeast cell wall disruption 
For the recovery of recombinant protein expressed in yeast cells, it is essential to disrupt yeast 
cells efficiently. The yeast cell wall is known for its robust structure. The cell wall mainly 
consists of mannoprotein and fibrous β1, 3 glucan, with a minor portion including β1,6 glucan 
and chitin which also contribute to its structure. The β1,3 glucan and chitin complex form the 
yeast inner cell wall, the glycosylated mannoproteins the outer cell wall and the β1,6 glucan 
holds the inner and outer cell walls together. This three layered structure gives a packed 
structure and limits cell permeability (Lipke & Ovalle, 1998) but is a challenge for subsequent 
purification. Accordingly, a cell disruptor was assessed for cell lysis in which 10 ml of 
compacted yeast cells was pressurised within 5 seconds, a mechanical force that ruptures the 
cells. The advantage of the cell disruptor was the wide choice of the pressure; 10 MPa to 410 
MPa and once a suitable pressure was found, the result should be repeatable. One 
consideration for this lysis method was that the sample temperature should not rise due to 
pressurising. As the PV VLPs are not thermostable, this method could be challenging and any 
assembled VLP conformation could be altered or disassembled by the process. The sample 
Figure 4.1. S. cerevisiae expression vector, pKT10 schematic representation produced by DNA dynamo 
The vector consists of URA3, 2µ form, pUC ori, ampicillin resistance, and GAPDH promoter and terminator. URA3 
and 2µ maintain the recombinant plasmid in yeast to express foreign protein using GAPDH promoter and terminator. 
pUC origin and ampicillin resistance genes are essential for simplified DNA cloning in E. coli. The vector was gifted 
by Dr Yuko Morikawa 
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temperature was therefore constantly monitored during the lysis and processing.Synthesis of 
viral proteins and their assembly into VLPs 
4.2.4 Expression vector cloning  
To examine the possibility of PV VLP assembly in yeast, a suitable yeast expression vector 
was constructed. The cassette, consisting of a contiguous sequence encoding P1 (PV1 
Mahoney) and 3C, with various control elements, was explanted from the insect cell expression 
vector described in chapter 3 and cloned into the pKT10 yeast cell expression vector to 
produced RAY3A-D-PV1-3C. The cloning procedure is detailed in section 2.2.1. In brief, the 
expression cassette (P1-2A-FS-3CEV71) was amplified by PCR with a forward and reverse 
primer which each introduced unique restriction sites (EcoRI and StuI) found in the MCS of 
pKT10. The PCR product was digested with the requisite enzymes and inserted into pKT10 
using the same restriction sites. The schematic representation of expression vector is shown 
in Figure 4.2. The final plasmid was sequenced to confirm the desired construction. The vector 
was then transformed into the RAY3A-D strain of S. cerevisiae using the LiAc method 
(Herskowitz, 2012). The transformed cells were selected on synthetic defined (SD) media agar 
lacking uracil. After several days of incubation at 30 ˚C, colonies were visible whereas the 
plating of non-transformed cells gave no colonies. To confirm the transformants, colonies were 
grown in small scale (10mls) and any episome present extracted using a yeast plasmid 
extraction kit. Extracted vector was then transformed back into competent E. coli cells and 
those transformants again grown for plasmid isolation. The recovered vector was assessed by 
restriction digest and selected samples were sent for DNA sequencing. All transformants had 
bona fide yeast PV vectors as initially designed. The complete process is summarised in Figure 
2.2 in section 2.4.1. 
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4.2.5 Viral protein expression 
Once transformation into RAY3A-D was confirmed, an expression analysis for the presence of 
PV antigen was carried out. Following overnight growth in YPD media recombinant yeast cells 
were disrupted by alkaline extraction (Kushnirov, 2000) which denatures the entire cell and its 
contents as described in section 2.6.1. The alkaline extract was analysed by SDS-PAGE and 
the separated proteins processed for western blot. PV1 VLP expressing insect cells were 
included as a control. Figure 4.3 shows PV antigen detection by anti-VP0 rabbit sera by WB. 
The image showed a sharp band at ~40kDa in PV1 yeast lanes which co-migrated with a band 
present in the insect cell origin PV1 VLPs. No band at ~100kDa was observed, suggesting the 
efficient proteolysis of P1 and background reaction was generally low. This result suggested 
that PV antigen expression and it cleavage by 3C was occurring in yeast cells.
Figure 4.2. Schematic representation of PV1 VLP expression vector (RAY3A-D-PV1-3C) based on pKT10 produced 
by DNA dynamo 
PV VLP cassette consisting of P1-2A-HIV-1 frameshift-modified 3CEV71 was inserted into pKT10 cloning site which 
was shown in Figure 4.1. 
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4.2.6 Assembly of PV VLPs in yeast cells 
As processed antigen was present in the selected transformants, one isolate was grown at 
larger scale for the assessment of PV antigen size in solution.  To do this 100ml of culture was 
grown to 1.04 OD600U/ml and prepared as described in 2.4.2. The harvested cell pellet was 
lysed by cell disruptor (2.5.1) with the temperature monitored throughout the process. Once 
lysis was complete, unbroken cells and large debris was removed by centrifugation (15000rpm 
for 30 minutes at 4ºC) and the clarified sample was purified further by ultracentrifuge, first by 
sedimentation through a 30% sucrose cushion and then by sedimentation of the resuspended 
pellet on a 15%-45% linear sucrose gradient, carried out at 21000rpm, 4°C for 16h using a 
SW40 rotor. Details of the procedure are as described in 2.5.2. The gradient was fractionated 
manually from the top by taking 1ml samples from the meniscus and 30μL of every 1ml fraction 
were analysed on WB as before using an antibody to VP1. 
Figure 4.3. WB analysis by VP0 detection using anti-VP0 rabbit sera following post-alkaline extraction of RAY3A-
D-PV1-3C  
A sharp band at ~40 kDa corresponding the species corresponding VP0 molecular weight was seen in the PV1 
yeast lane. PV1 insect lane showed reactivity at various sizes. ~100kDa band may indicate P1 partial proteolytic 
processing. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-
Tris Plus Gel (ThermoFisher) and Novex™ sharp pre-stained protein standard (ThermoFisher) were used.   
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Figure 4.4 shows the distribution of VP1 throughout the 15%-45% linear sucrose gradient.  No 
western blot signal was present at the top or bottom of the gradient in keeping with the pre-
banding cushion step which selects for high MW antigen. While some non-specific bands were 
detected throughout the gradient the most prominent feature is a ~30kDa band in fraction 5 
and in fractions 7-9. The peak intensity found in fraction 7-9 corresponds to a sucrose 
concentration of around 35% while the more minor peak in fraction 5 corresponds to ~25% 
sucrose. Clearly, VP1 as a soluble monomer or assembled into a VP1-VP0-VP3 (MW ~100 
kDa) protomer would be insufficiently large to enter the gradient so this banding pattern 
suggests that VP1 antigen expressed in yeast cells following cleavage of the P1 precursor is 
assembled into larger molecular weight complexes. These large MW complexes could include 
pentamers (MW ~500kDa) in fraction 5 and fully assembled VLPs (MW ~6000kDa) in fractions 
7-9. 
Figure 4.4. WB analysis for presence of VP1 following RAY3A-D-PV1-3C lysis on 15-45 % sucrose gradient using 
anti-VP1 (MAB8566, Millipore) 
A total of 13 fractions were analysed on 2 gels which have been merged here. The prominent reactivity is at ~30kDa 
in fractions from the middle of the gradient (indicated) corresponding to a sucrose concertation of ~35% consistent 
with empty PV capsids. VP1 reactivity in fraction 5 may represent banding of protomer or pentamer subunits. Higher 
MW bands at ~ 60kDa could be VP3-VP1 intermediates. Protein molecular markers are show to the left of the gel 
(M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder 
(Geneflow) were used.  
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However, as Figure 4.4 also showed various bands detected by the anti-VP1 Ab, consistent 
with some degradation of VP1, a further round of purification was completed. To do this, the 
peak fractions, 7-9, were pooled together and the concentration of sucrose reduced by a three-
fold dilution with PBS. The sample was then loaded onto a second sucrose gradient, again 
developed by centrifugation at 21000rpm, 4°C for 16h using the SW32 rotor. The procedure is 
detailed in 2.5.2. The gradient was fractionated from the top of the tube as before, producing 
40 fractions, and alternate fractions were analysed by SDS-PAGE and western blot as before.  
The WB analysis for VP1 detection is presented in Figure 4.5. The WB images showed a 
similar detection pattern by the anti-VP1 Ab to the fractions from the first gradient with VP1 
detection in fraction 12 to fraction 30. Some VP1 was seen in fraction 40, possibly due to 
aggregation as this was the fraction containing the pellet formed at the bottom of the tube. The 
pattern of VP1 detection reflected that in the first gradient; a minor peak in fraction 15 and a 
more major spread peak in fraction 22 to 24. As before the 2nd peak was around 35% consistent 





Figure 4.5. WB analysis using VP1 antibody (MAB8566, Millipore) following 2nd 15%-45% sucrose gradient for lysed 
RAY3A-D-PV1-3C 
Fractions 7-9 of Figure 4.4 were pooled and applied as the sample. 1ml fractions were taken from the top of the tube 
after the ultracentrifugation. Alternate fractions except fraction 14-18 (every fractions) were run on 3 gels. The resultant 
blot image is a composite of these. Reactivity at ~30 kDa occurs in fractions 14 to 30 (indicated). Reactivity in fraction 
40, the bottom of the gradient including the pellet, may indicate aggregation. Protein molecular markers are shown to 
the left of the gel and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein 
Ladder (Geneflow) were used. 
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4.2.7 TEM imaging of purified PV VLPs 
Ultracentrifugation suggested the assembly of PV VP1 antigen into a species corresponding 
to molecular weight broadly in the same range as that shown for 80S PV VLPs in the sucrose 
gradient (Jiang et al., 2014). As a result, the most obvious technique to confirm the presence 
of VLPs would be direct visualisation. Accordingly, the peak fraction (fraction 23 from the 
second gradient) was prepared following the method described in section 2.7.2. 
Figure 4.6 shows TEM images for fraction 23 which contained particles with the dimensions 
expected of poliovirus empty capsids with average size of 46.7nm. The background image 
also displayed globular forms, possibly assembly intermediates or particles that had broken as 
a result of the TEM preparation methods as well as some large cells debris. From this image, 
VLP seem to be present although the TEM was indistinct and the level of intactness uncertain. 
This was encouraging but indicated the need for improvement in the culture condition, the lysis 
and the purification method if VLPs for PV assembled in yeast were to be confirmed. 
Figure 4.6. TEM imaging for negatively stained VLP of RAY3A-D-PV1-3C , 2
nd
 15-45% sucrose gradient, fraction 
23 
Fraction 23, a peak fraction from Figure 4.5 showed two VLPs which is indicated with arrows. Globular forms which 
are at lower half image and debris are also present in the fraction. The average VLP size was 46.7 nm. 2 % uranyl 
acetate was used as stain on a carbon coated formvar copper grid (Agar scientific). 
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4.3 Discussion 
Following difficulty in the separation of VLPs from baculovirus capsids following expression in 
insect cells, a yeast expression system for the production of PV VLPs was explored. PV VLP 
synthesis in S. cerevisiae was first shown by Jore et al. (1994) but the VLPs produced were of 
the H conformation, which does not induce protective immunity in mice. Subsequently, the 
same authors produced VLPs of the N conformation following expression in S. cerevisiae by 
the addition of a "pocket" binding drug which was discussed in chapter 1  (Rombaut & Jore, 
1997). These publications demonstrated that the yeast cytoplasm was a suitable environment 
for the assembly of VLP but, surprisingly, no follow-up study has been done on PV VLP 
production in S. cerevisiae. With improvements in biotechnology, this platform for PV VLPs 
production should be investigated further. For our in-house expression system in S. cerevisiae, 
the cassette system used for insect cell expression was introduced in the expression vector, 
pKT10. Following its transformation into a laboratory strain of S. cerevisiae, RAY3A-D to 
produce RAY3A-D-PV1-3C, the synthesis of viral proteins from P1 by 3C protease was 
analysed. PV related proteins appeared to be synthesised as both WB analysis with anti-VP0 
sera indicated antigen of the expected moleculer weight (Figure 4.3). Analysis for the self-
assembly of PV VLPs was carried out by sucrose gradient after cell lysis was carried out by 
the cell disruptor. The antigen detection pattern for the sucrose gradient fractions (Figure 4.4 
and Figure 4.5) peaked in the mid fractions of the gradient, although evidence of considerable 
degradation was present with bands detected at 35kDa – 30kDa, and this pattern matched the 
distribution of naturally occurring 80S empty PV VLPs in sucrose gradients suggesting self-
assembly into VLPs. Concentrated peak fractions from the sucrose gradient under TEM 
confirmed the presence of capsid like structures (Figure 4.6) although the size is larger than 
the expecetd corresponding size of 30nm. These two findings indicated the assembly of the 
VLPs although the number of VLPs found by TEM imaging was low, possibly associated with 
either transient heating during lysis or the degradation of the VP1 signal seen on western blot. 
Nevertheless, VLP production in yeast strain RAY3A-D using the cassette system previously 
constructed for baculovirus expression but moved into yeast expression vector pKT10 has 
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repeated the work published by Jore et al. (1994) although improvements in the purification 
method will be needed to enhance VLP yield.
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  Optimisation of PV VLP purification 
5.1 Introduction 
In chapter 4, PV1 wildtype Mahoney VLP purification from yeast cells was carried out using a 
cell disruptor which revealed some broken PV VLP with a homogenous background that, 
consistent with the numbers and sizes, were suspected to be protomers and pentamers (the 
initial and intermediate assembly units of picornavirus capsids). While yeast expression may 
be useful therefore, the implication that PV VLP were disassembling during the purification 
method suggested this might not be the most suitable extraction procedure for PV VLPs. 
Hence, an improvement in the yeast cell lysis method was required. For yeast cell preparation, 
numerous methods have been published. Amongst these are methods in which the cells are 
homogenized by high pressure, by glass bead vortexing or by enzymatic lysis. In order to find 
the most suitable method for yeast cell lysis to obtain good quality PV VLP several of these 
purification methods were assessed. Both cell disruptors and bead-beaters utilise mechanical 
forces to physically break the cells. Lyu et al. (2015) showed the production of antigenic EV71 
and EV71/CAV chimeric VLPs from S. cerevisiae using high pressure homogeniser. Rombaut 
and Jore (1997) succeeded to produce PV VLPs from S. cerevisiae using bead-beating 
although sample vortexing was also supplemented with detergent. For the experiments 
described here, the lysis method described by Kim et al. (2010) was adapted for PV VLPs 
using a bead-beater, the FastPrep-24™ with Lysing Matrix C (the type of bead used). When 
mechanical force is used to lyse a sample heat is produced as a by-product and as PV VLPs 
have thermostability issues (the N and H antigenic forms), the heat generated during lysis has 
to be monitored to minimise the possibility of VLP damage. For this, the cell disruptor was 
equipped with a cooling system as described by Lyu et al. (2015). Samples were pre-chilled in 
ice and also periodically during processing. Sample temperature was closely monitored during 
the process to prevent PV VLP disassembly. In addition to cell disruption by physical means a 
non-physical lysis approach was also assessed for PV VLP purification. A yeast cell wall 
lyticase, zymolyase, enabled the removal of the yeast cell wall to leave only the yeast plasma 
membrane. Zymolyase is derived from Arthrobactoer luteus and hydrolyses the β-1,3 glucan 
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layer of the yeast cell wall to disturb its structure (Kitamura & Yamamoto, 1972). Figure 5.1 
summarises the yeast cell wall structure and indicates the function of zymolyase. After the 
removal of the yeast cell wall, spheroplasts, which consist of membrane bound yeast cells in 
an isotonic solution, are produced. At this stage, membrane dissolution can be accomplished 
by gentle non-thermal cell disruption using N2 decompression. Wang et al. (2014) reported a 
S. cerevisiae subcellular fraction which maintained its functional integrity using zymolyase and 
N2 cavitation. The benefit of N2 cavitation is that its operation temperature and gentle 
processing preserve sample function. In the process, N2 gas is forced into solution inside cells 
in a pressurised chamber. When the pressure is suddenly released, the dissolved nitrogen 
comes out of solution as bubbles which expand the membrane and cell which eventually bursts 
(Parr Instrument Company, 2015). 
In addition to the method of yeast cell lysis, improvements in PV VLP separation were also 
tested by switching to Nycodenz as the ultracentrifuge medium for isopycnic centrifugation 
rather than velocity gradients. In this method, particles undergo separation by differences in 
their buoyant density and particles migrate to the equilibrium point where their buoyant density 
and the gradient matrix density are equal. At this point, the isodensity level, the sample does 
not migrate any further (Mazzone, 1998). 
 
 
Figure 5.1. Schematic representation of common yeast cell wall composition and zymolyase function 
Once yeast outer wall is weakened, zymolyase hydrolyses β-1,3-glucan and releases laminaripentaose. The Figure 
was modified from Brown et al. (2014).  
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In order to maximise the yield of stable PV VLPs by these various methods, a further change, 
the use of PV3 Skt SC8 as the P1 open reading frame in the expression vector, was also made 
during these experiments. PV3 Skt SC8 was already reported to produce more stable VLPs 
based on experiments making small amounts of empty VLPs in mammalian cells (Fox et al., 
2017) and larger quantities in plants (Marsian et al., 2017). Their expression here was done 
as described for PV1 in chapter 4, essentially a change of the P1 region in the resident vector 
to produce S. cerevisiae producing PV3 Skt SC8 VLP, RAY3A-D-PV3SC8-3C. Finally, the 
yeast cell culture size was also increased to obtain higher amounts of PV VLPs. Yeast cell 
cultures were grown for 2 days as described in Lyu et al. (2015).  
In all a total of 3 purification methods are assessed to decide the optimal method for PV VLP 
purification from yeast cells and the optimized methods used with PV3 Skt SC8 to obtain 
thermostable PV VLPs in higher amount. As an aside the purification method was also used 
for purification of VLPs from insect cells to discern if the VLP yields were improved. 
 
5.2 Purification methods for Yeast cells 
5.2.1 Cell disruptor method 
Yeast cell expression cultures were prepared as described in 2.4.2. 2 L of RAY3A-D-PV1-3C 
liquid culture was grown overnight to ~2.0 ODU/ml as described in Lyu et al. (2015). The yeast 
cell pellet was resuspended in PBS pH 7.2, 1 mM PMSF, 1 mM β-mercaptoethanol and applied 
to the cell disruptor. The cells were pressurised to 1800 bar twice and the temperature of the 
sample exiting the cell disruptor was recorded. Then, NP40 was added to be final 
concentration of 1 % and incubated in ice for 1h after which the cells were centrifuged at 10000 
rpm, 4 °C for 30 minutes to obtain the supernatant. PEG8000 to a final concentration of 8 % 
(w/v) and NaCl (to be 0.2 M) were added to the supernatant for PEG precipitation. The mixture 
was gently stirred at 4 °C overnight. The following day, it was centrifuged at 10,000 xg, 4 °C 
for 1 hour and the pellet was resuspended in PBS, pH 7.2. Following clarification, the 
supernatant was loaded onto a 30 % sucrose cushion and centrifugation carried out at 21,000 
rpm, 4 °C for 16 hours. The pellet was resuspended as described in 2.5.2. After a clarifying 
spin, it was loaded onto a 10-30 % Nycodenz step gradient of 10 % increments, each layer 2.5 
 139 
ml. The layered tube was centrifuged at 28,000 rpm, 4 °C for 3 hours using SW40 rotor. After 
the spin, the tube showed 2 visible bands, 1 band at the interface of sample load and the 10 % 
Nycodenz layer and 1 band between the 20 % and 30 % layers. 1 ml fractions were collected 
from the top except for the visible bands which was collected separately. These fractions were 
analysed by WB for PV VP1 detection. Figure 5.2 shows very faint VP1 detection in the PV 
standard lane at 35 kDa but neither of the bands at 75 kDa and 30 kDa visible on fraction 9-
12 of the gradient blot image matched the VP1 band size indicated by PV standard. However 
the reactivity at Nycodenz concentration of 20-30 % is consistent with PV empty capsids. In 
general, PV empty capsids are obtained around the concentration of 25 % for Nycodenz rather 
35 % for sucrose. Despite this size abnormality the peak fraction was observed under TEM 
following the method described in section 2.7.2. Figure 5.3 shows a very low level of VLPs 
found by TEM with typical VLP characteristics. Thus, despite an uncertain western blot 
assembled PV VLPs were found in the expected fractions by direct EM observation. However,  
yields were very low and it was concluded that physical disruption was unlikely to be a method 
of choice for VLP release without considerable further optimization.
 140 
 
Figure 5.2. WB analysis of VP1 by MAB8566, Millipore following RAY3A-D-PV1-3C treatment with cell disruptor 
and nycodenz step gradient  
A total of 12 fractions were analysed across 2 gels which are merged in this figure. Reactivity at ~30 kDa and ~75 
kDa is visible at fractions 7 to 12 (indicated), peaking in fraction 9 which corresponds to a visible band layer at the 
20%/30% interface. Protein molecular markers (M lane) are show to the left of the gel and are in kilodaltons. St lane 
contains PV standard (European PV standard) which acts as a control for VP1 detection. Bolt™4-12% Bis-Tris Plus 
Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used. 
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5.2.2 Bead-beater method 
A 2L yeast cell culture was grown to 1.5 ODU/ml following the culture preparation explained in 
2.4.2 and the method used was modified from the yeast cells lysis method of Kim et al. (2010). 
The cells (wet weight 8.6 g) were resuspended in ice-cold breaking buffer (section 2.1.8) at 
1:1 ratio with the cell pellet wet weight. The resuspension was then transferred to MP bio 
Lysing Matrix C tubes and homogenization carried out for 8 times at 6.0 M/S for 30 seconds. 
The cells were rested for 5 minutes on ice between beat cycles to prevent a temperature rise. 
The pooled homogenate was centrifuged at 15000 rpm, 4 °C for 30 minutes and the 
supernatant applied to a 30 % sucrose cushion as before. The pelleted sample was dissolved 
in PBS pH 7.2 and the clarified sample was ultracentrifuged in 10-30 % Nycodenz gradients 
as described. The interface layers between the sample load and the 10 % layer as well as 
between the 20 % and 30 were collected and analysed as above.  
TEM imaging was obtained from the 20-30 % interface (Figure 5.4). Only one VLP like particle 
was observed (Figure 5.4, left and right in different magnifications) and generally speaking, 
Figure 5.3. TEM image with negative staining of peak fraction of Figure 5.2.  
The concentrated 20 % and 30 % nycodenz interface fraction which is indicated with * on Figure 5.2 was stained 
with 2% uranyl acetate prior to micrograph. (Left) One complete shape VLP which indicated by the penetration of 
stain and the morphology was seen in the centre with two more below, possibly damaged. (Right) Two further VLPs 
with some impurities. The average VLP size on the images is 37nm. 2 % uranyl acetate was used as stain on a 
copper grid with carbon coated formvar film (Agar scientific). 
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both images have a white background which might suggest the grid was covered with an 
unknown material which obscured clear imaging. As the background was too high to determine 
true VLP assembly and there was uncertainty about the degree of temperature rise during the 
homogenization bead beating was abandoned as a likely final extraction procedure, at least 
for this scale of culture.  
 
 
5.2.3 Zymolyase and N2 cavitation method 
A 300 ml yeast cell culture was prepared as before to 1.5 ODU/ml. The procedure followed 
was based on Wang et al. (2014) with some modifications. The cell pellet (0.9 g wet weight) 
was washed in 10 ml PBS pH 7.2, 10mM DTT and finally taken up in 10 ml 1.2 M sorbitol and 
centrifuged again. The pellet was resuspended in 6 ml 1 M sorbitol, 1 mM EDTA, 10 mM 
sodium citrate and zymolyase 100T was added to the mixture at 5 μg/ml and then incubated 
at room temperature with rotation at 250 rpm for 1.5 hours. The sample was then centrifuged 
Figure 5.4. TEM image with negatively stained VLP of RAY3A-D-PV1-3C VLP purified with beads-beater and 
nycodenz gradient.  
Figure 5.4 was prepared from 20 % and 30 % nycodenz interface. (Left) A particle holds VLP morphology and stain 
penetration was seen but it appears slightly compressed compared to VLP from Figure 5.3. (Right) The identical 
field image to the left at higher magnification. There is unknown material all over the grid. The size of this particular 
VLP is 30.4 nm. 2 % uranyl acetate was used as stain on a copper grid with carbon coated formvar film (Agar 
scientific). 
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and resuspended in 30 ml homogenization buffer (HM / section 2.1.8) and this process 
repeated once more. The resuspension was loaded into the N2 cavitation vessel and incubated 
with nitrogen gas at 500 psi for 10 minutes and then at 350 psi for 10 minutes. After that the 
treated sample was clarified at 15,000 rpm, 4 °C for 20 minutes and the supernatant applied 
to a 30 % sucrose cushion and centrifuged at 28,000 rpm, 4 °C for 3 hours. The collected pellet 
was allowed to re-suspend overnight in PBS pH 7.2 and then clarified before being loaded 
onto a 10-30 % Nycodenz gradient and ultracentrifuged at 27,000 rpm, 4 °C for 3 hours. The 
resultant tube showed a 20-30 % interface band only. 1ml fractionation was done from the top 
of the tube and the interface band was concentrated (as per section 2.7.2) and visualized 
under TEM. 
Figure 5.5 shows assembled VLP present in this fraction with a typical empty capsid staining 
pattern in each case, and a diameter of typically ~35 nm, broadly as expected for PV VLPs. 
Debris is also present but the background obtained from these images was much lower than 
that seen in Figure 5.4. At this point, this method seemed to be the most efficient purification 
method and could be applied to much larger culture volumes.  
Figure 5.5. TEM imaging with negative staining of VLPs from RAY3A-D-PV1-3C prepared by zymolyase and N2 
cavitation method and nycodenz gradient. 
Concentrated 20–30% nycodenz interface fraction was stained with 2% uranyl acetate for the microgram. (Left) PV 
VLP showing the negative staining of empty capsid. Three particles were imaged in total although one (on the left) 
appeared incomplete.  (Right) TEM image at higher magnification. The capsid diameter is ~ 35nm. 2 % uranyl 
acetate was used as stain for copper grid with formvar carbon film (Agar scientific) 
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5.3 S. cerevisiae origin PV VLP yield optimization  
In this section, PV VLPs prepared using the PV3 Skt SC8 sequence were extracted with 
zymolyase and N2 cavitation or cell disruptor methods as described. To do this the plasmid 
pKT10 Saukett SC8 P1_2A_FS_3CEV71 was constructed by replacing the resident PV1 
Mahoney sequence with that of Skt SC8 franked with EcoRI and StuI (cloning explained in 
section 2.2.1). Once the plasmid was confirmed by sequence analysis, the PV3 expression 
vector was transformed into S. cerevisiae RAY3A-D and successful transformants re-extracted, 
transformed back into competent E. coli cells and plasmid preparation again done to confirm 
the transformation by DNA sequencing as described in 2.4.1. 
5.3.1 PV3 VLP purification using zymolyase and N2 cavitation method 
A 2L liquid culture of PV3 Skt SC8 expressing S. cerevisiae was prepared to 2.3 ODU/ml which 
gave a 13.5 g wet weight pellet and processed as before - the procedural details are described 
in 2.4.2. The cell pellet obtained was processed using zymolyase and N2 cavitation method as 
described but with small modifications to adapt the method to the culture size, that is larger 
volumes of buffer and the addition of a cOmplete ULTRA EDTA-free protease inhibitor tablet 
prior to the loading of the sample into the N2 cavitation vessel. Small fractions of cells were 
taken out before and after N2 cavitation and examined by EVOS confocal microscopy to 
confirm cell lysis. The confocal microscopy image shows the typical yeast cell lysis using this 
method (Figure 5.6). The clarified lysis supernatant was ultracentrifuged as described earlier. 
The resultant centrifuge tube gave 3 distinct bands; a 1st interface between sample load and 
10 % Nycodenz layer, a 2nd interface between the 10 % and 20 % layers and a 3rd interface 
between the 20 % and 30 % layers. 1 ml fractions were collected from the top of the tube 
except for the visible bands, which were taken separately. A pellet at the bottom of the gradient 
was also resuspended in PBS and stored.  
The fractions from the Nycodenz gradient were analysed by VP1 WB (Figure 5.7). The image 
indicated detection of a high intensity band around 30 kDa in the middle of Nycodenz gradient 
as had been observed for Figure 5.2, although now more intense. In order to confirm the 
presence of PV VLP, TEM imaging for all 3 interfaces were carried out following the method 
described in section 2.7.2 (Figure 5.8). At each interface, lower magnification image is shown 
 145 
on the left to illustrate the wider field to provide VLP number as well as purity. Whereas a 
higher magnification image (right) gives more accurate VLP size estimation. Grids of the 1st 
interface sample showed material of a size smaller than typical PV VLPs with few regular 
features while grids of the 2nd interface showed some PV VLPs present in a high background 
similar to Figure 5.4 with average size of 46.9 nm (+/- SEM = 4.01, n=10). The 3rd interface 
layer contained VLPs which have average VLP size of 32.5 nm (+/- SEM = 1.98, n = 6) and 
typical characteristics but also contained other debris. These images confirm the purification 
of PV3 Skt SC8 VLPs from yeast using a combination of enzymatic removal of the cell wall 
and gentle pressure induced lysis.  
  
Figure 5.6. Confocal microscope (EVOS) image shows RAY3A-D-PV3SC8-3C cells break down by zymolyase and 
N2 cavitation 
(left) S. cerevisiae cells are still intact before N2 cavitation. There were almost no RAY3A-D-PV3SC8-3C cells left 











Figure 5.7. WB analysis for detecting VP1 by MAB8566 (Millipore) following RAY3A-D-PV3SC8-3C VLP purification 
using zymolyase and N2 cavitation method and 10-30% Nycodenz step gradient 
The fractions from the gradient and PV standard were run on 2 gels which are merged for this presentation. Visible 
interface layers were fractionated separately and denoted *I - *III. 30 kDa bands were detected in fractions 6-11 as 
indicated. The intensity peaked in fractions 9 and 10 (20% Nycodenz concentration) while reactivity in the 10% 
fractions was also strong. Fraction 13 reactivity may indicate aggregation as the pellet was collected with the last 
fraction. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. PV standard, far right 
lane (St) is for a PV1 reactivity control. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained 

























Figure 5.8. TEM imaging of the 3 interfaces which is seen on Figure 5.7.  
White arrows in the images indicate VLPs, characterised by stain penetration and the morphology. The 1
st
 interface 
showed numerous stained structure sizes from 10 nm to 26 nm with irregular shapes. The 2
nd
 interface images 
appeared as a white background image, similar to Figure 5.4. There were some VLPs characterised by the stain 
penetration with distorted shapes. Average VLP size is 42.9 nm (+/- SEM = 4.01, n=10). The 3
rd
 interface fraction 
contained VLPs which are more uniformly shaped, although some seem broken. Average VLP size was  32.5 nm 
(+/- SEM = 1.98, n = 6). A background was present in this fraction but it was lower than that in the 2
nd
 interface 
fraction. 2 % uranyl acetate was used as stain on a copper grid with carbon coated formvar film (Agar scientific). 
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5.3.2 RAY3A-D-PV3SC8-3C VLP purification using Zymolyase and cell disruptor method 
A yeast cell culture was grown for 2 days to reach 17.7 ODU/ml, 21.0 g wet weight per litre of 
culture. The cells were treated as the same way as in section 5.3.1. However, the buffer volume 
was adjusted to compensate for the bigger cell pellet. Zymolyase processing was done in 120 
ml buffer and lysis performed by cell disruptor, 9 strokes of 250 MPa were required for 
complete destruction as shown by light microscopy. The sample temperature was maintained 
< 20°C throughout. Clarification, sucrose cushion and then 10-30% Nycodenz gradient were 
done as before (section 5.3.1). The gradient showed 2 visible bands at the 10-20 % and 20-
30 % interface as well as a pellet at the bottom of the tube. 1 ml fractions were taken from the 
top and the fractions containing visible bands were concentrated for TEM imaging. One fraction 
below the 20-30 % interface fraction was also concentrated for TEM (section 2.7.2).  
TEM images revealed PV VLPs in the 20-30 % interface sample with average size of 43.8 nm 
(+/- SEM of 1.78, n = 7), as expected from the other optimisation experiments described. A 
fraction below the interface also contained PV VLPs (Figure 5.9) with average size of 42.0 nm 
(+/- SEM of 2.70, n = 17). Previously, experiments appeared to suggest that zymolyase and 
N2 cavitation was not efficient when the yeast culture was left to grow beyond mid-log phase 
as the cell wall becomes very thick and the physical disruption required to break it is too harsh 
for the PV1 VLPs used for initial experiments. Here however, using PV3 VLPs the physical 
disruption appeared compatible with VLP isolation although it should be noted that no 
measurement of H/N antigenic form was done for these samples, nor were any structures 
obtained to substantiate the VLP structure. Nevertheless, yeast expression is clearly a viable 
option for PV VLP production and suitable methods can be found to extract VLP intact from 
large scale cultures. 
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5.4 Purification methods for Insect cells 
The lysis methods described in this chapter were designed for the processing of yeast cultures 
but having shown some improvement over the period of testing, it was interesting to ask if the 
same methods would allow purification of PV VLPs from insect cells. Thus, the cell disruptor 
and N2 cavitation methods were assessed as methods to lyse insect cells expressing PV1 
VLPs as described in chapter 3.  
5.4.1 Cell disruptor method 
Suspension cultures of High Five cells, following infection with Bac-PV1P1-3C, were prepared 
as per 2.3.3.  The cells were resuspended in 25 ml PBS pH 6.8, 1 mM CaCl2, 0.5 mM MgCl2 
supplemented with cOmplete ULTRA EDTA-free protease inhibitor tablet. The resuspension 
was pressurised to 70 MPa and only one stroke was required for insect cells disruption as 
Figure 5.9. TEM image with negative staining of RAY3A-D-PV3SC8-3C VLPs after zymolyase and cell disruptor 
purification and 10-30 % Nycodenz step gradient 
(Left) Concentrated 20-30 % interface was observed. There were some VLPs as well as some background 
structures. The average size of VLPs is 43.8 nm (+/- SEM of 1.78, n = 7). (Right) A fraction below the 20-30 % 
interface (concentrated) showed VLPs with average size of 42.0 nm (+/- SEM of 2.70, n = 17). Some structures 
with stain penetration which sizes up to 75 nm were also visualised. 2 % uranyl acetate was used as stain on a 
copper grid with carbon coated formvar film (Agar scientific). 
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judged by light microscopy. The sample temperature was maintained at < 20°C throughout. 
Thereafter NP40 was added to be 1 % (v/v) and incubated in ice for 1 hour. The supernatant 
obtained after 15000 rpm, 4 °C for 30 minutes centrifugation was processed as before and 
loaded onto a 15-45 % linear sucrose gradient and ultracentrifuged at 21,000 rpm, 4 °C for 16 
hours. It was fractionated from the top of the tube and each fraction was analysed by WB for 
the presence of VP1 (Figure 5.10). The procedures are detailed in section 2.5 and 2.6. VP1 
appeared from fraction 2 to fraction 13 and also in the resuspended pellet fraction. Among the 
fractions, the VP1 band intensity fluctuated with a peak in fraction 7 and 8 which then declined. 
VP1 intensity increased again in fraction 12. Assembled PV VLP were expected in the middle 
of the gradient and TEM visualisation of fraction 7, 8 and 12 was carried out after concentration 
by spin-filter as per section 2.7.2. The images are shown in Figure 5.11. The concentrated 
sample for fraction 7 and 8 showed VLP particles of average size of 38.6 nm with +/- SEM of 
2.56, n = 7 with a high background of smaller material. Fraction 12 also revealed particles 
around VLP size but many were distorted or broken. Fragmented baculovirus particles were 
also be present in the debris. This fraction is likely to be aggregated material which has trapped 
some PV VLPs and the level of VLP here might be lessened by improved extraction so that 
the pellet fraction is reduced. Nevertheless, the lysis of High Five cells using a cell disruptor 





Figure 5.10. WB analysis for VP1 detection using MAB8566 (Millipore) for Bac-PV1P1-3C VLP following purification 
with cell disruptor and 15-45 % sucrose gradient 
35 kDa bands were detected throughout the gradient. However the intensity reached peak at fraction 7 and 8 as 
indicated then again at fraction 11 to 13. The St lane is the PV standard included as VP1 detection control. The P 
lane in right hand side WB is loaded with pellet resuspension. Protein molecular markers are shown to the left of 
the gel (M) and in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein 
Ladder (Geneflow) were used. 
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5.4.2 N2 cavitation method 
As the N2 cavitation is a gentle non-thermal method for lysis of cells, the insect cells were also 
lysed using this method for purification of Bac-PV1P1-3C  VLPs. The procedure developed for 
yeast cells was used with a slight change in nitrogen gas incubation pressure and duration.  
High Five cells in 200 mL suspension culture infected with Bac-PV1P1-3C as before were 
resuspended in ice-cold 25 ml homogenization buffer (2.1.8). The cells were pressurised at 
500 psi for 30 minutes in N2 cavitation vessel. Thereafter, the sample was incubated with NP40, 
clarified and used as the load to a 30 % sucrose cushion followed by a 10-30 % Nycodenz 
gradient. After the ultracentrifugation (section 2.5.2) there was no visible clear band but the 30 
% layer appeared hazy. At the bottom of the tube, a pellet was formed. 1 ml fractionation from 
the top of tube was carried out as before.  
The fractions were analysed with WB for the presence of VP1. The blot images are shown in 
Figure 5.12. VP1 detection fluctuated and peaked at fraction 9 and declined until the aggregate 
at the bottom of tube, as before. Fraction 9, i.e. the interface fraction between 20 % and 30 % 
Nycodenz, was concentrated and observed under TEM as per section 2.7.2. Figure 5.13 
reveals the presence of PV VLP (average size of 41.8 nm with +/- SEM of 2.85, n = 28) and 
Figure 5.11. TEM image with negative staining of VLPs in peak fractions (fraction 7 and 8) and bottom fraction 
(fraction 12) from Figure 5.10 
White arrows in the images indicate possible VLPs. (Left) Peak fractions showed some VLPs with various forms. 
However the stain penetration typical to VLP is not seen. The average size of VLP is 38.6 nm with +/- SEM of 2.56, 
n = 7. (Right) Smaller positive stained structures similar to Figure 5.8 1
st
 interface was seen in the field. Fraction 12 
showed some probable VLPs as well as background material. 2 % uranyl acetate was used as stain on a copper 
grid with carbon coated formvar film (Agar scientific). 
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other vesicle like structures of with various sizes. The lower magnification image (left) showed 
both PV VLP and baculoviruses, characterised by the long rod shape. Those images 
suggested that N2 cavitation is efficient for PV VLP purification. However, this method requires 
further optimisation due to baculovirus content and VLP size variety. 
 
Figure 5.12. WB analysis detecting VP1 by MAB8566 for Bac-PV1P1-3C VLP following N2 cavitation and 10-30 % 
Nycodenz gradient. 3 d.p.i. of Bac-PV1P1-3C infected High Five cells were prepared for analysis. 
Total of 13 fractions were run on 2 gels. The image above is composite. ~37 kDa reactivity occurs across Nycodenz 
layers (fraction 4 to 13 as indicated). Fraction 9 at 20-30 % nycodenz interface showed increased reactivity. The 
reactivity decreased for fr10 and started to increase again from fraction 11 and reached the highest at 13. Far right 
lane (St) contains PV standard as VP1 reactivity control. Protein molecular markers are show to the left of the gel 
(M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder 
(Geneflow) were used 
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5.5 Discussion 
In this chapter, cell lysis and different separation techniques were assessed for the successful 
release of intact VLPs, primarily from yeast. Table 5.1 summarises the purification methods 
used and the result obtained. The best findings were also transferred to PV1 wildtype VLP 
isolation from insect cells. Three different methods were studied to improve the purification for 
PV1 Mahoney wildtype VLP originated from S. cerevisiae as preliminary data shown in chapter 
4 had indicated that yeast cell lysis that maintained VLP conformation was difficult. Thus, cell 
homogenization by pressure, bead-beating and enzymatic lysis with membrane disruption by 
N2 cavitation were used for yeast cell lysis. The cell disruptor method showed low VP1 
detection on the WB (Figure 5.2) and a low level of VLP under TEM (Figure 5.3). On the grids, 
other material was also observed on the grids. Although the yield and purity was not optimal, 
the method purified PV VLPs to some degree and was relatively easy to perform. It was noted 
that temperature control was an important consideration for this method. The bead-beater 
method also led to the visualisation of some empty VLPs but the background was high 
preventing confirmation of VLP dimensions and structure (Figure 5.4). Both of the methods 
that used mechanical force showed a temperature rise during the procedure, a key concern 
Figure 5.13. TEM image with negative staining for VLPs from Figure 5.12 concentrated fraction 9 at 20-30 % 
nycodenz interface  
(Left) There are numerous PV VLPs which is characterised with stain penetration and average size of 41.8 nm with 
+/- SEM of 2.85, n = 28 and rod shaped baculoviruses. (Right) A field from the same grid indicated some background 
material as seen in Figure 5.11 fraction 12. 2 % uranyl acetate was used as stain on a copper grid with carbon 
coated formvar film (Agar scientific). 
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for the thermostability of PV VLPs. The zymolyase and N2 cavitation method also showed the 
presence of PV VLP (Figure 5.5) and had the advantage of low operational temperature, useful 
for PV VLP purification. With these benefits, zymolyase with N2 cavitation was considered to 
be the most suitable method for PV1 VLP purification from yeast cells. A consistent observation 
when western blotting was done for the detection of mature VP1 from yeast expression 
cultures was the presence of a 30 kDa band, rather than the anticipated 35 kDa. On a western 
blot all proteins are denatured prior to electrophoresis and a VP1 subunit nicked by proteolysis 
would be detected by blot even if the folded VP1 protein remained intact in solution, as in a 
VLP. It has been shown that trypsin digest of PV substantially reduces its ability bind to cell 
surfaces (Piirainen et al., 1996) and that in the context of VLPs, the N terminus of VP1 can be 
exposed, depending on buffer conditions (Basavappa et al., 1998). Moreover the antibody 
used to detect VP1 is known to bind to the C-terminus of the protein (Gary et al., 1997) so 
cleavage to the 30 kDa form must occur N terminal to the bound epitope. Together it is 
reasonable to suppose that, in the yeast background, or during sample processing the N 
terminus of VP1 may become exposed to protease and subject to nicking or degradation. 
Evidently however VLPs remain intact although their conformation and the effect of such 
cleavage on yield was not assessed.  
As these studies were ongoing a variant form of PV3, the PV3 Skt SC8 mutant, was shown to 
have increased thermostability (Fox et al., 2017; Marsian et al., 2017) and a new construct 
using this sequence was adopted for expression and production. As PV1 VLP yield had 
improved by the use of the zymolyase and N2 cavitation method, this method was also applied 
to the new Skt SC8 strain. The zymolyase and N2 cavitation method successfully processed 
the cells from a 2 L culture (Figure 5.6) providing a distribution pattern of VP1 reactivity on WB 
(Figure 5.7) which suggested a higher yield of VLPs. The improved PV3 Skt SC8 
thermostability and direct observation by TEM (Figure 5.8) confirmed VLP presence. The 
zymolyase and cell disruptor method produced Figure 5.9 and again indicated an increased 
number of VLPs and less impurity in the equivalent fractions to the zymolyase and N2 cavitation 
method. Although a strict side-by-side comparison was difficult, the increased VLP yield 
suggested that the use of strains with improvised thermostability contributed to an increase in 
VLP purity and should be adopted whenever available.  
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The yeast cell purification trials led to some experimental trial of the same methods for PV VLP 
isolation from insect cells. The cell disruptor method demonstrated VP1 reactivity in the middle 
fractions of a 15-45 % sucrose gradient (Figure 5.10), typical of where empty capsids band. 
The TEM imaging of the peak fraction revealed a high background but abundant VLPs (Figure 
5.11). The WB result (Figure 5.13) for the N2 cavitation method indicated that VP1 peak 
reactivity at 20-30 % interface layer of Nycodenz gradient, which corresponded to the finding 
from the yeast cell purification protocol. Again, TEM image (Figure 5.12) confirmed numerous 
VLPs as well as baculovirus capsids (obviously missing in the Yeast derived images). Thus, 
these purification trials benefited the VLP extraction from insect cells and the quality of the 
VLP is obvious, although there is impurity and vector baculoviruses are present.  
Overall this chapter has shown an effective method for the purification of PV VLPs from yeast 
cells using zymolyase and N2 cavitation. Possibly the cell disruptor method is more efficient for 
the thermostable VLP purification from yeast cells as the potential for physical disruption of the 
VLP is less. Both cell disruptor and N2 cavitation methods improved VLPs yields and these 
methods could be very beneficially used for insect cells also if baculovirus removal is achieved 
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Table 5.1. Summary of cell lysis and purification method used in chapter 5 
 158 
  The factors of capsid assembly and contribution to 
VLP antigenicity 
6.1 Introduction 
Although there are two types of vaccine available for poliovirus, neither are a suitable choice 
for the post eradication world due to the requirement for live virus culture. At the same time 
any vaccine replacing the existing OPV and IPV stocks is expected to improve other current 
limitations, such as the thermostability of the vaccines as discussed in chapter 1.  
Since the studies success in VLP production in S. cerevisiae (Rombaut et al., 1994) and its 
conformation change to immunogenic VLP (Rombaut & Jore, 1997) as detailed in chapter 4, 
no follow-up of this observation has appeared in the literature and investigation of the improved 
stability of VLPs from S. cerevisiae, or any other recombinant system, by the addition of 
Pirodavir or similar compounds has not been reported.  
Other than the VP1 pocket region, the association of protomers to form a pentamer is driven 
by dynamic capsid change during the assembly process of picornaviruses and detailed PV 
capsid rearrangement has been studied in 135S (Butan et al., 2014) and 80S particles (Levy 
et al., 2010). As discussed in chapter 1, dynamic capsid change involves the N-terminus of 
VP4 and the N-terminus of VP1 and the assumption is that they may make a contribution to 
capsid assembly and stability. During the course of these investigations, the Mahoney SC6b 
sequence, a thermostable variant, also became available and was used to produce VLP 
incorporating those mutations. 
This chapter focuses on attempts to improve VLP stabilisation to produce VLPs that are 
predominantly or wholly in the N conformation. The experiments target the site known to be 
the binding site for Pirodavir-like antiviral drugs, the hydrophobic pocket in the mature VP1 
protein in expectation that they will make a contribution to capsid stability and VP4 and the N-
terminus of VP1 which are contributing to pentamer formation.  
First, the conformation of VLPs produced in the baculovirus and S. cerevisiae expression 
systems was assessed using ELISA with mAbs specific for the N or H conformational forms. 
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Next, manipulation of the occupancy of the VP1 pocket is investigated by introducing amino 
acid mutations that alter the side chains that protrude into the hydrophobic space. Then an 
attempt was made to supplement cultures and purification steps with antiviral compounds such 
as Pleconaril and GPV13 (De Palma et al., 2008b) to address whether conformational change 
can be achieved post expression. Finally the contribution of VP4 and the N-terminus of VP1 to 
VLP assembly are tested individually by exchanging VP4 amino acids with another 
myristoylated protein and by the addition of short GS linkers to the N-terminus of VP1. 
6.1.1 Antipicornavirus compounds and VP1 mutations 
As discussed in chapter 1 and 4, antipicornaviral compounds such as WIN compounds were 
originally designed to bind VP1 pocket at high affinity to inhibit capsid conformation change 
and prevent the infection. For PV, the binding mode of those compounds was found to inhibit 
conformational change but is still able to bind the receptor (Rossmann, 1994). This feature is 
therefore suited as a strategy for stabilising VLP and indeed, Pirodavir addition improved VLPs 
produced in S. cerevisiae by changing H conformation VLP to N conformation (Rombaut & 
Jore, 1997).  
In this chapter, Pleconaril and GPV13 (Figure 6.1) are used as the pocket binding compounds 
to prevent N antigen conversion to H antigen. Pleconaril, also known as WIN63843 was 
produced as part of the WIN compound development and inhibition of viral uncoating was 
observed widely for enteroviruses (Florea et al., 2003; Pevear et al., 1999). Pleconaril entered 
clinical trials as a HRV inhibitor for the common cold treatment but its development has since 
ceased (De Palma et al., 2008b). In PV, De Palma et al. (2008a) demonstrated that Pleconaril 
inhibited Sabin PV2 and PV3 replication although it was less efficient towards Sabin PV1. Very 
similar activity was obtained for Pirodavir, the capsid binding compound used by (Rombaut & 
Jore, 1997) for capsid stabilisation of S. cerevisiae derived VLPs. This suggests that Pleconaril 
may be as effective as Pirodavir in maintaining the N conformation of VLPs. GPV13 is similar 
to a SCH47802 analogue, SCH48973 (Figure 6.1A) produced by Schering-Plough (De Colibus 
et al., 2014). The antiviral properties of these compounds were observed in PV2 along with 
several echoviruses and coxsackieviruses (Cox et al., 1996; De Palma et al., 2008b). The 
crystallographic imaging (Figure 6.1B) showed the binding of SCH48973 to the VP1 pocket 
and has confirmed that the site of the binding is almost identical to that of the natural pocket 
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factors (De Palma et al., 2008b; Lentz et al., 1997). The effect of GPV13 on PV VLP is not 
known. However as binding in the VP1 pocket prevents the conformational change, it is 
expected to behave as a capsid stabiliser.  
  
Figure 6.1. Chemical structures of antipicornavirus compounds 
(A) Pleconaril, SCH47802, SCH48973 (De Palma et al., 2008b) and GPV13 (De Colibus et al., 2014). (B) 
Crystallography of PV2 VP1 filled with SCH48973. The compound is labelled with yellow backbone. Some of 
residues close to the compound are indicated (De Palma et al., 2008b).  
 161 
An alternate approach to antipicornaviral compound binding to the VP1 pocket to conserve the 
capsid N status for PV capsids may be the introduction of hydrophobic side chains via VP1 
residues facing into the VP1 pocket. The pocket is then filled permanently as if by a pocket 
factor or antiviral compound. Suitable residues for change in VP1 were chosen from modelling 
in silico carried out by project collaborators at the University of Oxford and the introduction of 
leucine (aliphatic amino acid) and tryptophan (aromatic amino acid) in their place was chosen. 
Tryptophan contains an indole structure made up of a benzene ring which contributes to VP1 
pocket filling because of its bulky structure. Leucine was selected as a milder choice than 
tryptophan as it too contains a hydrophobic side chain but does not have the bulky structure 
of tryptophan.  
 
 
6.2 Antigenicity of PV VLPs 
The antigenicity of PV VLPs was analysed by enzyme-linked immunosorbent assay (ELISA) 
sandwich assay by Sarah Knowlson at NIBSC. The immunosorbent plate wells were coated 
with a PV particle capture Ab which does not induce conformational change of PV particles 
and the PV sample applied. The immobilised PV is then probed with conformation specific 
mAbs (either N or H specific mAb). A conjugated secondary Ab is added to the wells for 
 VP1 residue 
Mutation M132L, M132W, M132W-H207W, M132W-F237W, H207W-F237W, 
M132W-H207W-F237W (Triple), Y159W, Y159W-Y205W, Y205W, H207W, 
F237W 
Leucine (Leu, L) = Aliphatic 
 
Tryptophan (Trp, W) = Aromatic 
 
Table 6.1. List of VP1 residues facing to the VP1 pocket. Substituting amino acids are indicated in blue. The amino 
acid structures of leucine and Tryptophan are shown below 
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enzyme-substrate interaction. The detail of antibodies used and procedures were described in 
section 2.8. As a positive control for N antigen, IPV reference material available from NIBSC 
was included in the assay.  
6.2.1 Insect cells origin VLPs 
Three day infections of 1 L High Five cells with Bac-PV1P1-3C were prepared to obtain the 
cell pellet as described in 2.3.3. After the VLPs were purified from insect cells by cell lysis 
followed by 30 % sucrose cushion and 15-45 % linear sucrose gradient (section 2.5), the 
immunogenic conformation of VLPs was examined by ELISA as described in 2.8. Insect cells 
expressing poliovirus VLPs showed the H-conformation (Figure 6.2) suggesting an inability to 
raise neutralising antibodies if used as a vaccine. The IPV control showed its N dominant 
characteristics validating the assay format.
Figure 6.2. Antigenicity ELISA analysis for IPV (PV standard) and Insect cell origin PV VLP detected by N/H specific 
antibodies at NIBSC 
Duplicates of IPV and VLP samples were analysed. (Left) IPV sample are predominantly N specific starting at the 
2-fold dilution from 1/40 to 1/320 while H specific remained low readings throughout the dilution. (Right) the same 
dilution was applied for insect PV VLPs. Insect cell sample O.D. readings were much lower than IPV. N-specific 
readings were observed at 1/40 and 1/80. At 1/160, N specific readings reached non-significant readings and 
remained unchanged through the later dilutions.  
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6.2.2 S. cerevisiae origin VLPs 
Yeast expressed PV VLPs were also tested for the antigenicity by N/H ELISA at Reading and 
purified samples from three different purification methods (see chapter 5) were included. The 
individual culture and purification methods are detailed in section 5.2. Previously, VLPs 
produced in S. cerevisiae were identified as H confirmation (Rombaut & Jore, 1997), so the 
expectation was for H antigenicity. However, the data in Figure 6.3 indicated that the 
antigenicity varied according to the purification method used. ELISA for IPV validated the 
assay for detection of N antigenic particles (Figure 6.3, Left) and VLPs purified by zymolyase 
and N2 cavitation (shown as N2 Bomb on the ELISA result) showed almost equal amounts of N 
and H specific antigen (Figure 6.3, Centre). The N-specific Ab binding showed a decline 
according to dilution consistent with the presence of N antigenic VLPs although the readings 
were generally low when compared to the IPV assay. This method of purification also provided 
the highest number of VLPs (Figure 6.3, right) and this in part may reflect higher OD reading 
for both N and H Abs when compared to the other two purification methods. VLPs purified by 
the cell disruptor (CD) method failed to give significant readings for either N or H- specific Ab 
although VLPs were confirmed by TEM (Figure 5.3) and should have been captured by the 
trapping layer. Plausibly, the heat generated by the CD caused changes that prevented binding 
but further work would be required to prove this. VLPs extracted by the bead-beater showed a 
constant decline in N-specific Ab binding with dilution but unchanged OD reading for the H-
specific Ab. TEM of this sample showed very few visible VLPs, consistent with a poor binding 
overall. From these data it seems possible that N conformation VLPs could be produced in S. 
cerevisiae at some level but that the preservation of the conformation may depend on 
treatment. Broadly, the numbers of VLP and level of intactness as demonstrated by TEM were 
in accord with the ELISA data and it would be useful to re-investigate the steps in each 




6.3 VP1 pocket manipulations 
The results of VLP conformation tests for material from both insect cells and S. cerevisiae 
showed that, even if N-type VLPs were present, they were not the major products. Therefore, 
attempts at conversion of the H conformation to the N conformation of VLP are required. As 
discussed, the hydrophobic VP1 pocket plays an important role in the thermostability of PV 
and occupation of the pocket by the introduction of mutations in residues lining it. Other capsid 
Figure 6.3. Antigenicity ELISA analysis to determine the status of RAY3A-D-PV1-3C origin VLPs purified using 
various purification methods at Reading 
(Left) IPV as the assay control showed mainly N specific particles. 1/20 IPV was used in 2-fold serial dilution up to 
1/320. (Centre) VLPs from of RAY3A-D-PV1-3C which are purified by using either N2 Bomb (N2 cavitation), CD (cell 
disruptor) or Beads beater. Undiluted concentrated sample were applied and 2-fold serial dilution to 1/8 were carried 
out. N2 Bomb samples showed similar readings for both N and H through the dilutions. The N and H specific readings 
for VLP prepared by CD remained unchanged, un-correlating with the dilution. VLPs prepared by bead beater 
showed higher N specific readings and the pattern declined with the dilution while H specific readings were lower 
and remained significantly unchanged throughout the dilutions. (Right) TEM images of negatively stained VLP 
samples used for ELISA assay (from chapter 5).  
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stabilisation methods, that is, the addition of pocket binding compounds will be discussed in 
Section 6.4. 
6.3.1 Expression of VP1 pocket surface mutants 
Molecular modelling carried out by collaborators at University of Oxford predicted the VP1 
residues that line the pocket where side chain changes could act to fill the space are listed in 
Table 6.1. The mutations were introduced into pOPINE Mahoney P1_2A_FS_3CEV71 for the 
expression in insect cells as described in 2.2 and recombinant baculoviruses listed in 2.1.4 are 
produced (section 2.3.1). Small scale infections with Sf9 cells were performed to examine the 
expression of PV proteins and their cleavage measured by VP1 WB as before. There is a 
dynamic equilibrium in expressing cells between assembled and disassembled capsids with 
the latter being prone to degradation, as has been shown to also be the case for other 
picornaviruses (Katpally & Smith, 2007). In the case of improved stability therefore the level of 
the VP1 product as seen by the WB band intensity should increase as a result of less capsid 
degradation. 
The WB analysis (Figure 6.4) shows very different levels of VP1 antigen detection associated 
with each mutation made. Bac-M132L, Bac-Y205W and Bac-H207W showed clear VP1 bands 
albeit substantially less than the level of VP1 produced by the parental construct Bac-PV1P1-
3C. One of the isolates of Bac-Y159W essentially abolished expression. The two isolates of 
Bac-Y159W arose as, during the course of the work, two forms of the parental PV1 Mahoney 
sequence were used, the first was cloned from the virus sequence donated by collaborators 
at NIBSC and was not codon optimised whereas the other was produced using a Sf9 codon 
optimised synthetic DNA fragments. This change arose as the cost and availability of the 
synthetic approach reduced substantially over the course of the project, becoming the default 
method. A comparison among the non-codon optimised showed Bac-Y159W to be detrimental 
whereas the codon optimised Bac-Y159W was tolerated. This indicates a role for codon 
optimised in the expression level seen and leaves the exact effect of Bac-Y159W in question. 
However Bac-M132L, Bac-Y205W and Bac-H207W reduced expression.  
The expression of the remaining VP1 pocket mutants, many multiple, which now used codon 
optimised sequences throughout, was also analysed by WB VP1 detection (Figure 6.5). The 
lanes for Bac-F237W, Bac-M132W-F237W, Bac-Triple mutants and Bac-PV1P1-3C showed 
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VP1 levels similar or equal to the parental construct. However, in the case of Bac-M132W-
F237W, Bac-H207W-F237W expression of VP1 was substantially reduced. These results may 
indicate that only the F237W mutation is able to be tolerated for expression, and therefore the 
assembly of VLPs. The combination mutants with F237W also showed different VP1 
expression levels. Although M132W-F237W and the triple mutations showed expression, 
H207W-F237W did not. The data in Figure 6.4 and Figure 6.5 indicate that capsid stability is 
indeed affected greatly by the residues that line the VP1 pocket, validating the approach to 
improved stability. However, none of the introduced mutations, single or multiple, benefited 
VP1 levels, all were deleterious to some degree indicating the challenge of predicting the 
outcome of even minor changes in the structure of a large assembled complex.  
To ensure that the data obtained in insect cells was not an artefact of the expression 
background some of the VP1 pocket lining mutations were introduced also into the S. 
cerevisiae expression system. Based on the data of Figure 6.4 and Figure 6.5, the mutants 
M132L, M132W, Y159W, Y205W and triple (M132W-Y207W-F237W). pKT10 Mahoney 
P1_2A_FS_3CEV71 - M132L, M132W, Y159W, Y205W and M132W-Y207W-F237W (Triple) 
were transformed to produce recombinant RAY3A-D with VP1 pocket mutants RAY3A-D-PV1-
3C-M132L, M132W, Y159W, Y205W and M132W-Y207W-F237W (Triple) as per section 2.4.1. 
However they were not codon optimised for S. cerevisiae expression as they were to be 
compared like with like. After the transformation and confirmation of the desired mutations in 
each case, 3 day old colonies were analysed by WB analysis using anti-VP1 antibody following 
NaOH disruption as explained in 2.6.1. The result showed no significant VP1 expression (data 




Figure 6.4. WB analysis for Bac-PV1P1-3C with hydrophobic pocket mutations for capsid stability improvement 
3 d,p,i of Sf9 cells with corresponding recombinant baculovirus in 6 well dish was loaded on the gel.  
The image is composite of 2 gels. Samples in blue box indicates non-codon optimised P1 in their transfer vector. 
The blot showed the different level of antigen detected by VP1 antibody (MAB8566, Millipore). Bac-H207W, M132L, 
Y205W mutants showed ~35kDa reactivity which is VP1, however the level is not as high as Bac-PV1P1-3C. Y159W 
variant constructs showed different levels of VP1 reactivity. Non-codon optimised Bac-Y159W showed low antigen 
level at ~35 kDa. Sf9 cells codon optimised Bac-Y159W showed VP1 reactivity which was slightly lower than Bac-
PV1P1-3C. Sf9 lane contains only the cells to act as negative control. Bac-GFP lane was included as mock 
baculovirus infection. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-
12% Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used.  
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6.3.2 Supplementation in insect cells expression system 
GPV13 
After setting up small scale infection as described in 2.3.2, the insect cell media was changed 
+/- GPV13 at 8 h.p.i. 10 µg/ml GPV13 (the same concentration as Pirodavir used by Rombaut 
and Jore (1997) and significantly higher concentration than Lentz et al. (1997) used for solving 
the PV2 Lansing structure at 0.4 µg/ml) was added to a 2-day infection of Bac-PV1P1-3C, Bac-
Y159W and Bac-Y205W. At the time of the experiment, they were the only Sf9 codon optimised 
mutants which had different VP1 expression levels (Figure 6.4). Alongside, the same infections 
without GPV13 acted as controls. The harvested cells were analysed by WB using anti-VP1 
antibody (section 2.6). The result is shown in Figure 6.6, left. The antigen level of WT Bac-
PV1P1-3C infection without GPV13 (PV–) serves as control. Bac-PV1P1-3C infection with 
GPV13 (PV+) showed a higher level of antigen on the WB while for Bac-Y159W infection, 
Figure 6.5. WB analysis using anti-VP1 antibody (MAB8566, Millipore) for Bac-PV1P1-3C mutants at M132, H207, 
F237 and their combinations (codon optimised) for 3 d.p.i of Sf9 cells with Bac-PV1P1-3C mutants prepared in a 6 
well dish.  
VP1 reactivity (~37kDa) were seen in lanes for F237W, M132W-F237W, Triple mutants (M132W-H207W-F237W) 
and Bac-PV1P1-3C at the rate of M132W-F237W<F237W=Bac-Triple=Bac-PV1P1-3C. The other mutants showed 
rather background reactivity which was seen in Sf9 cells (negative control) and Bac-GFP (mock baculovirus 
infection) lanes. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% 
Bis-Tris Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used. 
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Y159W+ demonstrated a lower level of VP1 reactivity compared to Y159W–. On the other 
hand, Y205W+ showed an increased VP1 detection compared to Y205W–. The antigen 
comparison graph (Figure 6.6, right) indicated that WT PV+ VP1 reactivity was stimulated 
about 1.4 times while Y159- showed about a 20% higher VP1 reactivity than Bac-Y159W+. In 
contrast, Bac-Y205W+ showed at least a 4 times higher reactivity than Y205W–. 
 
Pleconaril in insect cells expression system 
The other PV pocket binding drug, Pleconaril was also investigated for its effectiveness for 
increasing VP1 expression, which in turn indicates increased stability. Pleconaril was added 
to High Five cells infection (250ml) with Bac-PV1P1-3C at the concentration of 10 µg/ml, 
sufficient for all VLPs produced from S. cerevisiae to be in the N-specific conformation 
(Rombaut & Jore, 1997). The concentration of Pleconaril was maintained during the 
purification. The insect culture preparation detail is described in 2.3.3. In order to test the VLP 
Figure 6.6. The analysis of GPV13 effect on VP1 reactivity level in Sf9 cells infection by Bac-PV1P1-3C, Bac-
Y159W and Bac-Y205W 
(Left) WB analysis by anti-VP1 antibody (MAB8566, Millipore). GPV13+/- infection was prepared with Bac-PV1P1-
3C (PV+/-), Bac-Y159W (Y159W+/-) and Bac-Y205W (Y205+/-). ~35kDa VP1 reactivity was seen in all lanes, but 
the levels are different. The VP1 reactivity for PV+ and Y205W+ was higher than PV- and Y205W-, however not for 
Y159. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris 
Plus Gels (ThermoFisher) and BLUeye Pre-Stained Protein Ladder (Geneflow) were used. (Right) VP1 reactivity 
quantitative comparison. PV+ is calculated to produce 1.4 times more antigen than PV-. Y159W+ displayed roughly 
20% lower VP1 reactivity than Y159W-. Y205W+ showed 4 times higher detection than Y205W-. 
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formation, the cell lysis and 10-30 % nycodenz step gradient was carried out (section 2.5). 
Following the WB analysis to determine the peak fractions from the gradient (section 2.6), the 
sample was examined by N/H ELISA as detailed in section 2.8. The WB analysis using anti-
VP1 antibody (Figure 6.7) showed VP1 reactivity in lanes for fraction 7-13, peaking at fraction 
7, 8 and 9. This reactivity at around 20 % nycodenz is equivalent to 35 % in sucrose and 
suggests the formation of VLPs. The middle fraction, fraction 8 was analysed by N/H ELISA at 
Reading to assess VLP conformation (Figure 6.8). The result indicated that the VLPs are 
neither N nor H antigenic form although the assay format was confirmed by the PV standard. 
The levels of VLP were low as judged by the WB of gradient samples, but it was clear that the 




Figure 6.7. WB analysis with anti-VP1 antibody (MAB8566, Millipore) for High Five cells infection by Bac-PV1P1-
3C with Pleconaril followed by non-ionic detergent lysis and 10-30 % nycodenz gradient 
The figure is composite of 2 gels. VP1 reactivity was shown in fraction 7-13 which peaked at fraction 7-9 and faded 
towards the bottom of tube except for fraction 13. Fraction 8 (indicated) was used for N/H ELISA analysis. There 
was no apparent VP1 reactivity from fraction 1 to 6. Far right lane (St) contains PV standard as VP1 reactivity 
control. Protein molecular markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris 




Pleconaril in yeast cells expression system 
RAY3A-D-PV3SC8-3C was chosen to study whether Pleconaril increases the N conformation 
VLPs by converting H conformation VLPs. Although PV3 Skt SC8 had the enhanced capsid 
stability for PV (Fox et al., 2017) and plant originated VLPs (Marsian et al., 2017), in the work 
described here VLPs from RAY3A-D-PV3SC8-3C were always H conformation dominant 
(Figure 6.3). For this experiment, 500ml RAY3A-D-PV3SC8-3C culture with and without 
Pleconaril was prepared and purified side by side following the method in 2.4.2. For the yeast 
cell culture grown with Pleconaril, 10 μg/ml was added and was kept for the purification steps. 
The harvested cells were lysed by zymolyase and N2 cavitation method as described in 5.2.3 
and VLP separation was carried out by a 30 % sucrose cushion by ultracentrifugation (2.5.2). 
The clarified 30 % sucrose cushion pellet resuspension was examined by N/H ELISA for the 
conformation as described in 2.8. The data in Figure 6.9 confirmed the assay format with the 
EU standard by showing the N specific OD readings are higher than H readings throughout 
the dilution and the readings declined as the sample are further diluted (left panel). However 
the result for Pleconaril supplemented (+) and non-supplemented (-) culture origin VLPs were 
Figure 6.8. N/H ELISA analysis for 10-30 % nycodenz gradient peak fraction (Figure 6.7) for Mahoney wt VLPs 
from High Five cells infection by Bac-PV1P1-3C purified with Pleconaril at Reading 
(Left) ELISA assay for IPV standard as assay control. It shows the constant N specific reading decline with dilution 
while H specific readings remained not significantly changed.  (Right) VLPs from High Five cells infection by Bac-
PV1P1-3C showed no major difference between N- and H- specific OD readings. 
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almost identical and as with the insect VLPs the level of VLP was low as indicated by the 
overall OD values. It is unclear whether the PV1 pocket is filled with any other molecule or 
simply that Pleconaril is not able to bind to the pocket in our culture condition.  
 
 
6.4 VLP stabilising mutations for PV1 at VP4 and VP1 
During the course of this work to stabilise the VLPs by VP1 pocket factor mimicking, Wang et 
al. (2018) produced EV71 VLPs wholly lacking in VP4, using the baculovirus expression 
system, which proved to be highly immunogenic and gave protection against EV71 challenge 
in mice. As discussed in chapter 1, the mature capsid changes to the 135S particle by the 
Figure 6.9. N/H ELISA for VLPs conformation from RAY3A-D-PV3SC8-3C +/- Pleconaril at Reading. 
VLPs from RAY3A-D-PV3SC8-3C were prepared following zymolyase and N2 cavitation method and 30% sucrose 
cushion. 10 μg/ml Pleconaril was maintained through the purification for Pleconaril + sample. 
(Left) PV standard (IPV reference) serving as assay control. IPV was diluted into 1/20 at the beginning of a 2-fold 
serial dilution to 1/320. N specific reading (indicated in blue) showed decline pattern with dilution while H specific 
(orange) showed lower reading than N readings generally but also a decreasing pattern. (Right) PV VLPs produced 
from S. cerevisiae either with Pleconaril supplemented (+) / non-supplemented (-) culture and purification.  
Pleconaril +, N specific readings (blue) and Pleconaril -, N specific readings (orange) showed almost identical 
readings while Pleconaril +, H specific readings (grey) and Pleconaril -, H specific readings (yellow) showed similar 
reading pattern. N readings were above H readings.  
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externalisation of VP4 during uncoating (Butan et al., 2014) which is followed by loss of VP4 
and RNA to form the 80S empty capsid (Bergelson & Coyne, 2013) and the authors thought 
to produce 80S-like empty capsids, suggesting that a VLP∆VP4 might improve EV71 vaccine 
stability by minimising the autocleavage of VP0 into VP4 and VP2 which occurs in VLPs with 
time (Li et al., 2013; Zhang et al., 2015). Expression of VLP∆VP4 lead to cryo-EM and 
immunisation. The vaccine potency results for immunogenicity and virus challenge test 
showed that the VLP∆VP4 was superior to VLPfull suggesting it as an EV71 vaccine candidate 
but more generally the study challenges a number of traditional views in the picornavirus field. 
The assembly of VLP∆VP4 was myristoylation independent, previously supposed to be essential 
for pentamer formation, and further suggests that VP4 has no essential role in assembly. 
These findings are intriguing and point towards further areas of manipulation for PV VLP 
assembly.   
 
PV1 Mahoney SC6b 
As mentioned in chapter 1, an improved PV thermostable mutant, Mahoney SC6b, was 
isolated from the study of Fox et al. (2017). As the various introduction of pocket lining 
mutations and the addition of pocket binding drugs had not significantly improved expression 
or thermostability in PV1 VLP produced in insect cells, the Mahoney SC6b P1 sequence was 
assessed a source of improved VLPs. The P1 sequence was codon optimised for Sf9 cells 
and was introduced by switching the P1 region of pOPINE Mahoney P1_2A_FS_3CEV71 (WT) 
at the BstEII and NotI sites that flank the P1 coding region to produce pOPINE Mahoney SC6b 
P1_2A_FS_3CEV71 as described in 2.2.1. Following sequence confirmation, it was transfected 
as per 2.3.1 to produce a recombinant baculovirus, Bac-PV1SC6bP1-3C. The high titre virus 
was used for small scale Tnao38 3 day infections to compare VP1 expression with WT 
recombinant baculovirus expression as explained in 2.3.2. WB analysis with an anti-VP1 
antibody as described in 2.6. Figure 6.12 showed higher VP1 reactivity for SC6b indicating 
that the use of the mutant sequence had improved VLP protein expression. Following WB 
analysis, a 100 ml Tnao38 cells infection with Bac-PV1SC6bP1-3C was set as per 2.3.2 and 
at 3 d.p.i. the cells were harvested and lysed by NP40 and loaded to a 30 % sucrose cushion 
followed by removal of cell debris as explained in 2.5. The pellet was resuspended and the 
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clarified supernatant was observed under TEM following the method in section 2.7.2 (Figure 
6.10A). The image revealed baculoviruses and PV VLPs characterised by the negative 
staining. Helen Fox at NIBSC analysed the same sample by N/H ELISA to determine 
conformation status. Figure 6.10B indicated that PV SC6b VLPs are still dominantly the H 
antigenic form but notably the OD readings were much higher than previous N/H ELISA results 
(Figure 6.2, Figure 6.3, Figure 6.8 and Figure 6.9). 
Figure 6.10. PV Mahoney SC6b VLP TEM image by negative staining (A) and N/H ELISA result (B) 
3 d.p.i Bac-PV1SC6bP1-3C infection of Tnao38 was lysed with NP40 and ultracentrifuged at 30% sucrose cushion 
to obtain VLPs. (A) 2% uranyl acetate was used for grid staining. PV VLPs (indicated by white arrows. Average size 
of 44.3 nm) as well as baculovirus were visible in the sample. 2 % uranyl acetate was used as stain on a copper 
grid with carbon coated formvar film (Agar scientific).. (B) SC6b VLP readings are indicated by orange for H specific 
reading and blue for N specific. The sample were applied as 1/5 dilution and 2-fold dilution is made to 1/640. H 
readings showed the decline as the dilution went further whereas the N reading remained almost unchanged. IPV 
(PV standard) readings served as control, staring the dilution from 1/10 to 1/640 by 2-fold dilution, showing N 




6.4.1 Modification of the VP4 N-terminus 
The assembly of EV71 VLP∆VP4 has questioned the VP4 involvement in capsid assembly. VP4 
is known for its conformation flexibility and myristoylation in many picornaviruses. During the 
PV capsid uncoating, VP4 is extruded from the inner surface of the virion (De Sena & Mandel, 
1977) and the N-terminus of VP4 is myristoylated and has been previously considered as 
essential for virion assembly (Chow et al., 1987) as 5S protomer association to form 14S 
pentamers is promoted by myristoylation (Ansardi et al., 1992) for the infectious and naturally 
occurring empty capsid assembly. For PV, the first 3 amino acids of VP4, which includes the 
Gly at position 2 where myristic acid is added (Moscufo et al., 1991). To study the N terminus 
of PV VP4 in VLP assembly, a conservative strategy was adopted in which residues were 
changed but the signal for myristoylation was maintained. Accordingly, the first 10, 15 and 20 
amino acids were exchanged for the sequence of another myristoylated protein, the HIV matrix 
protein (p17) which is part of the HIV-1 gag polyprotein which also forms virus capsids and 




In order to exchange the first 10, 15 or 20 amino acids of VP4 with HIV matrix protein p17, 
Geneblock for Ex10, Ex15 and Ex20 were designed as shown in Figure 6.11. The detail of 
cloning is described in 2.2.1. Using unique sites BstEII and EcoRI in pOPINE Mahoney SC6b 
P1_2A_FS_3CEV71, VP4 mutations were introduced to produce pOPINE Mahoney SC6b P1 
Figure 6.11. Schematic representation of VP4 N-terminus mutant sequences exchanged with N-terminus of HIV 
matrix protein, p17 
N-terminus of VP4 amino acid sequences are shown indicating the p17 sequence insertion. Ex10 mutant contains 
first 10 amino acids from p17. For Ex15, 15 amino acids are contained and 20 amino acids for Ex20.  
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Ex10, Ex15 and Ex20_2A_FS_3CEV71 using a Quick-Fusion Kit. Once the exchange was 
confirmed by sequencing, transfection of Sf9 cells was carried out to produce recombinant 
baculoviruses, Bac-PV1SC6bP1Ex10, Ex15 and Ex20 as before. Once virus had been 
produced, small scale infections with Tnao38 cells were set and, at 3 d.p.i. the cells were 
harvested and prepared for the WB analysis using anti-VP1 antibody (Figure 6.12). The image 
showed VP1 reactivity for all the mutants with the VP1 expression level being 
Ex10>Ex15≥Ex20>Sc6b>WT. The result showed that VP1 reactivity for all mutants was 
improved compared to Mah SC6b and Mah WT but especially for Ex10. In order to investigate 
the effect of the mutation on capsid assembly, mutant Ex10 was prepared for VLP purification 
by a 15-45 % sucrose gradient. A 100 ml Tnao38 cells infection with Bac-PV1SC6bP1Ex10 
was set, harvested at 3 d.p.i., the cells lysis and cell debris were removed by centrifugation 
followed by VLP enrichment through a 30 % sucrose cushion. The pellet formed at the bottom 
of the tube was then resuspended and clarified before banding on a 15-45 % sucrose gradient. 
1 ml fractions were made from the top of the tube as described in 2.5.2. and WB analysis by 
anti-VP1 antibody (as per section 2.6) for all fractions was carried out. Figure 6.13 showed the 
VP1 reactivity from fraction 3 to fraction 13 as well as pellet resuspension. The reactivity was 
highest in fractions 5 to 9 peaking in fraction 7, a sucrose concentration of 25-35 % which is 
where PV empty capsids sediment. The additional reactivities at higher molecular weight than 
VP1 may indicate partially processed P1 and some partial VP1 cleavage or capsid degradation 
for lower molecular weight reactivity. After fraction concentration, the sample was visualised 
under TEM as before. Figure 6.14 showed numerous VLPs with average size of 34.6 nm with 
+/- SEM of 2.28, n = 10 and the number of VLP was greater than the equivalent culture volume 
of SC6b although the VLP appeared filled rather than having the typical “hollow” VLP 
appearance with uranyl acetate penetration. The VLPs also appeared somewhat distorted 
although this could be an artefact of the grid preparation. Overall the Ex10 mutant clearly 
stimulated PV antigen expression levels without compromising VLP assembly, adding to the 




Figure 6.12. WB analysis using anti-VP1 antibody (MAB8566, Millipore) for small scale 3 d.p.i. of Bac-PV1P1-3C 
(shown as Mah wt), Bac-PV1SC6bP1-3C (Mah SC6b), Bac-PV1SC6bP1Ex10, Ex15 and Ex20 
~37 kDa reactivity which agrees with MW of VP1 was seen in all samples. The reactivity level was highest for Ex10, 
slightly lower for Ex15, further lower for Ex20 and Sc6b is slightly higher than WT which is the lowest. Additional 
reactivities were seen at higher molecular weight (~60 kDa and ~100 kDa) and at lower molecular weight (~32 kDa, 
~23 kDa and ~18 kDa). Those reactivity reflected the intensity of VP1 reactivity. Protein molecular markers are 
show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and Novex™ 




Figure 6.13. WB analysis with anti-VP1 antibody (MAB8566, Millipore) for 3 d.p.i. of Bac-PV1SC6bP1Ex10 for 
Tnao38 cells following NP40 lysis, 30 % sucrose cushion and 15-45 % sucrose gradient  
1ml fractions were taken from top of the tube to the bottom and analysed over 2 gels which were processed for WB. 
The image is the composite of the two WB membranes. A ~37 kDa VP1 reactive band is seen in fractions 3 - 13 
peaking around fractions 7 - 9 and declining to fraction 12. There is also signal in the pellet and preceding fraction. 
Fraction 7 (as indicated) was used for TEM. Protein molecular markers are show to the left of the gel (M) and are 
in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and Novex™ sharp pre-stained protein standard 
(ThermoFisher) were used. 
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6.4.2 Modification of the VP1 N-terminus 
A conclusion from Wang et al. (2018) described above was that in the EV71 VLP∆VP4 particles 
the VP1 N-terminus was externalised. During PV virion uncoating, the externalisation of the 
VP1 N-terminus has been suggested to involve a number of different steps including anchoring 
to a susceptible cell surface which leads to the association with the tip of the VP2 propeller 
feature. The association is also associated with a rearranged GH loop in VP3 and some 
rearranged GH loop in the neighbouring protomer both of which suggest that the VP1 N-
terminus could be involved in capsid assembly (Butan et al., 2014). It follows that the 
movement of the VP1 N-terminus could be part of instability seen in PV VLPs. As the 
movement must have some basis in the sequence of this region alterations of the N-terminus 
of VP1 could modify stability although it has to be accepted these could all be detrimental 
changes, much as were the pocket lining residues. 
Figure 6.14. TEM image for negatively stained of VLPs of Mahoney SC6b Ex10 from Figure 6.13 concentrated 
fraction 7 (3 d.p.i. of Bac-PV1SC6bP1Ex10 for Tnao38 cells)  
2 % uranyl acetate was used for grid staining. A grid full of VLPs was observed although they appear filled rather 
than having typical stain penetration. The average sizes of VLP is 34.6 nm with +/- SEM of 2.28, n = 10 which is 
expanded for PV VLPs. The number of VLPs were greater than Figure 6.10A. 2 % uranyl acetate was used as stain 
on a copper grid with carbon coated formvar film (Agar scientific). 
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In order to investigate the contribution of the VP1 externalisation for our PV VLP assembly, a 
flexible GS linker (GGGGSGGGGS) was substituted for the resident sequence in three 
separate positions in the VP1 N-terminus with each insertion shifted by 4 or 5 amino acids 
from the last. GS linkers are commonly used when flexibility is required, for example in the 
assembly of single chain antibodies (van Rosmalen et al., 2017). The insertions began after 
the 4th amino acid as it was considered that a minimum number of amino acids may be required 
for accurate 3C proteolytic processing at the VP3/VP1 junction. The detail of the GS linker 
insertions, which were all made in the PV1 SC6b background, is indicated in Figure 6.15. 
 
Geneblock fragments was designed to contain the mutations, and an extra 15 nucleotides 
upstream and downstream for each mutant and used in an infusion reaction with pOPINE 
Mahoney SC6b P1_2A_FS_3CEV71 using unique sites, BseJI and NotI, both which flank the 
region to be changed.  The newly constructed transfer vectors, pOPINE Mahoney SC6b P1 
VP1_1, VP1_2 and VP1_3, _2A_FS_3CEV71 were transformed into E. coli competent cells for 
plasmid preparation and sent for sequencing (section 2.2.1). Positive plasmids were used for 
Sf9 cell transfection to generate recombinant baculoviruses, Bac-PV1SC6bP1VP1_1, VP1_2 
and VP1_3 as described in 2.3. Once high titre viruses were produced, a small scale infection 
of Tnao38 cells was set and the cells harvested at 3 d.p.i. as before and analysed for VP1 
expression by WB (section 2.6). Figure 6.16 shows VP1 reactivity in VP1_2 and Ex10 (as 
control), indicating the reactivity being VP1_2<Ex10 and no reactivity for VP1_1 and VP1_3 
Figure 6.15. Schematic representation for N-terminus VP1 mutations designed to contain GS linkers consisting of 
GGGGSGGGGS in 4 or 5 amino acid shifted positions. 
VP1_1 contains GS linker at V14 replacing the resident 10 amino acids. For VP1_2, the GS linker was inserted at 
I10 and at M5 for VP1_3.  
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lanes. This result confirms this area of VP1 as highly sensitive to change as, in two of the tests 
expression was abolished undoubtedly as assembly fails and the protomers are degraded. 
However insertion 2 indicates that some positions are tolerate to the insertion. To confirm that 
this mutant is still VLP competent a 100 ml Tnao38 cell infection was prepared as described 
before. At 3 d.p.i. the infected cells were harvested and lysed followed by a 30 % sucrose 
cushion, and a 15-45 % sucrose gradient. 1 ml fractions were collected and analysed by WB 
using an anti-VP1 antibody. The procedure followed was the same as the method in 6.5.1. 
Figure 6.17 showed VP1 reactivity in fraction 4 to fraction 9 which peaked in fraction 5 and 
gradually declined to fraction 9. These fractions are in sucrose concentration of 20 % to 30 % 
which corresponds the sedimentation position in sucrose for PV empty capsid. Fractions 6 and 
8 were concentrated separately and visualised under TEM. Fraction 6 did not show any VLPs 
and very few baculovirus. Fraction 8 (Figure 6.18) showed VLPs which were at a slightly lower 
level to Ex10 VLPs (cf. Figure 6.14) but the VLPs appeared as typical empty capsids 
characterised by the penetration of uranyl acetate with average size of 48.2 nm with +/- SEM 
of 3.65, n = 9. These results indicate that the VP1_2 mutant is self-assembly competent 




Figure 6.16. WB analysis by anti-VP1 antibody (MAB8566, Millipore) for small scale 3 d.p.i. of Bac-
PV1SC6bP1VP1_1, VP1_2, VP1_3 and Bac-PV1SC6bP1Ex10 for Tnao38 cells 
Amongst the VP1 mutants, only VP1_2 showed ~37kDa VP1 reactivity. The level was much lower than Ex10 which 
showed additional reactivities at higher and lower molecular weight as seen in Figure 6.12. Protein molecular 
markers are show to the left of the gel (M) and are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) 
and Novex™ sharp pre-stained protein standard (ThermoFisher) were used. 
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Figure 6.17. WB analysis using anti-VP1 antibody (MAB8566, Millipore) for 15-45 % sucrose gradient fractions of 
3 d.p.i. of Tnao38 cells Bac-PV1SC6bP1VP1_2  
100ml Tnao38 culture infected with Bac-PV1SC6bP1VP1_2-3C was harvested at 3 d.p.i. and lysed with NP40 and 
ultracentrifuged at 30 % sucrose cushion and 15-45 % sucrose gradient. The blot image is the composite of 2 WBs. 
~37 kDa VP1 reactivity was found throughout the gradient, but more prominent in fractions 4 to 8 and fraction13. 
The peak of the reactivity occurred in fraction 5. Protein molecular markers are show to the left of the gel (M) and 
are in kilodaltons. Bolt™4-12% Bis-Tris Plus Gels (ThermoFisher) and Novex™ sharp pre-stained protein standard 
(ThermoFisher) were used.  
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The results from section 6.5 showed that the VLP assembly for Ex10 and VP1_2 and a higher 
yield of VLP from all previous constructs. These VLPs are analysed by N/H ELISA for their 
conformation status. For this analysis, VLPs were directly coated to the ELISA plate rather 
than capturing the VLPs with the capture Ab. The sample used for TEM imaging was diluted 
1/2 with bicarbonate coating buffer, pH 7 and 2-fold dilutions made to 1/64. Following overnight 
incubation at 4°C, the plate was washed 3 times with PBST and the primary mAbs were added. 
After this step, the same method as that described in 2.8 was followed.  
Figure 6.19 shows that both H readings for Ex10 and VP1_2 VLPs declined as the sample was 
diluted while the N readings remained almost unchanged indicated that both VLPs are of the 
H specific conformation. The H readings difference (Ex10 readings being higher than VP1_2) 
reflects the VLPs concentration difference. It has to be noted that this assay did not contain 
the IPV standard and that VLPs were directly coated to the plate which could have induced the 
H conformation in any N antigenic form VLPs present. Thus, the result cannot be compared 
directly with the other N/H ELISA results. Although the mutation was considered for 
Figure 6.18. TEM image for negative staining of VLPs of Mahoney SC6b VP1_2 from concentrated fraction 8 
indicated in Figure 6.17 (Bac-PV1SC6bP1VP1_2 infection of 100 mL Tnao38 cells) 
2 % uranyl acetate was used for the grid staining. Well scattered VLPs and a baculovirus were found. There were 
two types of particles; empty capsids which are characterised by the penetration of uranyl acetate (majority) and 
capsids which appeared white and filled as seen for Ex10 VLPs (Figure 6.14). The average size is 48.2 nm with +/- 
SEM of 3.65, n = 9. 2 % uranyl acetate was used as stain on a copper grid with carbon coated formvar film (Agar 
scientific). 
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improvement in the antigenicity, the data obtained suggest the VLPs are still an H specific 
conformation. 
 
Figure 6.19. N/H ELISA analysis for concentrated peak fractions from 15-45 % sucrose gradient for PV Mahoney 
SC6b Ex10 (fraction 7) as seen under TEM in Figure 6.14 and VP1_2 (fraction 8) of Figure 6.18 at Reading 
VLPs were directly coated onto the ELISA plate surface and probed with N- and H- specific antibodies. H specific 
readings of Ex10 and VP1_2 showed a decline with dilution while N specific readings remained unchanged. H 
specific reading of Ex10 was generally higher than VP1_2 throughout the dilutions.  
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6.5 Discussion 
Improvements in capsid thermostability is one of the criteria for a new PV vaccine as current 
vaccines are less than ideal (Milstien et al., 1997). PV particles undergo conformational change 
during prolonged storage and/or storage temperature (Breindl, 1971) and assume a Heated 
conformation which cannot induce protective immunity, whereas Native conformation particles 
can (Hummeler & Hamparian, 1958). For any PV vaccine replacing the current two types, it is 
essential that the N conformation of capsid is maintained, and this includes VLP candidate 
vaccines. The conformation of expressed VLPs was examined by ELISA assay using 
antibodies specific for the H or N conformation and VLPs extracted from insect cells were found 
to be in the H conformation. VLPs from yeast cells also contained H type antigenicity but 
showed some N reactivity dependent on the purification method. VLPs derived from PV 
infection themselves can exhibit the H conformation (Fox et al., 2017). Similarly recent high 
yielding sources of VLP such as expression in plants, have also observed a variable level of 
the H/N types (Marsian et al., 2017). While improved therefore, a system providing universal 
N reactivity remains to be found. The VP1 pocket is a structural feature among enteroviruses 
and is located in the VP1 interior and normally filled with a pocket factor (Filman et al., 1989). 
When PV undergoes uncoating upon receptor binding, the pocket factor is dislodged from the 
pocket to trigger capsid disassembly and lead to RNA release into the host cell (Plevka et al., 
2013). Thus the VP1 pocket could be turned to an advantage to maintain capsid structure via 
molecular engineering of the pocket to mimic pocket occupation. If successful, the capsid 
should remain in the N conformation and possibly present the PV receptor binding cleft for a 
longer period which might result in enhanced immunity. Accordingly, residues lining the VP1 
pocket were altered and, separately, pocket binding compounds were introduced. For VP1 
lining residues, mutations to provide higher hydrophobicity and some structure reinforcement 
were introduced. The synthetic compounds were expected to bind to the VP1 pocket with 
higher affinity than any natural pocket factor. The expression assay of VP1 mutants in insect 
cells demonstrated that none of the mutants improved the VLP yield and some of amino acid 
changes lead to the cessation of VLP synthesis. There was no significant expression difference 
among the other mutants. The small-scale expression assay for insect cells infection carried 
 187 
out with GPV13 showed that the drug is tolerated in the system and that it influenced the 
expression level. Bac-PV1P1-3C and Bac-Y205W infection showed that the expression level 
was enhanced by GPV13. On the other hand, analysis of Bac-Y159W indicated an adverse 
effect on expression. Depending on the side chains that line the pocket, the drug might further 
stabilise or destabilise the cavity, with associated gain or loss of expression level. Following 
the enhanced expression observed with GPV13 for Bac-PV1P1-3C, Pleconaril was added to 
the insect cell culture and a full purification carried out but overall yields were low and a 
conclusion on N or H predominance was not reached. The same result was obtained for the 
addition of Pleconaril in yeast cells despite the use of PV3 Skt SC8 which is supposed to have 
higher initial capsid stability. Further titration of drug level and its effect on overall synthesis 
are clearly needed.  
Overall, the addition of pocket binding drugs or mutation of VP1 residues lining the pocket did 
not bring about to capsid stability improvements in either system. However, the difference in 
VP1 levels by WB for each mutant confirmed a contribution of the VP1 pocket to the expression 
of viral proteins which then affects capsid assembly and stability. The reactivity level difference 
for the M132 mutants is particularly interesting. VP1 expression was observed for M132L 
whereas no VP1 was detected for M132W. This indicates that the degree of the VP1 pocket 
filling by amino acids alters protein expression and suggests a much wider range of amino acid 
replacements may need to be tested. Similarly, the combination of mutations showed different 
VP1 reactivity levels, M132W-H207W-F237WM132W-F237W>H207W-F237W (no 
expression) whereas the F237W showed VP1 reactivity among the single amino acid 
mutations. Therefore the context of each mutant must also be taken into account and mutations 
are not additive. M132W and H207W appear to be notably destabilising and even when some 
expression was seen, such as in M132W-F237W, it was at a lower reactivity compared to WT 
Bac-PV1P1-3C. On the other hand, the triple mutation M132W-H207W-F237W showed 
expression as high as Bac-PV1P1-3C. These findings suggest a consideration of the overall 
shape of the cavity is important and that the WT PV capsid has possibly the default VP1 cavity 
shape or hydrophobicity. Only a narrow margin of variation within this envelope may be 
accepted.  
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Whilst the VP1 pocket was being targeted for stability improvement in this work, further 
research from Fox et al. (2017) isolated the PV Mohoney SC6b mutation which improves 
thermostability. The P1 sequence of this mutant was inserted into the standard transfer vector 
and the expression level of VP1 compared to the wildtype sequence. This showed an 
increased reactivity on a cell for cell basis and TEM imaging confirmed abundant VLP 
assembly. However, when antigenicity was analysed the N/H ELISA result showed it retained 
the H antigenic conformation as least when purified as described. In addition, Wang et al. 
(2018)produced a high potency empty 80S-like VLP for EV71 by deleting VP4 sequence from 
full P1 sequence entirely raising the question of whether VP4 is needed at all for VLP 
assembly. The density mapping of the VLP by cryo-EM showed the lack of VP4 but also that 
the N-terminus of VP1 was externalised. During PV virion assembly, VP4 is characterised by 
flexibility N-terminal myristoylation which is believed to be required for assembly of the 
protomer into pentamers (Ansardi et al., 1992). The N-terminus of VP4 has various functions 
during the capsid uncoating such as reversible capsid anchoring to susceptible cells and 
formation of a finger-like structure together with reorganised GH loop of VP3 (Butan et al., 
2014). In order to assess if either of these areas had an effect on PV VLP assembly and 
stability, mutations were introduced separately. It is worth noting that structure based 
approaches here are impossible as the flexibility of these regions means they are poorly 
mapped in either cryo-EM or crystal structures. At the VP4 N-terminus, the N terminal 
sequence from another myristoylated protein, HIV matrix protein p17, was exchanged with first 
10(Ex10), 15(Ex15) and 20(Ex20) amino acids of VP4. Expression level notably increased for 
all mutants with Ex10 being the most stimulatory when compared to SC6b. It should to be 
noted that, because of the conservation of residues necessary for myristoylation, the amino 
acid sequence difference between Ex10 and HIV matrix protein, p17 is only 6 amino acids 
(Figure 6.11). Among these residues are some which are obviously inhibitory for PV VLP 
assembly in the WT form. For the N-terminus of VP1, a GS linker at 4 or 5 amino acid shifted 
positions (VP1_1, VP1_2 and VP1_3) was introduced. Of 3 mutants tested, VP1_2 showed 
protein expression and assembly but this was lower than that observed for Ex10. The 
difference in the expression among the mutants confirms that the N-terminus of VP1 is an 
essential part of virus particle assembly and indicates an area for more analysis. 
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Disappointingly the H antigenicity observed for both Ex10 and VP1_2 VLPs indicated that the 
neutralising site conformation is not maintained, although noting the difference observed by 
many groups in VLP preparation, these assays need to be repeated. 
The results from the VP4 and VP1 mutational analysis suggests that VLP assembly maybe 
more flexible than previously thought, also supported by the myristoylation independent 
mechanism of VLP assembly shown for EV71 VLP∆VP4 (Wang et al., 2018). Although Wang et 
al. (2018) showed that the EX71 VLP∆VP4 is an EV71 80S-like particle having an externalised 
VP1 N-terminus without VP4, the detailed 135S and 80S (Levy et al., 2010) capsid cryo-EM 
structures for PV indicated that loss of VP4 occurs later than the externalisation of the N-
terminus of VP1 but before RNA loss (Butan et al., 2014). The virion uncoating process is 
therefore in flux and various types of intermediate capsids exist. Some of these intermediates 
could be, or tend towards, the H antigenic form but as the mechanisms involved must depend 
on the sequence, mutants able to cement the N conformation could be realistically expected.  
However, attempts to produce N conformational VLPs from our insect and yeast cell 
expression systems has not been achieved to date. However, the amino acid substitution to 
aliphatic and aromatic amino acids at VP1 pocket interior residues and the pocket binding drug 
addition to one of the mutants have demonstrated that there is strict preference of 
hydrophobicity or overall shape for the VP1 pocket, for the assembly of VLPs. This area may 
therefore be a relatively poor target for further mutational analysis. The modification of VP4 or 
the N-terminus of VP1 and the maintenance of VLPs is entirely new and somewhat 
unexpected. It may indicate areas for further manipulation in pursuit of a VLP form that is 100 
% N type irrespective of the expression system or purification protocol. 
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  General Discussion 
The aim of this project was to produce PV VLPs from insect and/or yeast cells and to 
investigate their stability and conformational status to assess if empty PV capsids could lead 
to be a future PV vaccine. Throughout the research, attempts to optimise purification methods 
for higher VLP yield were also explored. VLP vaccines for picornaviruses have been developed 
since around 1990. PV VLP was produced originally in insect cells using baculovirus and yeast 
expression system. Insertion of the complete PV1 genome into a baculovirus transfer vector 
led to the synthesis of structural proteins and assembly of PV empty capsids which showed 
weak neutralising responses (Urakawa et al., 1989). Co-expression of PV structural protein, 
P1 and its protease, 3CDpro in yeast resulted in viral protein expression and VLPs which were 
non-immunogenic unless a capsid stabilising drug was added (Rombaut & Jore, 1997). Both 
VLP produced in foreign expression systems did not meet the criteria necessary for a viable 
vaccine candidate and they were not pursued further. More recently however, VLP vaccine 
development for some other members of the picornaviridae such as FMDV and EV71 has 
attracted renewed research interest. FMDV VLP production in insect cells defined the minimal 
requirements for empty capsid synthesis. In the system described, the structural protein (P1-
2A) was processed by a modified protease 3Cpro (Sweeney et al., 2007) combined with a HIV-
1 ribosomal frameshift (Dinman et al., 2002) which together lowered protease activity to a point 
where cellular toxicity was reduced. This modification produces P1 as majority product and 
P1-2A-3Cpro as a minor product. The expression cassette (P1-2A-FS-3C*) improved yields 
substantially and demonstrated potential for not only FMDV but also for other picornavirus 
empty capsid production in insect cells (Porta et al., 2013). Research within the host group at 
Reading first adapted the cassette for EV71 empty capsid synthesis (Cone, 2015). In the 
process, EV71 3Cpro with a S128A mutation, which reduces the protease activity in an 
equivalent way to the 142 mutation in FMDV 3C, was produced (Cui et al., 2011). As EV71 
and polio 3C proteases share 55 % homology and are structurally very similar (Cui et al., 2011; 
Zhang et al., 2010) PV VLP synthesis was attempted using the EV71 3C sequence to cleave 
PV P1. That is, for PV VLP production for this project the P1 region of the EV71 cassette was 
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adapted by just replacing with PVP1. This resulted in the expression cassette consisting of 
(PVP1-PV2A-FS-EV713C*).  
This chimeric expression cassette, in a single expression vector, was shown to synthesis 
cleaved viral proteins and that they self-assembled into VLPs in both the baculovirus and yeast 
expression systems. The result revealed that PV structural protein P1 can be proteolytically 
processed into viral proteins efficiently by modified 3CEV71. PV structural protein cleavage has 
been widely accepted to be most efficiently achieved by PV 3CDpro (Harris et al., 1992; 
Kitamura et al., 1981; Kräusslich et al., 1988; Lawson & Semler, 1990; Pallansch et al., 1984; 
Parsley et al., 1999). However, PV 3CDpro activity was not efficient in the baculovirus 
expression system describe here and only poor protein processing was observed. The findings 
support of control of protease activity more than the origin of protease, assuming their cleavage 
recognition sites are the same. A detailed examination of 3CD levels may have allowed an 
efficient cassette to be constructed but this was not done. To reconcile this finding with the 
originally published data, translation of much larger 3CDpro will require a longer time compared 
to that of 3Cpro and, as a consequence, less 3CDpro than 3Cpro will be produced. The lower level 
of 3CD in the original papers may have suited the in vitro translation experiments done but 
maybe too low in the expression cassette assembled here. Indeed, abundant P1 was observed 
on the gels when all constructs using 3CD were analysed, consistent with poor levels of 
processing. In the insect cells and S. cerevisiae expression systems used in this project 
however, an efficient ratio of P1 to 3C was met by use of the HIV-1 ribosomal frameshift and 
lowered activity 3CEV71 and this was the basis of all further constructs. 
Purifying VLPs following expression of the capsid proteins in insect cell and yeast systems 
proved difficult and changes to the purification method were adopted throughout the course of 
the work. A combination of PV sequence changes and improvements in capsid extraction, in 
part suggested by collaborators based on their experience in other systems, led to substantial 
yield enhancements over the course of the study. Enhanced capsid stability, which is part of 
the improvements, should benefit during not only the purification of VLPs but also their storage 
and transport if and when they became a vaccine. The instability of PV VLPs are known from 
previous studies (Rombaut & Jore, 1997; Urakawa et al., 1989), particularly heat sensitivity 
(Filman et al., 1989; Macadam et al., 1989). All purification procedures were therefore carried 
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out at 4°C or below whenever possible but VLP loss was nevertheless encountered. Physical 
homogenization, mechanical pressurising and bead-beating was able to lyse cells efficiently in 
a short period of time but appeared to damage the VLPs. A simple non-ionic detergent (NP40) 
seemed suitable for insect cells but could not remove the yeast membrane after cell wall 
removal. N2 cavitation seemed to show more promising VLP recovery. For heat sensitive 
products such as PV VLPs, a low temperature purification method is required so mechanical 
methods that generate heat were generally not compatible. For yeast cells, zymolyase digest 
of the yeast cell wall was essential as it decreased the robustness of the cell prior to 
mechanical breaking. However this could become a cost sensitive step for very large cultures. 
Overall, some PV VLP yield improvement by using N2 cavitation and NP40 method for insect 
cell derived PV VLPs and N2 cavitation and zymolyase method for yeast origin VLPs was 
demonstrated during the study. 
Capsid stability is also intimately related to VLPs antigenicity. The “H” antigenic form is defined 
as heated and is a known sensitivity for current vaccines where improvements are made. A 
characteristic of the PV capsid structure is the hydrophobic cavity, the “pocket” which is located 
at the bottom of canyon within the body of VP1. Stable mature PV particles have long 
molecules, pocket factors, bound and pocket factor removal is observed during capsid 
conformational change after the PV particle has attached to the receptor and prior to RNA 
release (Plevka et al., 2013). This feature has been targeted for anti-viral drug development to 
stop PV infection. Those compounds replace the natural pocket factor and bind so tightly to 
the capsid that conformational change is prevented. VLPs do not need to uncoat for virus 
replication and so modifications aimed at locking the pocket, in the manner analogous to a 
bound drug, which would be lethal for the virus, are permitted and could provide a level of 
stability. This strategy was attempted as part of these studies by the introduction of 
hydrophobic and bulky amino acids such as leucine and tryptophan in place of the residues 
that naturally line the pocket. In addition the addition of pocket binding drugs, pleconaril and 
GPV13 was investigated. PV viral protein expression levels varied depending on the mutation 
made but universally to lower levels, almost to the point of losing expression completely. 
Combination of mutations performed similarly. These findings confirm that maintenance of the 
pocket structure contributes to the conformation of the capsid in the content of VLPs but no 
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significant increases in expression (stability) were seen. It seems that even variation in the 
pocket area is poorly acceptable for VLP assembly and that disassembled material degrades, 
lowering the levels observed. Similarly supplementing with pleconaril or GPV13 failed to 
improve stability significantly although when combined with one mutation a positive trend was 
observed and further work in this area could be productive. Katpally and Smith (2007) have 
shown for HRV16 an inability to uncoat due to increased stability achieved through pocket 
filling mutations in the pocket area so the strategy has a clear precedent. Although stable VLP 
were not obtained in these tests, it was clear that pocket shape was important for VLP 
assembly and it seems likely a much greater range of mutations will need to be assessed, as 
those predicted failed to achieve the desired outcome (also since confirmed following vaccinia 
expression by Oxford collaborators). In addition to pocket region manipulations for enhanced 
thermostability, mutations discovered from a novel virus thermostability screen (Fox et al., 
2017) were used in the VLP expression cassette. Empty capsid with these novel mutations 
were shown to be thermostable while remaining immunogenic in animal models. A PV3 
construct, termed SC8, and SC6 for PV1 that contained these mutations did increase yield 
somewhat in the expression systems tested here and equivalent mutations in PV2 would be 
worth investigating.  
 
Results from section 6.4 also suggested that novel mutations, not based on any previous 
selection criteria, could also benefit VLP yield. In particular modification of the N-terminus of 
the VP4 sequence was shown to enhance expression levels and retain VLP assembly. The 
rationale for these mutations was that the N terminus of VP4 moves during capsid breathing 
and that if this was prevented the capsid could become more rigid. However, neither the 
structure of the N-terminus of VP4 within the VLP, nor its precise track to the exterior is clear 
from current PV structures so the requirement for any mutation to prevent such movement is 
impossible to design. In the event, as myristoylation of VP4 has been reported to be essential 
for PV assembly (Chow et al., 1987) a sequence from another myristoylated protein, the HIV 
matrix protein was exchanged for the resident VP4 N-terminus. VLP synthesis was abundant 
for the new Ex10 mutant but the reasons why it should be so are not clear and further analysis 
of the mutant is required, not least for its N/H ratio following careful purification. Nevertheless, 
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the data indicate that many more mutants within the ~900 residues of PVP1 could have an 
effect on capsid stability, especially in the context of VLPs with a non-cleaved VP0 protein. 
How such a wide ranging set of mutations could be screened is difficult to see but it is clear 
that “wild” mutations could have a role to play.  
 
Whatever the ideally stable VLP is, if it was achieved it could obviously deliver a vaccine for 
the polio free world but could also act as the platform technology for the development of 
recombinant PV capsids as carrier for other cargoes. One approach may be to improve the 
breadth of the immune response to provide a single vaccine for all three serotypes. A study 
carried out with a related picornavirus, FMDV, has shown that mutations in dominant epitopes 
can result in immune refocusing which improves neutralising activity (Tobin et al., 2008). 
Capsids of PV could perhaps be similarly engineered to introduce the defocusing mutation into 
the major epitopes. Another approach to the use VLPs as a generic vaccine platform is the 
icosahedral capsid itself, which offers abundant copies of a unit which is available for the 
presentation of diverse epitopes (Burke et al., 1991; Evans & Almond, 1991). Indeed once 
sufficient amounts of native antigenic PV VLPs are obtained and the immunogenicity of the 
vaccine is confirmed, the PV vaccine could become a platform with a future that is not only 
polio free but also free of many other diseases where current vaccination strategies are limited.  
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